






















































similar! to! their! adult! counterparts,! clinicians! have! become! concerned!
that!paediatric!patients!with!SLE!are!at!increased!risk!of!CVD.!!




wave! velocity! (PWV).! These! findings! were! compared! with! clinical!
information,! traditional! cardiovascular! risk! factors,! disease! activity,!
medications!and!adipokine!activity.!













This! cohort! of! children! with! JSLE! show! structural! changes! in! their!
vessels!indicative!of!early!CVD!but!with!adaptive!changes!resulting!in!
normal!functional!scans.!In!contrast!to!adult!data!this!group!displays!an!
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entire! UKJSLE! study! group,! and! particularly! Louise! Watson,! Carla! Roberts,!
Lucinda!Dawson!and,!of!course,!Michael!Beresford,!whose!advice!early!in!the!
project!allowed!it!to!move!from!concept!to!a!fullyXfledged!research!plan.!!My!
thesis! examiners! David! Isenberg! and! David! D’Cruz! provided! invaluable!










This! work! would! never! have! been! finished! and! written! up! without! the!
caffeinated!beverages!provided!by!the!amazing!staff!in!The!Espresso!Room!in!
London! and! Sandrocks! in! Melbourne.! The! Dead! Flags! soundtrack! kept! my!
fingers!typing!even!when!it!was!sunny!outside!and!I!just!wanted!to!go!to!the!


























































































































Cardiovascular! disease! (CVD)! was! first! identified! as! a! major! cause! of!
mortality! in! adults! with! systemic! lupus! erythematosus! (SLE)! in! the!
1970s!but!its!aetiology!remains!poorly!understood.!It!is!unclear!whether!
SLE! (or! the! treatment! of! SLE)! acts! as! an! independent! risk! factor! or!
whether! the! increased! risk! of! CVD! in! adults! is! due! to! a! clustering! of!
traditional!cardiovascular!(CV)!risk!factors.!!
SLE!is!a!lifelong!autoimmune!disease,!affecting!multiple!organ!systems!
and! leading! to! a! relapsing! and! remitting! chronic! inflammatory! state.!
Diagnosis!is!usually!made!from!the!clinical!presentation,!classical!system!
involvement! and! abnormal! autoantibodies.! For! research! purposes!












risk! is! a! general! feature! of! SLE! or! whether! it! only! affects! select!
subgroups!of!patients!there!is!certainly!an!increased!risk!of!CVD.!Indeed,!
even! after! controlling! for! the! traditional! Framingham! risk! factors! the!








understand! its! pathogenesis.! Since! children! are! highly! unlikely! to!






risk! factors! for! CVD,! obesity,! inactivity! and! smoking,! and! thus!
represent!a!“clean”!population!in!which!to!study!the!effect!of!SLE!and!
the!treatment!of!SLE!on!the!vascular!phenotype.!
2.  JSLE! is! associated! with! an! increased! risk! of! CVD! and! that! this! is!
associated! with! an! abnormal! vascular! phenotype.! This! will! be!
ascertained! by! measuring! wellXvalidated! measures! of! subXclinical!
CVD!to!establish!the!vascular!phenotype!of!children!with!JSLE.!
3.  The! increased! risk! of! CVD! in! JSLE! is! further! exacerbated! by! the!
presence! of! hypertension,! renal! impairment,! the! use! of!
corticosteroids!and!the!duration!of!disease.!
4.  The! increased! risk! of! CVD! in! JSLE! is! related! to! increased! disease!
activity! leading! to! abnormalities! in! serum! lipids! and! adipokine!

























is! the! formation! of! autoantibodies! against! nuclear! antigens.! It! has! a!
variable! presentation! and! clinical! course! with! multiXsystem!
inflammation!affecting!the!skin,!joints,!kidneys!heart,!lungs!and!nervous!
system.!The!pathogenesis!of!SLE!is!multifactorial!disease!with!hormonal,!




Patient! survival! in! SLE! has! improved! considerably! over! the! last! few!
















































include! steroids,! nonXsteroidal! antiXinflammatory! drugs,!
hydroxychloroquine,! azathioprine,! methotrexate,! cyclosporine,!
cyclophosphamide,!mycophenolate!mofetil,!tacrolimus!and!intravenous!











higher! incidence! of! arthritis,! LN,! neurological! manifestations! and!
haematological! involvement.! (6,19,20)! Half! of! patients! with! JSLE! will!
present! in! adolescence! and! the! median! time! from! symptom! onset! to!
diagnosis! is! 3.2! months,! reflecting! the! difficulty! of! diagnosing! a! rare,!
multisystem! disorder! with! frequently! nonspecific! symptoms! at!
presentation.! After! 4! –! 5! years! of! follow! up,! 80%! of! patients! have!!
Cardiovascular!Morbidity!in!Juvenile<onset!Systemic!Lupus!Erythematosus!
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compared! with! their! adult! counterparts.! Patients! with! JSLE! are! more!























risk! of! CV! events! among! adults! with! SLE! has! been! confirmed! by! a!
number!of!prospective!studies!which!have!demonstrated!an!increased!
relative!risk!of!CV!events!in!individuals!with!SLE!when!compared!to!their!
















Similarly! Ward! (25)! examined! hospitalisation! for! acute! myocardial!
infarction,! cerebrovascular! accident! or! congestive! heart! failure! for!
women!with!SLE!in!California!from!1991!to!1994,!showing!that!women!
aged! 18X44! with! SLE! were! 2.27! times! more! likely! to! be! hospitalised!
because! of! a! myocardial! infarction! and! 2.05! times! more! likely! to! be!




set! limited! itself! to! hospitalised! patients! and! so! could! not! estimate!
population! odds! ratios! and! restricting! analysis! to! only! cardiovascular!
diagnoses! that! are! objectively! verifiable! could! underestimate! disease!




by! the! patient’s! physician! to! active! SLE,! and! 31! to! atherosclerosis.!






transient! ischaemic! attack,! stroke! or! pacemaker! insertion)! and! only!
found!age!and!male!gender!to!be!associated!with!atherosclerotic!events.!!
Before! examining! the! pathogenesis! of! CVD! in! SLE! I! will! firstly! put!











enrolment! in! 1976.! All! were! free! of! a! diagnosis! of! SLE! or! CVD! at!
enrolment.! ! In! this! study! a! CV! event! was! defined! as! a! myocardial!!
Cardiovascular!Morbidity!in!Juvenile<onset!Systemic!Lupus!Erythematosus!
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In! 28! years! of! followXup! (2.9! million! personXyears)! 8169! CV! events!






adjusting! for! age,! ethnicity,! CV! risk! factors! and! medication! use! the!
relative!risk!of!a!CV!event!in!women!with!SLE!compared!to!those!without!
was!2.26.!The!relative!risk!for!coronary!heart!disease!was!2.25!and!for!
cerebrovascular! accident! was! 2.29.! Thus! demonstrating! a! clearly!
increased!risk!of!CVD!in!women!with!SLE.!
Similarly! the! following! SLE! register! studies! have! followed! adults!
diagnosed! with! SLE! longitudinally! and! have! shown! an! increased!
prevalence! of! CVD! when! compared! with! the! general! population.!
Different!studies!have!used!different!definitions!of!CV!events!making!it!
challenging!to!compare!results.!However,!they!have!consistently!shown!



























Likewise! in! a! 12Xyear! follow! up! of! 156! patients! with! SLE,! by! Becker!
Merok!et!al,!(29)!41!(26%)!had!a!vascular!event.!Vascular!events!were!
defined! as! myocardial! infarction,! angina! pectoris,! intermittent!
claudication,! cerebrovascular! accident,! deep! venous! thrombosis,!
pulmonary! embolism,! intestinal! infarction! not! related! to! vasculitis,!
avascular!necrosis!of!the!bone,!acute!arterial!ischaemia!of!extremities!
and!tissue!loss!related!to!vasculitis.!The!mortality!rate!in!the!group!that!




linearly! over! time! and! persistent! disease! activity! was! the! sole!










points! of! CVD.! These! include! measures! of! structural! vascular! damage!
such!as!carotid!artery!intima!media!thickness!(cIMT)!and!measures!of!
calcification! of! coronary! vessels! such! as! multiXdetector! computed!
tomography! (MDCT)! scanning! or! single! photon! emission! computed!
tomography! (SPECT).! They! also! include! measurements! of! functional!
change!in!vessels!such!as!pulse!wave!velocity!(PWV)!which!measures!the!
distensibility!of!vessels,!and!they!include!measures!of!intact!endothelial!












































SPECT! of! the! myocardium! at! baseline! and! after! 1! year! showed! an!
increase!in!coronary!calcium!deposits!in!the!placebo!group.!Shang!et!al!
(32)!measured!PWV!and!cIMT!on!32!patients!with!SLE!and!32!controls,!




18! years.! They! showed! an! increased! prevalence! of! atherosclerosis! in!
patients! when! compared! to! controls,! with! a! relative! risk! of! 2.4,!
interestingly! the! prevalence! was! 5.6! times! higher! among! patients!
younger! than! 40! years! of! age.! Multivariate! analysis,! including! age,!
hypertension,!diabetes,!smoking,!cholesterol!and!lupus!status,!showed!
that!only!age,!the!presence!of!lupus!and!serum!cholesterol!level!were!







plaque.! Other! factors! which! independently! correlated! with!
atherosclerotic!plaque!were!an!older!age!at!diagnosis,!longer!duration!of!
disease,!higher!disease!activity!and!not!using!cyclophosphamide.!!













Thus! the! evidence! for! an! increased! prevalence! of! subXclinical! CVD! in!











traditional! CV! risk! factors,! originally! identified! in! the! Framingham!





















suitable! control! group! that! reveals! a! shockingly! high! rate! of!
cardiovascular! events! among! SLE! patients.! However,! it! was! a!
retrospective!study.!!
Later!studies!have!shown!lower!rates!which!may!reflect!improvements!
in! overall! treatment,! earlier! recognition! of! the! signs! of! CVD! or! less!
steroid!use!in!the!era!of!biological!agents.!More!recently,!Esdaile!et!al!
(39)!retrospectively!examined!SLE!registry!data!from!296!patients!and!
showed! that,! even! after! controlling! for! traditional! cardiovascular! risk!
factors,!the!increase!in!relative!risk!was!10.1!for!nonXfatal!myocardial!
infarction!and!7.9!for!cerebrovascular!accident.!Clearly!a!retrospective!
study! carries! a! risk! of! inaccurate! diagnoses! and! this! study! did! not!
examine! softer! cardiovascular! symptoms! such! as! angina! or! transient!
ischemic!attacks!but!nonetheless!it!highlighted!that!the!increased!risk!of!
CVD! in! SLE! could! not! be! explained! solely! by! traditional! risk! factors.!
Furthermore! Bessant! et! al! (40)! examined! a! large! British! cohort! to!
compare!their!predicted!risk!of!CVD,!based!on!traditional!risk!factors,!
with! their! actual! rate! of! CVD! and! showed! that! while! traditional!
cardiovascular!risk!factors!predicted!the!risk!of!actual!CVD!in!patients!




These! risk! factors! are! outlined! in! table! 3! and! include! hypertension,!
obesity,! diabetes! mellitus,! chronic! kidney! disease! (CKD)! smoking,!
hyperlipidaemia,!hyperhomocysteinaemia!and!a!sedentary!lifestyle.!Not!
only!are!these!risk!factors!increased!in!adult!patients!but!they!tend!to!be!






blood! pressure,! body! mass! index! and! impaired! glucose! tolerance.!
Santos(41)! compared! 100! women! with! SLE,! 98! with! rheumatoid!
arthritis! and! 102! controls! and! found! that! modifiable! CV! risk! factors!
occur! more! frequently! in! SLE! and! rheumatoid! arthritis! with!
hypertension!and!an!atherogenic!lipid!profile!occurring!more!frequently!
in!SLE!than!rheumatoid!arthritis.!I!will!now!discuss!the!prevalence!of!



























placeboXcontrolled! trial! of! atorvastatin.! Subjects! had! MDCT! and! cIMT!
measurements! twice,! 2Xyears! apart.! They! showed! that! age! was!








increasing! age! was! independently! associated! with! the! progression! of!
cIMT! over! a! 2! year! period,! while! Sabio! et! al! (45X49)! showed! that!
increased! PWV! was! associated! with! increased! age.! Salmon! et! al! (31)!
showed!that!older!age!at!diagnosis,!longer!duration!of!SLE!and!higher!
























was! younger! than! the! Spanish! group! at! 27.2! years! for! men! and! 28.6!
years!for!women.!
Several!studies!have!suggested!that!oestrogens!contribute!to!the!onset!




defence! against! infection.! ! Peripheral! blood! mononuclear! cells!
demonstrate! enhanced! response! to! immunogen! stimulation! in! the!
presence! of! 17βXoestradiol.! Young! et! al! have! shown! TLRX8,! whose!




























disorder! with! calcium! containing! phosphate! binders,! vitamin! D! and!
dialysis.!Even!in!the!early!stages!of!CKD!there!is!a!significantly!increased!
risk!of!a!CV!event!with!an!adjusted!hazard!ratio!of!2!in!CKD!stage!2!and!
11! in! CKD! stage! 3B,! see! table! 4.! (64)! Children! on! dialysis! have!





























4)! partly! due! to! dysregulation! of! the! calciumXphosphateXparathyroid!
hormone! axis.(67)! Children! with! pure! CKD! typically! develop!




et! al! in! 1999! showed! that! the! vascular! smooth! muscle! cell! is! not!
terminally! differentiated! and! can! differentiate! to! become! adipocytes,!
chondrocytes!and!osteoblasts!leading!to!calcification,!lipid!accumulation!
and!cell!death.(68,69)!!
Fibroblast! growth! factorX23! (FGF23)! is! a! phophaturic! hormone! that!
contributes! to! several! hypophosphatemic! disorders! by! reducing! the!
expression! of! the! type! II! sodiumXphosphate! coXtransporters! in! the!















of! FGFX23! and! Klotho! leads! to! decreased! tubular! phosphate!
reabsorption,!decreased!intestinal!absorption!of!calcium!and!phosphate!
and! the! serum! phosphate! levels! are! maintained! in! the! normal! range.!
However,!as!CKD!progresses!FGF23XKlotho!is!overwhelmed!and!plasma!
phosphate!levels!rise!leading!to!overstimulation!of!parathyroid!hormone!
and! an! increase! in! serum! calcium.! Thus! maintenance! of! adequate!
vitamin!D!levels!early!in!CKD,!along!with!dietary!control!of!phosphate,!
















vitamin! D! binding! proteins! and! the! use! of! sunscreens! and! decreased!
conversion! of! 25X(OH)D! to! the! metabolically! active! 1,25! (OH)2D,!
secondary!to!renal!impairment!are!known!to!put!SLE!patients!at!risk!of!
Vitamin!D!deficiency.!!









al(77)! looked! at! 37! children! with! JSLE! and! compared! them! with! 21!
patients!with!juvenile!dermatomyositis!and!found!that!serum!25X(OH)D!
levels!were!inversely!associated!with!disease!activity!in!dermatomyositis!
but! not! in! nonXproteinuric! JSLE.! See! tables! 5! –! 7! for! disease! scoring!
systems.!
Studies!of!animal!models!and!cell!cultures!show!both!direct!and!indirect!
immunomodulating! effects! of! vitamin! D! involving! T,! B! and! antigenX












between! gene! polymorphism! and! disease! activity! and! no! difference!
between!genotype!frequencies!and!healthy!controls.!!
Bogaczewicz!et!al(82,83)!have!shown!that!some!patients!with!SLE!to!be!
positive! for! antibodies! to! 1,25! (OH)2D,! the! biologically! active! form! of!




risk! factors.! Lower! levels! were! associated! with! higher! diastolic! blood!
pressure,!LDL,!lipoprotein!(a),!BMI!and!fibrinogen!levels.!!
Low!levels!of!vitamin!D!remain!a!potentially!modifiable!risk!factor!in!





























that! waist! circumference! was! an! independent! predictor! of! increased!
cIMT!in!a!study!by!Sazliyana!et!al!(88)!and!Yildiz!et!al!(38)!showed!a!





The! impact! of! obesity! is! difficult! to! examine! in! isolation,! and! many!
studies!analyse!its!impact!as!part!of!the!metabolic!syndrome!(MetS).!It!is!





with! controls! matched! for! age,! physical! characteristics! and! physical!
activity!levels!and!this!impacts!on!obesity!and!CV!health.!Katz!et!al!(89)!












dynamic! muscle! strength! in! upper! and! lower! limbs,! lower! functional!
performance! and! greater! fatigue! than! controls.! So,! despite! reporting!
good! physical! activity! ratings! patients! with! SLE! have! reduced! CV!
capacity!for!physical!exercise!and!reduced!muscle!strength.!























and! a! significantly! reduced! FMD! in! sedentary! patients! compared! to!
controls! (3.6±1.3%! V! 8.1±1.2%)! and! that! this! was! significantly!
associated!with!markers!of!inflammation!and!disease!activity.!
Fatigue!is!a!common!feature!of!SLE!and!thus!patients!with!mild!disease!










MetS! is! a! known! risk! factor! for! CVD.! It! is! defined! by! the! National!
Cholesterol!Education!Program!Adult!Treatment!Panel!III!(101)!as!three!
or!more!of:!elevated!waist!circumference!(≥102cm!in!men!and!≥88cm!in!
women),! hypertryglyceridamia! (≥! 1.7mmol/L),! low! HDL! cholesterol!
(<1.03!mmol/L!in!men!and!<1.3!mmol/l!in!women),!high!blood!pressure!
(systolic!blood!pressure!≥!130mmHg!and/or!diastolic!blood!pressure!≥!












showed! an! increased! prevalence! of! MetS! in! SLE.! While! Sabio(106)!
showed!that!patients!with!SLE!and!MetS!had!a!higher!PWV!and!increased!
biomarkers! of! sublinical! atherosclerosis,! such! as! high! sensitivity! CX
reactive! protein! (hsCRP)! and! InterleukinX6! (ILX6),! compared! to! those!
without!MetS!in!a!crossXsectional!study.!!
The! Systemic! Lupus! International! Collaborating! Clinics! Registry! for!
Atherosclerosis!inception!cohort!(108)!studied!1494!patients!with!SLE.!
All!were!diagnosed!in!the!previous!15!months,!came!from!30!centres!
across! 11! countries! and! had! a! mean! age! of! 35.2! years,! younger! than!






Interestingly! unpublished! work! by! Prof! Ye! Shuang,! from! the! Renji!
Hospital! in! Shanghai,! presented! to! the! Australian! Rheumatology!
Association!Annual!Scientific!Meeting!in!May!2014!suggests!a!role!for!
metformin! in! the! treatment! of! SLE.! Metformin! is! commonly! used! in!
insulin! resistance! secondary! to! metabolic! syndrome.! However,! cells!
treated!with!metformin!in(vitro!showed!a!20%!reduction!in!neutrophil!
extracellular! trap! (NET)! (Knight)! formation,! along! with! a! decrease! in!






















depending! on! the! extent! of! their! renal! impairment.! However! even! in!
those! without! overt! CKD! excess! activation! of! the! reninXangiotensin!
system! and! functional! nitric! oxide! deficiency! may! increase! baseline!
blood!pressure.!
HTN!is!also!a!wellXdescribed!side!effect!of!corticosteroids,!secondary!to!
overstimulation! of! the! mineralocorticoid! receptor! and! thus! sodium!
retention!in!the!kidney,!leading!to!fluid!retention!and!HTN.!This!leads!to!
a! vicious! cycle! of! increased! inflammation! leading! to! increased!
corticosteroids!leading!to!increased!blood!pressure.!!
Cypiene!(109,110)!showed!that!mean!blood!pressure!was!the!major!risk!

















evidence! suggesting! that! HTN! may! itself! be! an! inflammatory! disease!
involving!the!immune!system.!




leading! to! inflammation! in! target! organs! including! the! kidney! and!
vasculature!which!manifests!as!HTN.!They!have!shown!that!mice!lacking!
T! and! B! cells! have! blunted! hypertensive! responses! to! angiotensin! II!
infusions,! normal! endotheliumXdependent! vasodilation! and! vascular!
superoxide!production!but!that!transplantation!of!TXcells!restores!the!









increased! vascular! risk! and! individuals! with! chronic! inflammatory!
conditions!are!known!to!have!elevated!risk!of!CVD.!Several!studies!have!
































broad! groups.! The! first! are! disease! activity! scores! such! as! the! SLE!
Disease! Activity! Index! (SLEDAI),! which! gives! an! overall! measure! of!
disease! activity,! and! the! British! Isles! Lupus! Activity! Group! (BILAG),!
which!gives!organ!specific!assessment!scales.!The!second!are!measures!
of! chronic! damage! such! as! the! Systemic! Lupus! International!









have! higher! disease! scores! such! as! SLE! Disease! Activity!
Index(SLEDAI)(120X124),! and! higher! Systemic! Lupus! International!
Collaborative! Clinics! (SLICC)! scores! have! been! correlated! with! preX
clinical!CV!abnormalities,(125,126)!such!as!aortic!calcification(94,127X
133).!Higher!SLEDAI!scores!have!also!been!correlated!with!lower!values!







in! JSLE! it! approaches! 80%.(6)! Proteinuria,(136)! elevated! serum!
creatinine(137X139)! and! a! history! of! nephritis(140)! have! all! been!
associated! with! subclinical! atherosclerosis! in! patients! with! SLE.!
Prothrombotic!factors!play!an!important!role!in!SLE!related!CVD,!with!
the!presence!of!any!antiphospholipid!(aPL)!antibody!or!von!Willebrand!




onset! SLE.! Antiphospholipid! syndrome! is! diagnosed! in! patients! who!
have!vascular!thrombosis!(arterial!or!venous)!and!pregnancy!morbidity!
(foetal! death! and! preXeclampsia)! with! persistently! positive!!
Cardiovascular!Morbidity!in!Juvenile<onset!Systemic!Lupus!Erythematosus!
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from! an! Indian! cohort! (145)! were! positive! for! antiphospholipid!
antibodies! while! 36! %! of! the! UK! JSLE! cohort! have! either! levels! of!







and! HDL! from! women! with! positive! antiphospholipid! antibodies! has!
reduced! nitric! oxide! bioavailability! and! impaired! antiXinflammatory!
properties.! (148,150)! These! factors! contribute! to! an! increased! risk! of!
CVD.!MacGregor!et!al!(151)!showed!that!an!increase!in!major!vascular!










autoantibodies,! (154,155)! and! their! multiple! effects! on! monocyte,!
lymphocyte! and! endothelial! cell! activities! may! contribute! to! the!
prevention!of!thrombosis!in!patients!with!antiphospholipid!syndrome,!
although! this! needs! to! be! validated! by! larger! trials.! (156)!
Hydroxychloroquine! has! been! suggested! to! reduce! the! risk! of!
thrombosis,!possibly!due!to!the!inhibition!of!platelet!aggregation!and!
(157)! is! associated! with! lower! prevalence! of! positivity! lupus!
anticoagulant! or! anticardiolipin! antibodies.! Furthermore,! a! small!
observational! study! of! 32! adult! patients! with! antiphospholipid!























































































Constitutional! Pyrexia! Musculoskeletal! Myositis!




! Fatigue/malaise/lethargy! ! Arthritis!
! Anorexia! ! Arthralgia!
Mucocutaneous! Skin!eruption! ! Tendonitis/tenosynovitis!
! Angio<oedema! ! Tendon!contractures!





! Digital!infarcts! ! Dyspnoea!
! Alopecia! ! Cardiac!failure!
! Angio<oedema! ! Friction!rub!
! Mucosal!ulceration! ! Effusion!
! Malar!erythema! ! Chest!pain!
! Subcutaneous!nodules! ! Progressive!chest!Xray!changes!




! Peri<ungual!erythema! ! Cardiac!arrhythmias!
! Swollen!fingers! ! Pulmonary!function!fall!by!>20%!
! Sclerodactyly! ! Cytohistological!evidence!of!
inflammatory!lung!disease!
! Calcinosis! ! Myocarditis!
! Telangiectasia! ! Cardiac!tamponade!









! Seizure!disorder! ! Shrinking!lung!syndrome!
! Status!epilepticus! ! Aortitis!
! Cerebral!vascular!disease! ! Coronary!vasculitis!
! Cerebral!vasculitis! Vasculitis! Major!cutaneous!vasculitis!including!
ulcers!
! Aseptic!meningitis! ! Major!abdominal!crisis!due!to!vasculitis!




! Demyelinating!syndrome! ! Livido!reticularis!








! Cranial!neuropathy! ! Abdominal!serositis!or!ascites!
! Plexopathy! ! Lupus!enteritis/colitis!
! Polynneuropathy! ! Malabsorption!
! Autonomic!disorder! ! Protein!losing!enteropathy!
! Disc!swelling! ! Intestinal!pseudo<obstruction!
! Chorea! ! Lupus!hepatitis!
! Cerebellar!ataxia! ! Acute!lupus!cholecystitis!














! Anxiety!disorder! ! Episcleritis!
! Organic!brain!syndrome! ! Scleritis!
Renal! Severe!hypertension! ! Retinal/choroidal!vaso<occlusive!disease!
! Proteinuria! ! Optic!neuritis!









































































would! also! reduce! CV! risk.! Unfortunately! in! some! cases! they! may!
independently!increase!CV!risk,!acting!to!increase!in!traditional!CV!risk!






































Originally! used! as! an! antimalarial! agent,! hydroxychloroquine! is! an!
inexpensive!drug!used!in!SLE,!predominantly!for!cutaneous!disease.!Its!
exact!mechanism!of!action!is!unknown.(162)!It!is!thought!to!block!TollX
like! Receptors! reducing! the! activation! of! dendritic! cells.! In! vitro!












Cyclophosphamide! is! an! alkylating! agent,! usually! reserved! for! the!





less! likely! to! develop! atherosclerosis! on! transXoesophageal! echo.!
(168,169)!!






that! 6Xmonths! postXtransplant! the! second! group! had! greater!




such! as! the! ApoeXnull! mouse,! have! shown! significant! decrease! in!
atherosclerotic! lesions! with! MMF! treatment.(346)! The!










et! al! examined! 24! patients! treated! with! MMF! compared! with! 163!














activator(IRA)! B! cells! develop! in! the! spleen! during! the! inflammatory!
phase!of!sepsis!and!produce!granulocyte!macrophage!colonyXstimulating!
factor(GMXCSF).(175)!GMXCSF!is!known!to!be!atherogenic!with!deficient!
mice! developing! smaller! atherosclerotic! lesions! (176)! and! exogenous!
administration!leading!to!larger!atherosclerotic!lesions.!Hilgendorf!et!al!
(177)! have! shown! that! IRA! B! cell! lines! expand! in! atherosclerosis,!
increasing!plaque!size!and!promoting!the!generation!of!dendritic!cells.!
SLE!BXcells!are!involved!in!cytokine!production!as!well!as!the!production!
of! autoantibodies! which! may! initiate! the! inflammatory! reaction,! they!
also!lead!to!TXcell!activation!and!thus!a!medication!that!targets!BXcells!
has!obvious!appeal.(178)!




widely! in! the! treatment! of! severe! SLE! the! results! of! two! largeXscale!
controlled!trials!(179X181)!have,!disappointingly,!failed!to!demonstrate!
efficacy.!Belimumab!is!a!fully!humanised!monoclonal!antibody!against!
soluble! BLyS,! a! type! II! transXmembrane! protein! that! functions! in! a!
healthy! immune! response! to! prolong! survival! and! promote!
differentiation!of!BXcells.!!
Since!some!animal!models!demonstrate!a!protective!role!for!endogenous!
BXcells! in! the! evolution! of! atherosclerotic! plaque! (182)! there! are!
concerns!about!the!potentiation!of!atherosclerosis!in!the!setting!of!BXcell!























development! of! CVD! in! an! otherwise! healthy! population! with!
hypercholesterolaemia.! (187)! Along! with! inhibiting! cholesterol!
biosynthesis!their!antiXinflammatory!effects!include!upregulation!of!NO!















population,! discussed! later,! Schanberg! et! al! (194)showed! no! effect! of!
atorvastatin!on!the!progression!of!cIMT!over!36!months,!in!patients!with!
JSLE.!Post!hoc!analysis!showed!some!benefit!in!postXpubertal!patients!
with! higher! hsCRP.! The! original! cohort! excluded! patients! with! renal!









It! is! characterized! by! vascular! inflammation,! which! leads! to! vascular!
remodeling! and! plaque! formation.! The! interactions! that! lead! to! the!
formation! and! maintenance! of! an! atherosclerotic! lesion! are! not! fully!
understood! but! the! “response! to! injury”! hypothesis! (195X197)! is! the!
most! widely! accepted! explanation.! This! hypothesis! proposes! that!
endothelial! injury! leads! to! vascular! inflammation! resulting! in! a!
fibroproliferative! response.! In! an! otherwise! healthy! individual!
endothelial! injury! may! result! from! toxins,! such! as! the! byXproducts! of!
tobacco,! hyperglycaemia,! oxidized! Low! Density! Lipoproteins! (LDL),!
hyperhomocystinaemia,! cholesterol! or! infectious! agents.! (198,199)!

















Injury! to! the! endothelial! wall! whether! resulting! from! toxins! or! an!








Figure! 3! depicts! the! initial! stages! of! AS,! showing! endothelial!
inflammation,!widening!of!the!intimal!space,!increased!permeability!of!
the! endothelium,! EC! expression! of! cell! adhesion! molecules! and! the!
differentiation!of!monocytes!to!macrophages.!!
As! LDL! moves! into! the! subXendothelial! space! it! becomes! oxidized! by!
various! enzymes! in! the! vessel! wall! including! xanthine! oxidase! and!
myeloperoxidase.! Accumulation! of! oxidised! LDL! stimulates! the! EC! to!
express!adhesion!molecules,!such!as!ICAMX1,!VCAMX1!and!MCPX1,!which!






!Figure! 4! depicts! the! movement! of! macrophages! into! the! widening!






Macrophage! Colony! Stimulating! Factor! (MCSF)! promotes! the!
differentiation! of! monocytes! to! macrophages! which! then! phagocytose!
the! oxLDL! molecules,! becoming! lipidXrich! “foam! cells”.(210X212)! An!
accumulation!of!these!“foam!cells”!along!with!TXlymphocytes!and!smooth!
muscle!cells!forms!the!earliest!pathological!lesion!of!atherosclerosis,!the!
fatty! streak.! These! lesions! can! be! found! in! the! aorta! from!
childhood.(213X215)!Vascular!smooth!muscle!cells!proliferate,!migrate!
and,! along! with! collagen,! ultimately! form! the! fibrous! cap.! This! acts,!
initially,!to!stabilize!the!developing!plaque!and!prevent!rupture.!A!fragile!
microvascular! network,! the! vasa! vasorum,! supplies! the! developing!
plaque,! it! is! prone! to! haemorrhage! which! further! contributes! to! the!
progression!of!the!plaque!through!the!release!of!inflammatory!mediators!







InterferonXγ,! produced! by! TXcells,! impairs! VSMC! proliferation! and!
collagen! synthesis,! along! with! matrix! metalloproteinases! (from! the!
activated!macrophages)!acts!to!degrade!collagen!and!weaken!the!fibrous!
cap,!leading!to!the!rupture!of!the!atherosclerotic!plaque.(211,215,220X







!Figure! 7! shows! organisation! of! the! plaque! and! highlights! luminal!







shown! by! registry! data! worldwide.! The! Australian! and! New! Zealand!
Dialysis! and! Transplant! registry! (ANZDATA)! and! the! Dutch! national!
cohort!study!have!shown!that!over!50%!of!deaths!on!dialysis!are!due!to!
CVD! or! cerebrovascular! causes.(65,226)! CVD! in! CKD! is! due! to! both!
atherosclerosis!and!arteriosclerosis.!
Arteriosclerosis!is!a!highly!regulated!process!involving!promoters!and!






down! the! cardiac! impulse! and! thus! prevent! shear! stress! to! the!
endothelial!cell!layer.!However,!as!CKD!progresses!the!VSMC!loses!its!
contractile!phenotype!and!undergoes!apoptosis!or!osteo/chondrocytic!
differentiation.(229)! Apoptosis! leads! to! the! release! of! matrix! vesicles!
containing! calcium! and! phosphate! which! act! as! a! nidus! of!
calcification.(62,230,231)! This! process! is! well! established! before! the!
clinical! signs! are! evident! and! recent! studies! have! confirmed! that! the!
vessels!of!children,!even!in!the!early!stages!of!CKD,!are!abnormal.(67)!





There! is! some! evidence! to! suggest! that! the! pathogenesis! of!
atherosclerotic!plaques!in!SLE!may!be!in!some!respects!unique.(234)!A!
proportion! of! adults! with! SLE! with! cardiac! symptoms! do! not! have!




Endothelial! activation! is! emerging! as! a! key! event! for! accelerated!
atherosclerosis.! An! imbalance! between! vascular! damage! and! repair,!
possibly! induced! by! interferon,! could! play! a! prominent! role! in! the!
induction!of!accelerated!AS!in!SLE.!(195)!Lupus!prone!NZ!black!and!NZ!
white!F1!mice!display!endothelial!dysfunction!and!abnormal!phenotype!





Circulating! AngiopoeitinX2(Ang2)! concentrations! have! been!
demonstrated!to!be!increased!and!concentrations!of!Ang1!decreased!in!
individuals! with! active! SLE! compared! to! healthy! controls.! Individual!
Ang2! concentrations! correlate! with! SLEDAI! score,! ds! DNA! titres! and!
sVCAMX1.!Ang2!mediated!disruption!of!protective!Ang1/Tie2!signalling!
may!be!operational!in!SLE.!(238)!
In! SLE! patients,! circulating! EC! counts! have! been! shown! to! be!
significantly!higher!than!in!healthy!controls!and!strongly!correlate!with!
SLEDAI!score.!The!active!phase!of!the!disease!may!be!associated!with!an!
increased! number! of! circulating! ECs! (239)! and! severe! SLE! flares! are!
characterised!by!enhanced!EC!apoptosis.!(196,240)!The!mobilisation!of!
endothelial! precursor! cells! (EPCs)! is! unaffected! in! SLE! but! there! is! a!
diminished!number,!altered!phenotype!(241)!and!altered!functionality!of!
circulating!CD34+/VEGFR2+!cells!which!may!reduce!the!ability!to!repair!
vascular! damage! and! thus! may! trigger! the! development! of!
atherosclerosis!in!SLE.(242)!!
In! SLE! autoXantibodies! may! contribute! to! the! pathogenesis! of!













a! CV! risk! factor! and! it! has! become! evident! that! white! adipose! tissue!
interacts!with!the!vasculature!through!the!secretion!of!adipokines!(243)!
predisposing!the!individual!to!inflammation!leading!to!atherosclerosis.!
SLE! has! been! shown! to! be! a! hyperleptinaemic! condition! (244)! and!




leptin! levels! when! compared! with! controls,! which! correlated! with!
disease!activity!and!measures!of!abnormal!vascular!structure.!(244,246X
248)!!





specific! Leptin! receptor! (LepR),! a! member! of! the! class! I! cytokine!
receptor!family!widely!expressed!on!different!types!of!cells,!and!acts!as!a!
proXinflammatory!cytokine,!leading!to!increased!serum!levels!of!TNFXα,!





Adiponectin! acts! to! protect! the! vasculature! from! atherosclerosis!





injury! and! decreases! VSMC! migration,! reducing! the! migration! of!
macrophages!and!their!transformation!into!foam!cells.!(241,255)!Recent!
work!shows!low!levels!of!serum!adiponectin!in!women!with!SLE,!that!










murine! cardiac! transplantation.! (259)! This! immunomodulator! effect!
could!be!mediated!by!its!ability!to!alter!dendritic!cell!functions.!(260)!In!
T! cells! cultured! with! dendritic! cells! which! had! been! treated! with!
adiponectin,!a!higher!percentage!of!CD4+CD25+Foxp3+!Treg!cells!was!




Adiponectin! has! traditionally! thought! of! as! an! antiXinflammatory!
cytokine!(263X265)!exerting!its!effect!on!endothelial!cells!through!the!
inhibition! of! TNFXα! induced! adhesion! molecule! expression! and! the!
inhibition!of!NFkB!activation,!and!by!increasing!the!secretion!of!ILX10!
and!ILX1!receptor!antagonist!by!monocytes,!macrophages!and!dentritic!
cells! and! suppressing! the! production! of! InterferonXγ! (IFNXγ)! by!
macrophages! and! TLRXinduced! Nuclear! factorXκB! (NFXκB)! activation.!
However! newer! studies! have! shown! that! it! can! also! act! as! a! proX
inflammatory! cytokine.! Its! levels! are! high! in! preXeclampsia! and! renal!!
Cardiovascular!Morbidity!in!Juvenile<onset!Systemic!Lupus!Erythematosus!
82!




Fetuin! A! is! a! negative! acute! phase! reactant! made! by! the! liver! and! a!
potent!inhibitor!of!calcification.!It!is!associated!with!an!atherogenic!lipid!
profile,! (225,270X272)! acting! to! inhibit! apoptosis! of! VSMCs! and! to!
protect! against! their! calcification.! Low! levels! appear! to! impair!
macrophage!function.!(256,273,274)!It!interacts!with!free!fatty!Acids!to!
activate! TollXlike! receptorX4! (TLR4)! and! increase! insulin! resistance.!
(270,275,276)!Downstream!activation!leads!to!increased!levels!of!TNFXα!
and! IL1.! Uncontrolled! activation! of! TLR4! leads! to! a! lupus! type!
autoimmune!picture!in!murine!models.!It!has!not!been!studied!in!SLE.!
(277X279)!
InterferonXα! (IFNXα)! promotes! a! cytokine! profile! that! enhances! antiX
angiogenic! responses,! promotes! vasculopathy! and! accelerates! AS.! In!
murine!lupus!it!acts!to!increase!HDL!oxidation.!(221)!It!promotes!the!
apoptosis! of! mature! endothelial! cells! (280)! and! can! affect! the!
megakaryocyte!transcriptome!and!increase!platelet!activation!in!vitro.!
(215)! Circulating! activated! platelets! lead! to! increased! atherosclerotic!
plaque!formation.!(281)!IFN  can!induce!foam!cell!formation!in!vitro.!
(211)!Its!expression!is!increased!in!areas!of!atherosclerotic!plaque!(282)!
and! has! been! associated! with! increased! markers! of! subclinical!
cardiovascular!disease,!such!as!increased!cIMT.!(283)!
T4cells!
All! T! cells! begin! as! CD4XCD8XTCR! cells! they! are! produced! from!
progenitor!cells!in!bone!marrow,!and!committed!to!their!lineage!in!the!
thymus.!Treg!cells!are!a!subset!of!T!cells,!usually!making!up!5X15%!of!




reducing! autoXimmunity.! CD4+Foxp3+! Tregs! are! also! called! naturally!
occurring!Tregs!and!FOXP3!can!be!used!as!a!marker.!Mutations!in!the!
FOXP3!gene!in!humans!is!associated!with!IPEX!syndrome!,!a!uniformly!
fatal! XXlinked! condition! characterised! by! immunodystrophy,!
polyendocrinopathy!and!enteropathy.!
Taleb!et!al(250,284)!showed!that!leptin!signalling!is!important!in!Treg!









atherosclerotic! lesion! size! and! inhibited! more! IFNXγ! production! than!
transfer!of!Treg!cells!from!wildXtype!mice.!
Lipoproteins!
High! Density! Lipoproteins! (HDL)! exert! a! number! of! physiological!
functions,! the! most! studied! of! which! is! their! ability! to! promote! the!
transport!of!cholesterol!to!the!liver!for!excretion!which!protects!against!
atherosclerosis.! (207,285X287)! HDL! is! a! complex! particle! made! up! of!
more! than! 50! proteins! along! with! phospholipids,! triglycerides! and!
choldesterol.! In! addition! to! protective! proteins,! such! as! apoJ,! apoAXI,!
PONX1,! PONX3,! and! hemopexin,! other! molecule! classes! such! as!
complement! proteins,! endopeptidase! inhibitors! and! proXinflammatory!
molecules,! such! as! serum! amyloid! proteins,! are! present.! Aside! from!









mechanisms! of! HDL! have! emerged,! including! antiXoxidative,! antiX
inflammatory,!and!antiXapoptopic!(289,290,293,294)!mechanisms!which!
may! be! altered! by! chronic! inflammation! and! the! ratio! of! proX
inflammatory! :! antiXinflammatory! proteins! in! HDL! can! be! changed!
through!postXtranslational!modification!or!hyperoxidation!
The!use!of!statins,!such!as!atorvastatin(34)!and!rosuvastatin,(295)!has!
been! shown! to! be! effective! in! reducing! hsCRP! and! restraining! the!
progression!of!atherosclerosis.!However!in!children!the!evidence!shows!
that! statins! may! slow! the! progression! of! cIMT! thickening! only! in! a!
subgroup! of! pubertal! patients! with! higher! hsCRP! (296)! and! does! not!
support!its!routine!use.!
More! recently! attention! has! focused! on! alterations! in! HDL! function,!
brought! about! by! inflammatory! states,! such! as! infection! or! immune!
mediated!disorders,!such!as!SLE.!(288)!HDL!has!been!shown!to!prevent!
the! oxidation! of! LDL! and! its! consequent! uptake! by! monocytes;! thus!
preventing!the!formation!of!foam!cells,!one!of!the!important!steps!in!
atherogenesis.! This! antiXoxidant! mechanism! is! due! mainly! to! the!
presence!of!Apolipoprotein!AX1!(ApoA1),!the!major!protein!fraction!in!
the!HDL!particle.!ApoA1!exerts!antiXoxidant!properties!by!stabilising!the!
enzyme! paraoxonase,! and! also! has! antiXinflammatory! properties! by!
blocking! the! contact! mediated! activation! of! monocytes! by! T! cells.!





the! oxidation! of! LDL! that! occurs! spontaneously! in! vitro! and! actually!
increases! oxidation,! and! thus! can! be! considered! proXoxidant! and!
proinflammatory.!
Several! studies! have! reported! altered! lipoprotein! profiles! and! altered!
HDL! function! (41,94,253,293)! in! SLE,! identifying! 2! patterns! of!
dyslipoproteinemia! in! SLE.! One! is! attributable! to! active! disease! and!
consists!of!reduced!HDL!levels!and!apoproteinXA1!with!elevated!levels!of!
Very!Low!Density!Lipoprotein!(VLDL)!and!triglycerides!(TG).!The!second!
is! mainly! attributable! to! corticosteroid! therapy! (301)! and! consists! of!





have! higher! serum! levels! of! TG! and! VLDL! and! lower! HDL! when!
compared!with!those!with!inactive!disease.!(302,303)!!
Interestingly,! a! study! by! McMahon! et! al! (293)! suggests! HDL! may!
undertake!a!dysfunctional!phentoype,!actively!contributing!to!AS,!under!




manner! to! Low! Density! Lipoprotein! (LDL),! influences! monocyte!
transcription,!accelerates!monocyte!migration!and!increases!Monocyte!
chemotactic! proteinX1! (MCPX1)! and! TNFXα! transcription.! The!
atherosclerotic! phenotype! is! driven! by! piHDL! in! part! through! its!













disease! severity! and! duration! are! closely! linked! to! CVD! in! the! adult!




from! studies! in! adults.! Although! childhood! lupus! is! often! a! more!
aggressive!disease!the!greater!plasticity!of!children’s!vessels!may!protect!
them! from! vascular! disease! making! extrapolations! from! adult! studies!
difficult.!PWV!has!been!shown!to!be!increased!in!active!SLE!(305)!and!
others! have! shown! an! increase! in! cIMT! and! PWV! that! correlate! with!
disease!activity.(306)!The!4!studies!to!date!that!have!directly!examined!
CVD!in!JSLE!are!summarised!in!table!9.!!
The! Atherosclerosis! Prevention! in! Paediatric! Lupus! Erythematosus!
(APPLE)!trial!(140,296,307)!assessed!cardiovascular!risk!in!221!patients!











male! sex,! increased! creatinine! clearance,! higher! lipoprotein(a)! level,!
proteinuria,! azathioprine! and! prednisolone! treatment.! In! multivariate!
analysis!moderate!dose!of!prednisolone!were!associated!with!decreased!
cIMT!while!high!and!low!doses!were!associated!with!increased!cIMT.!
(140,307)! Patients! were! randomised! to! 36! months! of! atorvastatin! or!
placebo!and!results!showed!no!statistically!significant!difference!in!cIMT!














PWV.! 31! patients,! 11! males,! had! all! the! vascular! studies.! cIMT! was!
measured!offXline,!using!ECG!gated!images,!with!electronic!calipers.!The!
group!showed!!showed!some!elevation!of!arterial!stiffness,!PWV!8.1m/s,!
but! cIMT! (0.43mm),! FMD! and! myocardial! perfusion! were! normal.!
Cumulative! prednisolone! dose! was! shown! to! be! correlated! with! total!











from! a! single! image! frozen! in! diastole! and! PWV! was! measured! by!
vicorder.! They! showed! an! increase! in! mean! cIMT! when! compared! to!
controls,! 0.54mm! versus! 0.35mm,! and! an! increase! in! PWV! when!















in! this! paper.! This! was! a! good! study! but! unfortunately! the! PWV!
measurement!method!cannot!be!extrapolated!to!other!studies.!!
Thus! the! studies! examining! CVD! in! JSLE! to! date! have! significant!
methodological! heterogeneity! which! makes! it! impossible! to! compare!
data!between!groups.!The!largest!study,!APPLE,!unfortunately!did!not!




































































studies! and! retrospective! reviews,! to! show! that! adult! onset! SLE! is!
associated! with! an! increased! risk! of! clinical! and! preclinical! CVD.! The!
increased!prevalence!of!traditional!risk!factors!in!this!cohort,!such!as!
obesity,!makes!it!difficult!to!study!the!effect!of!SLEXspecific!interventions.!
Many! will! already! have! a! significant! lifetime! CV! risk! due! to! nonX
modifiable! risk! factors! such! as! a! lifetime! of! smoking,! metabolic!
syndrome!and!age.!Additionally!SLEXspecific!risk!factors!such!as!disease!



























Avon! Longitudinal! Study! of! Parents! and! Children! (ALSPAC)!
(147,313,314)! and! the! Adolescent! Type! 1! Diabetes! CardioXRenal!
Intervention!Trial(315)!(AdDIT)!research!group.!This!has!resulted!in!the!




assays! performed.! I! devised! the! study! protocol,! obtained! ethical!
approval,! recruited! the! initial! 25! subjects,! interviewed! the! subjects,!
performed! and! analysed! their! vascular! scans! and! performed! and!
analysed! their! adipokine! assays.! My! independent! work! makes! up! the!
majority!of!this!thesis.!Professor!Jameela!Kari!continued!the!program,!


























The! UCL! Institute! of! Child! Health! in! partnership! with! Great! Ormond!
Street!Hospital!for!Children!NHS!Trust!is!the!largest!centre!in!Europe!
devoted!to!clinical!and!basic!research!in!children’s!health.!All!vascular!




The! adipokine! assays! were! performed! in! The! Institute! of! Molecular!








The! UK! JSLE! Cohort! Study! has! recruited! 276! patients! in! the! UK! who!
fulfilled!≥4!of!the!ACR!SLE!criteria!and!were!under!the!age!of!17!years!at!
the!time!of!diagnosis.!Approximately!60!children!with!JSLE!are!under!the!
care! of! the! nephrology! and/or! the! rheumatology! services! in! Great!




to! take! part! in! the! study.! They! were! provided! with! age! appropriate!



















Siblings! of! children! and! young! adults! under! the! care! of! the! renal! or!
rheumatology!team!in!Great!Ormond!Street!were!approached!and!asked!
to!take!part!in!the!full!study.!However!due!to!poor!recruitment!(only!one!
control! sibling! was! recruited)! a! historical! control! group! previously!
recruited!within!the!Vascular!Physiology!Unit!at!the!Institute!of!Child!
Health!was!used!for!comparison!of!the!vascular!phenotype.!This!control!
data! has! previously! been! published! and! was! used! with! the! kind!
permission!of!Dr!Rukshana!Shroff.(316)!
A!second!control!group!was!recruited!from!healthy!children,!over!the!age!
of! 5Xyears,! without! chronic! underlying! disease! who! were! free! from!
infection!or!inflammation!and!who!had!not!had!surgery!in!the!preceding!
6Xweeks.!They!were!recruited!from!the!Children’s!University!Hospital!in!
Dublin.! These! children! had! demographic! and! anthropometric! data!
recorded,!a!serum!sample!stored!and!were!used!for!comparison!with!the!
adipokine! studies.! These! children! were! drawn! from! the! emergency!
department! and! the! GP! phlebotomy! department! without! chronic!
diseases.! In! the! main! they! were! children! who! presented! to! the!
Emergency!Department!with!abdominal!pain,!which!was!subsequently!
diagnosed! as! constipation,! and! children! whose! parents! requested! a!
blood! test! as! they! looked! pale,! but! who! were! found! to! have! normal!
haematological! markers.! Similar! patients! were! not! available! in! Great!
Ormond!Street.!
Although!information!regarding!ethnicity!was!not!formally!collected!for!












The! study! was! approved! by! the! Institute! of! Child! Health! and! Great!
Ormond!Street!Hospital!research!ethics!committee!and!The!Children’s!




and! PWV! was! developed! by! the! Vascular! Physiology! unit! at! the! UCL!
Institute! of! Child! Health! for! use! in! multiXsite! studies! with! multiple!
operators!to!ensure!interXobserver!reliability.!The!protocols!are!outlined!
in! the! following! sections.! The! use! of! this! method! of! training! and! the!
protocols!for!measurement!and!analysis!represent!a!major!strength!to!
this!study!since!they!ensure!both!concordance!between!both!operators,!




event! and! over! the! last! 25Xyears! the! measurement! of! the! intima! and!
media!layers!lining!the!carotid!artery!using!ultrasonography!has!been!
established! as! a! surrogate! marker! for! atherosclerosis! and!
CVD.(62,228,316)! Paediatric! studies! have! determined! normative!
values(316)!and!its!use!in!largeXscale,!population!based,!cohort!studies!




increase! by! 0.006mm/year.! Futhermore! the! measurement! of! cIMT! by!
ultrasound!is!safe,!nonXinvasive!and!acceptable!even!to!young!patients.!!
There!are!several!techniques!which!have!been!used!to!measure!cIMT!
utilising! both! BX! and! MXmode! ultrasonography.! Most! studies! measure!
IMT!on!the!far!wall!of!the!carotid!artery!and!this!has!been!shown!to!be!
more!reliable!and!reproducible!(321)!than!its!measurement!on!the!near!




MHz! linearXarray! transducer.(322)! using! a! single! ultrasound! machine!
(Vivid7,! GE! Medical,! Horton,! Norway)! by! Catherine! Quinlan! (CQ)! and!
Jameela!Kari!(JK).!!
Identical!scanning!protocols!were!used!by!both!CQ!and!JK!and!both!were!
trained! and! certified! by! the! The! Vascular! Physiology! Unit! at! the! UCL!
Institute! of! Child! Health! to! perform! and! analyse! these! scans.! An!
accreditation!process!consisting!of!the!measurement!of!known!cIMT!in!5!
healthy!staff!volunteers!at!2!intervals,!2!weeks!apart,!ensuring!less!than!


























mediaXadventitia! interfaces! on! both! near! and! far! walls! over! the!
visible!length!of!the!vessel.!Occasionally!this!was!not!possible,!for!

















In! this! study! the! measurements! were! performed! offline,! using! an!














Training! in! vascular! scanning! techniques! took! place! in! the! Vascular!
Physiology!Unit!at!the!UCL!Institute!of!Child!Health!as!per!the!ALSPAC!
protocol! described! by! Donald! et! al(213)! including! the! reproducibility!















































































capillary! beds,! and! compromises! cardiac! perfusion.(329)! The!
assessment!of!arterial!stiffness!using!PWV!is!recommended!for!adults!by!
The! European! Guidelines! on! Cardiovascular! Disease! Prevention(330)!
and! for! children! by! the! American! Heart! Association! Atherosclerosis,!!
Cardiovascular!Morbidity!in!Juvenile<onset!Systemic!Lupus!Erythematosus!
106!
Hypertension! and! Obesity! in! Youth! Committee! of! the! Council! on!
Cardiovascular!Disease!in!the!Young.!(95,110,120,213,233,331,332) 
CarotidXFemoral!PWV!is!a!direct!measurement,!which!includes!the!aorta!
and! large! elastic! arteries,! and! thus! is! likely! to! have! more! clinical!
relevance! than! CarotidXRadial! PWV! as! changes! in! the! aorta! precede!
those!in!the!brachioXradial!arteries.!There!are!multiple!ways!to!measure!
PWV,! including! mechanotransducers,! ultrasound,! computerised!






applanation! tonometry! measures.(120,124)! However,! at! the! time! of!
formulating! the! study! protocol! the! gold! standard! was! held! to! be!
applanation! tonometry,! with! the! Sphygmocor! one! of! the! best!
validated(333)!and!thus!this!was!used!as!part!of!the!study!protocol.!!
















good! interXobserver! reproducibility.(233)! However,! in! the! Vascular!
Physiology! Laboratory! at! the! UCL! Institute! of! Child! Health! there! is! a!
rigorous!training!and!accreditation!program!designed!to!minimise!intraX
observer! variablility,! both! CQ! and! JK! were! trained! and! accreditated!
through! this! program.! Following! training! PWV! was! measured! in! five!
individuals!whose!correct!measurements!were!known!to!the!department!
twice,! 2Xweeks! apart.! These! measurements! were! required! to! be! both!
accurate! and! within! 5%! of! eachXother! in! order! for! the! scanner! to! be!
certified.!
PWV! is! defined! as! pulse! wave! travel! distance! divided! by! the! time!
difference!between!the!rise!delay!of!the!distal!and!proximal!pulse,!as!
measured!by!the!R!wave!on!the!ECG.!The!SphygmoCor!system!uses!a!







the! arterial! length! and! transit! time! using! the! intersecting! tangents!











Donald! et! al(314)! including! the! reproducibility! assessment.! This!
involved!scanning!of!5!healthy!staff!volunteers!on!2!occasions,!2!weeks!























































A! proforma! questionnaire! (Appendix! 5)! was! used! to! collect! patient!
information!in!order!to!maintain!consistency!between!CQ!and!JK.!A!pilot!
version! of! the! questionnaire! was! trialled! with! 10! patients! in! The!
Children’s!University!Hospital,!Dublin.!Following!this,!it!was!altered!for!
usability! and! was! used! by! CQ! and! JK! to! record! demographic! data,!
treatment!information!and!cardiovascular!risk!factors.!Patient!data!was!






Routine! blood! samples! were! processed! by! the! Departments! of!





























Serum! for! storage! was! left! to! settle! at! room! temperature! for! 1! hour.!
Then!spun!and!divided!into!0.5ml!aliquots!and!labelled!with!the!date,!























Estimated! glomerular! filtration! rate! (eGFR)! was! calculated! by! the!
Schwartz!formula!with!a!K!value!of!34,!as!calculated!locally.(336)!An!







see! table! 5.! The! BILAG! index! was! developed! as! an! intention! to! treat!
index!and!has!previously!been!validated!in!a!UK!paediatric!cohort(337)!
and! shown! to! be! more! sensitive! than! the! SLE! Disease! Activity! Index!
(SLEDAI)X2000!to!detect!active!disease.(338)!It!is!an!ordinal!scale!index!
with! 9! systems! (Constitutional,! Mucocutaneous,! Neuropsychiatric,!
Musculoskeletal,! Cardiorespiratory,! Gastrointesinal,! Opthalmic,! Renal!
and!Haematological)!which!divides!disease!activity!into!5!categories;!A!
represents! very! active! disease;! B! represents! moderate! disease;! C!
represents! mild! stable! disease;! D! represents! previous! disease;! E!













was! used! to! estimate! the! physical! activity! of! the! study! cohort,! see!
appendix!7.!The!short!version!of!this!questionnaire!was!chosen,!as!it!is!a!










Leptin! Immunoassay! kit,! catalog! number! DLP00,! from! R&D! systems).!
Product!information!sheets!are!included!in!Appendix!8.!The!assay!was!
performed! in! the! Institute! of! Molecular! Medicine! in! Trinity! College!
Dublin.!!



































7.  200µL! of! substrate! solution,! made! up! of! equal! parts! stabilised!








10. A! standard! curve! was! created! using! excel! software! to! generate! a!
log/log!graph!with!the!mean!absorbance!of!each!standard!on!the!yX
axis!and!the!concentration!on!the!xXaxis.!




Serum! levels! of! adiponectin! were! also! determined! by! a! commercial!
ELISA!kit!(Human!Total!Adiponectin/Acrp30,!Immunoassay!kit,!catalog!
number! DLP00! from! R&D! systems).! Product! information! sheets! are!
included!in!Appendix!8.!The!assay!was!also!performed!in!the!Molecular!
Medicine!Unit!in!Trinity!College!Dublin.!!
The! assay! used! a! quantitative! sandwich! immunoassay! technique.! The!
plates! were! preXcoated! with! a! monoclonal! antibody! specific! for!
adiponectin.! Standards! and! samples! were! added! to! the! wells! and! the!
antibody!bound!any!adiponectin!present!in!the!sample.!This!was!then!






























7.  200µL! of! substrate! solution,! made! up! of! equal! parts! stabilised!








10. A! standard! curve! was! created! using! excel! software! to! generate! a!
log/log!graph!with!the!mean!absorbance!of!each!standard!on!the!yX
axis!and!the!concentration!on!the!xXaxis.!







Based! on! control! data! (n=30)! generated! in! the! Vascular! Physiology!
Department!in!Great!Ormond!Street!by!Dr!Rukshana!Shroff,!using!iPWV!
as!our!primary!outcome!measure,!a!group!of!23!children!with!SLE!was!
calculated! to! provide! a! 90%! power! to! detect! a! significant! change!











previously.! Statistical! analyses! were! performed! in! GraphPad! Prism!
version! 6.0b! for! Mac! OS! X! and! multiple! regression! analysis! was!

















of! traditional! or! modifiable! risk! factors! for! CVD.! In! doing! so! I! will!
examine! my! first! hypothesis! that! children! with! JSLE! have! a! low!
prevalence! of! the! classical! modifiable! risk! factors! for! CVD,! obesity,!
inactivity!and!smoking,!and!thus!represent!a!“clean”!population!in!which!
to! study! the! effect! of! SLE! and! the! treatment! of! SLE! on! the! vascular!
phenotype.!This!information!will!also!be!used!in!subsequent!chapters!to!
identify! clinical! features! associated! with! the! development! of! an!
abnormal!vascular!phenotype.!!
In! the! general! population,! children! would! be! expected! to! have! a! low!
baseline!prevalence!of!traditional!risk!factors!for!CVD,!such!as!obesity!
and!smoking,!and!children!with!newlyXdiagnosed!JSLE!are!not!different.!








with! JSLE,! develop! a! cohort! of! patients! for! recruitment! to! clinical!
interventional! trials,! facilitate! international! collaborative! studies! and!
trials!and!perform!descriptive!analyses!of!disease!presentation,!activity!
damage!and!response!to!medication.!
The! UK! JSLE! data! collection! and! data! repository! has! previously! been!
described!by!Watson!et!al(6)!and!involves!prospective!recruitment!of!



















45! children! and! young! adults! were! recruited! to! this! study,! 39! were!
female.!The!mean!age!of!the!children!was!115±42!months!at!diagnosis!
















































Renal! function! is! outlined! below! but! renal! involvement! was! also!
assessed! using! the! pBILAGX2004! score! for! those! who! had! a! score!





































19! children! identified! themselves! as! AfroXCaribbean.! Of! these,! 13!
identified!themselves!as!being!African!or!of!African!descent,!2!identified!
themselves! as! Black! British,! and! 4! identified! themselves! as! Black!





























! ! UK!JSLE! CV!JSLE!
! ! N!(%)! N(%)!
Total! ! 196! 45!
Gender! Female! 168!(85)! 39!(87)!
! Female:Male! 5.1:1! 6.5:1!
Age! At!diagnosis!(years)! 12.6! 9.6!
! At!analysis!(years)! 17.4! 13.5!
Ethnicity! Caucasian! 103!(52)! 13!(29)!
! Black!Afro4Caribbean! 29!(15)! 19!(42)!
! Other!Asian! 12!(6)! 3!(7)!
! Indian! 18!(9)! 5!(11)!




! ARB! 24!(12)! 1!(2)!
Renal!Function! pBILAG!A4D! 141!of!176!(80)! 25!of!28!(89)!
! Proteinuria! 7(3.5)! 12!(27)!















Panel! on! Integrated! Guidelines! for! Cardiovascular! health! and! Risk!
Reduction!and!described!in!the!methodology!chapter.!!
Physical! activity! was! scored! using! the! iPAQ! (see! appendix! 7)! and!
expressed! in! Metabolic! Equivalent! of! Task! (MET).! “Low”! where! no!
activity!or!less!than!600!MET!minutes/week!are!recorded,!“moderate”!
where!600!–!1500!MET!minutes/week!are!recorded!and!“high”!where!
more! than! 1500! MET! minutes/week! are! recorded.! Median! physical!






Physical! Education! teacher! and! spent! almost! all! her! waking! hours!








(677! –! 2741)! V! 568! (0! –! 1689),! but! this! did! not! reach! statistical!
significance.!!
Median! BMI! was! 21.63! (18.19! –! 24.57)! with! a! mean! BMI! centile! of!
65.63±28.8.!For!the!control!group!median!BMI!was!21.7!(18.3!–!26.7)!
with!a!mean!BMI!centile!of!83.38±23.37.!The!difference!between!BMI!















were! 1.04! (0.76X1.93)mmol/l,! serum! HDL! was! 1.28±0.46mmol/l,! LDL!
was!2.35!(2.14X2.99)mmol/l!and!VLDL!was!0.64±0.4556mmol/l.!Table!
15.! Abnormalities! in! serum! lipids! were! correlated! with! duration! of!
disease,! younger! age! of! diagnosis,! mean! cIMT,! PWV,! eGFR,! increased!
systolic!blood!pressure!(SBP)!and!increased!BMI.!Those!with!a!serum!
cholesterol! greater! than! 5mmol/L! (n=9)! had! a! lower! mean! daily!
prednisolone!dose!of!0.26±0.27mg/kg!when!compared!to!those!with!a!














hsCRP!(mg/L)! 0.57(0.29<1.6)! 5! >1mg/dL!

























16! (35.6%)! of! children! were! on! medication! to! control! hypertension,!
however,! in! many! of! these! cases! they! were! treated! with! Angiotensin!
Converting!Enzyme!Inhibitor!(ACEXinhibitors)!and!angiotensin!receptor!
antagonists,!likely!chosen!as!much!to!minimize!proteinuria!as!to!control!




































2.9! (1.2X55.3)! mg/mmol.! In! an! effort! to! assess! the! effect! of! renal!
dysfunction!on!the!vascular!phenotype!I!examined!only!those!children!





















Age!(months)! 162±35! 160±38! 165±20!
Gender!(♀:♂)! 39:6! 29:4! 10:2!
BMI! 21.6(18.2<24.6)! 21.3(18.2<24.3)! 22.29(18.7<25.2)!
BMI!centile! 65.63±28.8! 63.7±29! 70.5±28.8!
Disease!duration!
(months)! 39(20.5<64.5)! 22(21.8<71)! 36.5(7.5<49.5)!
Positive!family!
history!of!CVD! 11!(24.4%)! 9!(27.3%)! 2!(16.6%)!
Treatment!for!






The! groups! were! similar! to! the! overall! cohort! with! regards! to! age,!






















they! have! a! significant! disease! burden! with! a! high! prevalence! of!
hypertension! and! renal! disease.! Thus! would! be! expected! to! have! a!
significantly!increased!risk!of!CVD.!!
When!compared!to!the!UKJSLE!cohort!study!the!ethnic!background!of!




mind,! however,! when! deciding! if! findings! from! this! cohort! can! be!
generalised!to!the!UK!cohort!as!a!whole.!!
The! fact! that! this! cohort! is! drawn! from! a! tertiary! paediatric! referral!









antiXhypertensive! were! evenly! split! between! low! and! moderate!

























greater! disease! duration,! increased! disease! severity! and! the! more!



























in! Great! Ormond! Street! has! been! used! with! her! generous!
permission.(62)!
Carotid!Intima!Media!Thickness!











There! was! no! statistically! significant! association! between! cIMT! and!
upper!or!lower!quartiles!of!age,!METs,!BILAG!score,!BILAG!renal!score!or!
disease!duration,!figure!18.!An!increase!in!cIMT!was!also!not!associated!
with! male! gender! or! a! family! history! of! CVD.! However,! cIMT! did!
correlate! weakly! with! sitting! minutes/week! (r2! =0.234,! p=0.176)! and!
BMI!centile!(r2!=0.276,!p=0.077).!See!also!tables!19!–!21.!For!upper!and!
lower!quartile!set!points!for!cIMT!and!PWV!see!table!22.!Those!with!a!










































Age!at!Diagnosis! ! ! ! !
Disease!Duration! ! ! 0.374! 0.019!
Age! ! ! 0.345! 0.023!
SBP! ! ! 0.352! 0.022!
METS/week! ! ! ! !
Sitting!Minutes/week! 0.234! 0.176! ! !
VLDL! ! ! ! !
LDL! ! ! 0.371! 0.048!
BMI!centile! 0.276! 0.077! ! !
eGFR! ! ! 0.331! 0.055!
!
Table!21.!PWV!and!cIMT!by!BILAG!score!
BILAG!Renal!Score! n! Mean!cIMT! Mean!PWV!
A/B! 5! 0.45±0.07mm! 5.7±1.09m/s!
C! 5! 0.48±0.04mm! 5.18±0.88!m/s!
D! 14! 0.46±0.05mm! 5.24±0.79!m/s!














cIMT! 44! 0.4543! 0.4450! 0.36! 0.55! 0.42! 0.4875!
PWV! 43! 5.272! 5.4! 3.4! 7.7! 4.7! 5.7!
!
Pulse!Wave!Velocity!





(p=0.77).! Increased! PWV! was! associated! with! disease! duration! (r2!
=0.374,!p=0.019),!age!(r2!=0.345,!p=0.023),!systolic!blood!pressure!(SBP)!
(r2! =0.352,! p=0.022),! LDL! (r2! =0.371,! p=0.048)! and! eGFR! (r2! =0.331,!
p=0.055).!!
There! was! no! statistically! significant! association! between! PWV! and!
upper! or! lower! quartiles! of! age,! BILAG! score,! BILAG! renal! score,!
prednisolone!dose,!METs!or!disease!duration,!see!figures!20!and!21.!An!
increase!in!PWV!was!also!not!associated!with!male!gender!or!a!family!
history! of! CVD,! see! tables! 19! –! 21.! Those! with! a! serum! cholesterol!
greater!than!5mmol/L!(n=9)!had!a!PWV!of!5.49±0.7m/s!whereas!those!
with!a!serum!cholesterol!less!than!5mmol/L!(n=36)!had!a!tendency!to!a!






















There! was! a! significant! association! between! the! use! of! antiX
hypertensives!and!an!increase!in!cIMT.!In!the!normotensive!group!not!
treated! with! antiXhypertensives! cIMT! was! 0.45±0.04mm! and! in! the!
group!treated!with!antiXhypertensives!it!was!0.47±0.05mm,!p=0.04.!The!
relationship! between! antiXhypertensive! use! and! cIMT! remained!
significant! even! after! controlling! for! total! BILAG! score,! prednisolone!



































the! Asian! population! and! both! the! Caucasian! and! AfroXCaribbean!






AfroXCaribbean! cohort! at! 0.47±0.04mm! lowest! in! the! Asian! cohort! at!
0.429±0.04mm.! In! the! Caucasian! cohort! it! was! 0.448±0.04mm.! This!
difference! was! statistically! significant! for! the! AfroXCaribbean! cohort!






















With! regards! to! their! vascular! phenotype! children! with! a! grossly!
elevated!UaUc!(described!previously)!had!an!elevated!cIMT!0.455!(0.43!–!
0.49)mm! V! 0.435! (0.42! –! 0.49)mm,! p=0.89! and! a! prolonged! PWV!




Median! cIMT! for! the! children! with! an! eGFR! <90! ml/min/1.73m2! was!
0.45!(0.4!–!0.5)!mm!and!for!those!with!an!eGFR!<70!ml/min/1.73m2!was!
0.45! (0.36! –! 0.55)! mm.! There! was! no! difference! when! compared! to!















Comparing! those! with! active! versus! quiescent! or! no! LN! was! not!
significant.! Those! with! a! renal! BILAG! score! of! A/B/C! had! a! cIMT! of!






































Age!(months)! 162±35! 160±38! 165±20!
Gender!(♀:♂)! 39:6! 29:4! 10:2!
BMI! 21.6(18.2<24.6)! 21.3(18.2<24.3)! 22.29(18.7<25.2)!


























There! were! significant! increases! in! cIMT! measurements! between!
controls!and!patients!receiving!no!prednisolone,!and!those!receiving!the!
lower! and! upper! quartiles! of! prednisolone! (0.087! and! 0.315mg/kg!
respectively).! The! cIMT! of! those! receiving! no! prednisolone! measured!
0.43±0.04mm,!and!this!increased!to!0.5±0.04mm!for!those!on!low!doses,!
and! 0.45±0.05mm! for! those! on! higher! doses.! There! was! a! significant!













Panel! on! Integrated! Guidelines! for! Cardiovascular! health! and! Risk!
Reduction!and!described!in!the!methodology!chapter.!These!children!had!
a!higher!PWV!than!those!with!a!negative!family!history!of!CVD,!5.6!(4.65!
–! 6.25)m/s! V! 5.25! (4.7! –! 5.75)m/s,! but! this! did! not! reach! statistical!
significance.!However,!this!was!not!reflected!in!their!cIMT!which!was!
marginally!lower!in!the!group!with!a!positive!family!history,!0.43!(0.4!–!







vessel! wall,! but! interestingly! has! not! shown! a! significant! increase! in!
PWV,! a! functional! measurement! of! vessel! health.! Indeed,! the! median!
PWV!was!lower!in!the!JSLE!cohort!than!in!controls,!suggesting!alternate!









(315),! which! used! the! same! protocols! as! ours,! showed! a! cIMT! of!
0.44±0.04mm! and! a! PWV! of! 4.86±0.7m/s! in! adolescents! with! wellX
controlled! diabetes! and! a! cIMT! of! 0.44±0.05mm! and! PWV! of!
5.0±0.84m/s!in!those!with!poor!control!and!proteinuria.!!
The! increase! in! both! cIMT! in! our! cohort! is! most! marked! in! the!
hypertensive! patients,! though! even! the! normotensive! patients! had!





and! either! the! overall! or! the! renal! BILAG! score,! or! indeed! the!





















early! compensatory! changes! resulting! in! normal! PWV! readings! are!
overwhelmed!with!time!and!if!the!increase!in!preXclinical!markers!of!
















body! mass! index! (BMI)! >30kg/m2,! waist! circumference! >88cm! or!
waist:hip! ratio! >0.85)! it! affects! up! to! 50%! of! adults! with! SLE.(87)!
Increased! waist! circumference! and! obesity! have! been! independently!





















and! one! patient! was! unable! to! remain! sufficiently! still! for! the! PWV!
scanning.!The!mean!age!of!the!children!was!123±43!months!at!diagnosis!
and!170±27.7!months!at!recruitment,!22!were!female.!15!children!and!









































on! the! oral! contraceptive! pill! and! 8! had! a! positive! family! history! of!
cardiovascular!disease.!Measures!of!physical!activity!varied!greatly!with!
a! median! of! 1499! (526! –! 3087)! METs/week,! corresponding! to! a!
moderate!degree!of!activity.!Daily!sitting!time!also!varied!greatly!with!a!
median!of!540!(480!–!840)!minutes/day.!!
Serum! cholesterol! was! 5.262±1.476mmol/L,! Triglycerides! were!
1.495±1.082! mmol/L,! HDL! was! 1.495±1.082mmol/L,! VLDL! was!
0.6478±0.455,! LDL! was! 3.18±1.34mmol/L.! GFR! was! estimated! at!
95.36±29.ml/min/1.73m2! and! 4! children! had! an! eGFR!
<90ml/min/1.73m2.!Median!BMI!centile!for!the!control!group!was!88.6!
(24! –! 98)! and! for! the! JSLE! group! was! 76.8! (36.8! –! 88.6)! and! the!
difference!between!groups!was!significant,!p=0.044.!!
Leptin!
Leptin! levels! were! 16.52(8.27! –! 27.27)ng/ml! in! the! JSLE! group! and!
7.56(0.99X16.7)ng/ml!in!the!control!group,!the!difference!between!the!






















Age!at!Diagnosis! 0.345! 0.0987! <0.159! 0.4573!
Age(M)! 0.352! 0.0847! 40.416! 0.0387!
cIMT! 0.196! 0.36! 0.433! 0.039!
PWV! <0.232! 0.27! 0.225! 0.302!
Systolic!BP! 0.482! 0.0172! 0.002! 0.9940!
Sitting!Time! 0.248! 0.2321! 0.440! 0.0276!
HDL! 0.045! 0.8638! 0.652! 0.0046!
LDL! 0.585! 0.0137! 0.267! 0.3007!
BMI!centile! 0.540! 0.0078! <0.220! 0.3130!
































































Leptin! 25! 24.14! 16.52! 0.48! 100.9! 8.274! 27.27!




level! of! 17.4! (7.8! –! 27.9)! ng/ml,! while! those! with! a! negative! family!
history!CVD!had!a!median!leptin!level!of!16.4!(7.9!–!30.9)!ng/ml.!
Adiponectin!







in! cIMT! (from! 0.45±0.05! to! 0.43±0.04,! p=0.39)! and! PWV! across! the!

































corresponding! rise! in! their! serum! adiponectin! levels,! 21.9±9.5! ug/ml!





































reduced! physical! activity! and! exercise(97).! This! is! potentially!







the! proteinuric! patients! and! the! nonXproteinuric! patients,! with! a!
doubling!of!both!leptin!and!adiponectin!levels!patients!with!a!UaUc!>!
20mg/mmol.! Though! these! are! small! numbers! they! reflect! what! has!
been!found!in!other!populations.!Proteinuria!has!been!linked!to!raised!
serum!leptin!levels!in!chronic!haemodialysis!patients(340)!but!the!study!
was! not! set! up! to! determine! whether! the! proteinuria! and! the! raised!
leptin!were!both!secondary!to!reduced!renal!function!or!whether!the!
raised! leptin! caused! the! proteinuria.! However,! in! examining! preX
eclampsia,!a!poorly!understood!placenta!mediated!condition,!specific!to!
pregnancy,! which! results! in! proteinuria! and! hypertension,! Ibrahim! et!
al(341)!investigated!the!effect!of!leptin!administration!on!systolic!blood!
pressure,!proteinuria!and!serum!markers!of!endothelial!activation!in!the!























controlling! for! smoking,! waist:hip! ratio,! microalbuminuria! and! serum!
lipids! suggesting! that! the! role! of! the! leptin:adiponectin! ratio! is!
multifactorial.!!
Interestingly,! there! is! some! evidence! to! suggest! that! the! protective!
effects!of!adiponectin!and!the!damaging!effects!of!leptin!in!potentiating!
atherosclerosis! could! disappear! in! individuals! with! advanced!





































functional! change,! demonstrated! by! a! normal! PWV.! This! structural!
change!is!particularly!marked!in!children!with!renal!inflammation,!as!
measured!by!proteinuria,!and!in!those!of!AfroXCaribbean!background.!!
Furthermore! I! have! shown! an! increase! in! both! serum! leptin! and!
adiponectin! in! patients! with! JSLE,! in! contrast! to! adult! data,! and!
suggested! that! an! increase! in! adiponectin! could! be! a! protective!











cardiolipin! Abs,! and! antiXC1q! Abs.! The! damage! caused! by! these!
antibodies!results!in!tissue!activation!and!a!generalised!state!of!systemic!
inflammation.! Specific! antibodies! such! as! antiXHDL! Abs! reduce! the!
body’s!defences!against!atherosclerosis!by!reducing!reverse!cholesterol!
transport.! While! within! the! vasculature! a! generalised! state! of!
inflammation! results! in! results! in! increased! endothelial! inflammation,!!
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increased! endothelial! cell! permeability! and! increased! endothelial!
adhesion!of!surface!molecules.!Further!autoXantibodies,!including!antiX
C1q! Abs,! lead! to! glomerulonephritis,! kidney! damage! and! proteinuria!
which!further!increases!CVD!(see!point!6).!
2.  Increased!serum!levels!of!leptin!are!seen!early!in!JSLE!as!evidenced!by!
this! cohort.! This! results! in! decreased! endothelial! cell! nitric! oxide!
mediated!vasodilation!reducing!the!blood!vessels!response!to!increased!
blood!flow!and!increasing!the!damage!caused!to!the!endothelial!cell!by!
the! sheer! stress! of! the! blood! flow.! Leptin! also! potentiates! a! proX!
inflammatory!Th1!response!and!decreased!Treg!function,!resulting!in!an!
atherogenic! phenotype.! It! stimulates! CD4+! T! cell! proliferation! and!
directly! stimulates! the! production! of! leptin! and! INFXγ! by! Th1! cells!
potentiating! macrophage! differentiation! to! foam! cells.! This!











4.  The! inflammatory! milieu,! leucocyte! production! of! INFXalpha! and! the!
generation! of! antibodies! against! antiXinflammatoryXHDL,! leads! to! the!
generation! of! proXinflammatoryXHDL.! This! results! in! activation! of! the!
endothelium! as! outlined! below! and! increased! generation! of! oxidised!
LDL.! A! reduction! in! antiXinflammatory! HDL! leads! to! reduced! reverse!!
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cholesterol! transport,! increased! generation! of! oxidised! LDL! and!
increased!macrophage!migration.!
5.  All! of! the! above! lead! to! endothelial! and! macrophage! activation.!
Endothelial!cell!activation!leads!to!increased!cell!permeability,!increased!
adhesion! of! surface! molecules! which! leads! to! increased! migration! of!
macrophages,! decreased! endothelial! cell! nitric! oxide! mediated!
vasodilation! and! increased! endothelial! cell! apoptosis.! Macrophage!
activation!and!migration!into!the!subXendothelial!space!acts!to!initially!
stabilise! the! inflammation! by! phagocytosis! of! oxidised! LDL.! This! is!
further!stimulated!by!production!of!INFXγ!by!leptin!activated,!Th1!cells.!






the! fledgling! atherosclerotic! plaque.! Differentiation! of! the! vascular!
smooth!muscle!cells!now!also!leads!to!medial!stiffening!and!thickening!












in! their! vessels! indicative! of! early! CVD! but! with! adaptive! changes!
resulting!in!normal!functional!scans.!!
The!current!evidence!does!not!support!pharmacological!treatment!of!the!
increased! CV! risk! in! JSLE! but! encouraging! children! to! keep! active,!
maintain!a!healthy!weight!and!avoid!cigarettes!is!important!as!is!the!
adequate! treatment! of! their! disease! and! any! renal! impairment.!
Educating!children!and!their!families!about!the!increased!CV!risk!in!SLE!
is!advisable!with!a!particular!emphasis!on!modification!of!traditional!CV!
risk! factors! and! the! adoption! of! a! healthy! lifestyle.! Somewhat!












endothelial! activation,! vitamin! D! and! the! plethora! of! idiosyncratic!








ethnicity,! and! is! limited! in! size.! Due! to! concerns! about! patient!
compliance! and! a! lack! of! normative! data! for! younger! children,! the!
vascular!scans!did!not!include!FMD,!which!could!have!provided!a!more!






beneficial! to! all! parties.! Furthermore! utilising! current! steroid! dose!
rather!than!cumulative!steroid!load,!though!expedient,!may!have!limited!
the!findings.!The!development!of!CVD!is!a!prolonged!process,!beginning!
in! early! childhood,! and! the! cumulative! steroid! and! disease! load! is!
arguably!more!significant!than!a!one!off!reading!which!could!reflect!a!





time.! This! follow! up! study! should! define! progression! of! cIMT! and!
identify! whether! PWV! becomes! abnormal! over! time,! along! with!
measurement!of!FMD!to!assess!endothelial!function.!It!should!examine!
more!closely!the!effect!of!treatment!modalities!and!renal!function!on!
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13 Abstract
14 Background The increased risk of cardiovascular disease
15 (CVD) in adults with systemic lupus erythematosus (SLE)
16 has been known since the 1970s, but studies in juvenile-
17 onset SLE (JSLE) have reported conflicting results and more
18 data are needed. The aim of this cross-sectional study was to
19 establish the baseline risk of CVD in a cohort of UK patients
20 with JSLE.
21 Methods Data were collected to establish disease duration,
22 disease activity, medication use and activity levels, as well
23 as demographic data, including family history of CVD.
24 Vascular phenotype was established using well-validated
25 measures of carotid intima media thickness (cIMT) and pulse
26 wave velocity (PWV).
27 Results In total, 45 children (39 female; mean age 13.5±
28 2.9 years) with JSLE were recruited to the study. Of these,
29 24 had a history of biopsy-proven lupus nephritis and five had
30 an estimated glomerular filtration rate of <90 ml/min/1.73 m
2.
31 Comparison of these JSLE patients with healthy controls
32 previously scanned at our hospital revealed that the cIMT
33 value was significantly higher in the former (0.45 vs.
34 0.37 mm, respectively; p<0.0001). This difference was asso-
35 ciated with the use of antihypertensives (p=0.04) and higher
36 or lower doses of prednisolone (p<0.0001). PWV was not
37 significantly different in the patient and control group (5.27
38 vs. 5.34 m/s, respectively; p=0.77). In the patient group, the
39 mean body mass index percentile was 65.63±28.8, and the
40 median physical activity score was 1,773 (676–2,854) meta-
41 bolic equivalents of task (METs). None of the patients ad-
42 mitted to cigarette smoking, and ten had a positive family
43 history of cardiovascular disease (CVD).
44 Conclusion This study shows that our patients with JSLE had
45 increased cIMTwithout an increase in PWV, suggesting pos-
46 sible early adaptive changes in JSLE. Follow-up data are
47 needed to determine whether these changes result in clinically
48 significant CVD.
49 Keywords Cardiovascular .Lupus .Ethnicity .Physical
50 activity .Lipids .Steroids
51 Introduction
52 Individuals with adult onset systemic lupus erythematosus
53 (SLE) were first identified as having an increased risk of car-
54 diovasculardisease(CVD)over35yearsagobyUrowitzetal.
55 [1]. In subsequent years, the increased risk of cardiovascular
56 (CV) events among adults with SLE has been confirmed in a
57 numberofprospectivestudies[2–4]whichhavedemonstrated
58 that individuals with SLE have a higher increased risk of CV
59 events than their unaffected peers.
60 The increased risk of CVD in chronic inflammatory dis-
61 eases is well recognised, and several adult studies have shown
62 an abnormal vascular phenotype in SLE. There is evidence
63 to suggest that the change in phenotype may be due not only
64 to disease-specific risk factors (such as severity and duration
65 of disease [5–7], renal impairment [8–10] and medications
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66 [1, 11–17]) but also to a clustering of traditional risk factors
67 (such as increasing age, obesity, smoking and reduced phys-
68 ical activity [15, 18–20]).
69 Children with SLE tend to have a more aggressive disease
70 thanadults,withahigherincidenceofarthritis,lupusnephritis
71 (LN) and neurological involvement [21]. Since disease sever-
72 ity and duration are closely linked to CVD in the adult SLE
73 population, it is reasonable to assume that the paediatric pop-
74 ulation would similarly be at increased risk of CVD. Despite
75 the wealth of data available on CVD risk in adults with SLE,
76 there is a dearth of information about CVD risk in children
77 with juvenile-onset SLE (JSLE), and most of our knowledge
78 is extrapolated from adult studies. Although childhood lupus
79 is often a more aggressive disease than its adult form, the
80 greater plasticity of children’s vessels may protect them from
81 vascular disease, making extrapolations from adult studies
82 difficult; published studies [22–27] to date have reported con-
83 flicting results. The cross-sectional study reported here was
84 designed to establish the baseline CVrisk of a cohort of chil-
85 dren with JSLE prior to subsequent longitudinal follow-up
86 studies. In addition, since children should be free of the clas-
87 sical risk factors for CVD, studying their risk profile may add




92 of Rheumatology classification criteria [28] and who attended
93 the nephrology or rheumatology services in Great Ormond
94 Street Hospital for Children NHS Foundation Trust were in-
95 vited to take part in the study ( Q1 referred to as the CV JSLE
96 Cohort Study). Those aged <5 years and diagnosed with
97 end-stagekidneydiseaseorwithin6weeksofamajorsurgical
98 procedure were excluded.
99 The study was approved by the Institute of Child Health
100 and Great Ormond Street Hospital research ethics committee
101 and The Children’s University Hospital, Dublin.
102 Measurement of carotid artery intima media thickness
103 In this study carotid artery intima media thickness (cIMT)
104 was measured by B-mode ultrasound of both common
105 carotid arteries using a single ultrasound machine
106 (Vivid7, GE Medical, Horton, Norway) equipped with a
107 12-MHz linear-array transducer [29]. Following visualisa-
108 tion of the common carotid artery, a 15-heartbeat cine-loop
109 recording was stored for offline analysis using Digital
110 Imaging and Communications in Medicine software (DICOM;
111 National Electrical Manufacturers Association, Rosslyn, VA).
112 The mean IMT of a 0.5- to 1-cm-long segment was measured
113 1c mp r o x i m a lt ot h ec a r o t i db i f u r c a t i o n ,u s i n ga na u t o m a t e d
114 edge detection system, on two separate images of the right and
115 left common carotid artery from true end-diastolic frames, as
116 determined by minimum vessel diameter. Approximately 120
117 individual measurements were made across a 1-cm length of
118 artery; this measurement was repeated for three different cardiac
119 cycles and the average of the three measurements from right and
120 left was recorded.
121 Measurement of pulse wave velocity
122 Pulse wave velocity (PWV) was determined by using a pressure
123 sensor over the carotid and femoral arteries and calculated as the
124 pulse wave travel distance divided by the time difference be-
125 tween the rise delay of the distal and proximal pulse, as mea-
126 sured by the R wave on the electrocardiogram. In this project,
127 PWV was calculated by SphygmoCor software (AtCor
128 Medical, Sydney, Australia) using the intersecting tangent algo-
129 rithm. The pulse travel distance was calculated as the distance
130 from the suprasternal notch to ther e c o r d i n gp o i n ta tt h ef e m o r a l
131 arteryvia the umbilicus minusthe distance fromthesuprasternal
132 notch to the recording point at the carotid artery [30].
133 Data collection
134 Ap i l o tv e r s i o no ft h eq u e s t i o n n a i r ew a st r i a l e di nT h e
135 Children’sU n i v e r s i t yH o s p i t a l ,D u b l i na n dw a su s e dt or e c o r d
136 demographic data, treatment information and risk factors for
137 CVD. Routine blood samples were processed by the depart-
138 ments of Haematology, Immunology and Clinical Chemistry at
139 Great Ormond Street Hospital for Children NHS Foundation
140 Trust.
141 Body mass index (BMI) and percentiles were calculated
142 using the Centre for Disease Control and Prevention BMI-
143 for-age growth chart (www.cdc.gov). A positive family
144 history of CVD was defined as per the Expert Panel on
145 Integrated Guidelines for Cardiovascular health and Risk
146 Reduction [31]a saC Ve v e n ti nam a l er e l a t i v eb e f o r e
147 55 years of age or in a female relative before 65 years of
148 age. Family history included siblings, parents, uncles, aunts,
149 grand-parents, grand-aunts and grand-uncles. Estimated glo-
150 merular filtration rate (eGFR) was calculated by the Schwartz
151 formula with a K value of 34, as calculated locally [32].
152 pBILAG–2004 score
153 Many of the children recruited to this study (CV JSLE Cohort
154 Study) were also co-recruited to the UK JSLE Cohort Study
155 [21]. As part of the protocol the paediatric adaptation of the
156 2004 British Isles Lupus Assessment Group (pBILAG–2004)
157 disease activity index was measured at 3-month intervals and
158 included in the analysis where available. The pBILAG–2004
159 indexwas developedasanintention-to-treatindex; it has been
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160 validatedinaUKpaediatriccohort[33]andshowntobemore
161 sensitive than the SLE Disease Activity Index (SLEDAI)–
162 2000 to detect active disease [34]. It is an ordinal scale index
163 with nine systems (Constitutional, Mucocutaneous,
164 Neuropsychiatric, Musculoskeletal, Cardiorespiratory,
165 Gastrointesinal,Opthalmic,RenalandHaematological)which
166 dividesdiseaseactivityintofivecategorieswhereArepresents
167 very active disease, B represents moderate disease, C repre-
168 sents mild stable disease, D represents previous disease and E
169 represents no current or previous disease. A continuous total
170 score has been developed and validated [35] and was used in
171 this study to represent systemic disease burden.
172 Calculation of physical activity
173 TheInternationalPhysicalActivityQuestionnaire(IPAQ)[36]
174 was used to estimate the physical activity of the study cohort.
175 This short version of this questionnaire was chosen as a well-
176 developed, internationally recognised instrument which en-
177 ables scoring of the cohort by metabolic equivalents of task
178 (MET). This questionnaire proposes three levels of physical
179 activity: “low” where there is no activity or <600 MET min/
180 week are recorded; “moderate” where 600–1500 MET min/
181 week are recorded; “high” where >1,500 MET min/week are
182 recorded. This scoring protocol was recently used by Katz
183 et al. [37] to show that 28 % of 138 women with SLE with a
184 mean age of 18 years scored <600 MET min/week.
185 Statistics
186 For normally distributed data results are reported as the mean±
187 standarddeviation(SD),andcomparisonsbetweenmeanswere
188 made using unpaired t test results (2-tailed). For non-normally
189 distributed data, results are reported as the median± interquar-
190 tilerange(IQR),andcomparisons betweenmedians weremade
191 using the Mann–Whitney test. Correlations were made using
192 Pearson’sc o r r e l a t i o nc o - e f f i c i e n to rS p e a r m a n ’st e s td e p e n d i n g
193 on data distribution.
194 Within this project a p value<0.05 was determined to have
195 reached significance. Statistical analyses were performed in
196 GraphPad Prism version 6.0b for Mac OS X, and multiple
197 regressionanalysiswasperformedusingGraphPadInStatver-




202 Forty-five children were recruited to our study, among
203 whom 39 were girls. The median age of the children was 9.75
204 (IQR 7.23–12.6) years at diagnosis and 14 (IQR 12.2–15.5)
205 years at recruitment. Forty-four consented to have all vascular
206 scans performed, and one patient was unable to remain suffi-
207 ciently still for the PWV scanning. Thirty-five children of these
208 children were also recruited to the UK JSLE Cohort Study;
209 pBILAG-2004 scores were calculated and vascular assessments
210 were performed for 28 of these children [Electronic
211 Supplementary Material (ESM)]. The control group comprised
212 subjects who had participated in previous studies [38]f r o mo u r
213 centre and who were matched for historical age. Demographic
214 details of patients and controls are outlined in Table 1.
215 Nineteen children identified themselves as Afro-Caribbean,
216 of whom 13 identified themselves as of African descent, two as
217 Black British and four as Black Caribbean. Thirteen children
218 identified themselves as Caucasian and ten as Asian (5 Indian,
219 1P a k i s t a n i1C h i n e s e ,3“other Asian”). One child was
t1:1 Table 1 Demographic, clinical and anthropometric characteristics
of children and young adults with juvenile-onset systemic lupus
erythematosus and controls






t1:3 Age (years) 14 (12.2–15.5) 13.2±4.8
t1:4 Female (n) 39 19
t1:5 Weight (kg) 50.5(36.5–62)
t1:6 Height (cm) 150.1±16
t1:7 BMI 21.63 (18.19–24.57)
t1:8 BMI percentile 65.63±28.8
t1:9 Biopsy-proven lupus nephritis (n) 24
t1:10 Disease duration (months) 39 (20.5–64.5)
t1:11 Age at diagnosis (months) 115±42
t1:12 Cigarette smoking (n)0
t1:13 Oral contraceptive pill (n)1
t1:14 Positive family history of CVD (n)1 1
t1:15 Current prednisolone (mg/kg) 0.07 (0–0.23)
t1:16 No prednisolone (n) 16
t1:17 Normotensive without anti-
hypertensive medication (n)
26





t1:23 METs/week 1,773 (676.5–2,854)
t1:24 Sitting (min/day) 505±144.2
t1:25 Mean cIMT (mm) 0.445 (0.42–0.49) 0.37±0.06
t1:26 Mean PWV (m/s) 5.272±0.88 5.34±0.97
Dataare presented asthemean±standard deviation (SD) oras themedian
with the interquartile range (IQR) in parenthesis, unless indicated
otherwise
JSLE, Juvenile-onset systemic lupus erythematosus; BMI body mass in-
dex; CVD, cardiovascular disease; METS, metabolic equivalent of task;
cIMT, carotid intima media thickness; PWV, pulse wave velocity
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220 Afghani, one was Turkish Cypriot and one declined to answer
221 this question. The ethnic composition of our patient group dif-
222 fers from that of the overall UK JSLE Cohort, as outlined in
223 Table 2,w h e r et h em a j o r i t yo fc h i l d r e nw e r eC a u c a s i a na n d
224 almost one-third were Black Afro-Caribbean. By contrast, of
225 the45childrenenrolledinourstudy(CVJSLECohortStudyin
226 Table 2), 19 were Black Afro-Caribbean and 13 were
227 Caucasian, which reflects the ethnic diversity of London rela-
228 tive to the rest of the UK.
229 Median disease duration was 39 (IQR 20.5–64.5) months.
230 Disease activity was assessed using the pBILAG–2004 dis-
231 ease activity score within 3 months of recruitment. The medi-
232 an pBILAG-2004 score was 3.5 (IQR 1.25–5.75), which is in
233 line with that of the treated national cohort group (UK JSLE
234 Cohort Study) which had a median pBILAG–2004 score at
235 12 months after diagnosis of 2 (IQR 1–4).
236 Traditional CV risk factors
237 No children admitted to cigarette smoking, and one child had
238 started taking the oral contraceptive pill 1 month previous to
239 recruitment. Ten children had a positive family history of
240 CVD as defined by Expert Panel on Integrated Guidelines
241 for Cardiovascular health and Risk Reduction.
242 The mean serum cholesterol level was 4.4 (IQR 3.95–5.2)
243 mmol/l, serum triglycerides were 1.04 (0.76–1.93) mmol/l, se-
244 rum high-density lipoprotein (HDL) was 1.28±0.46 mmol/l,
245 low-density lipoprotein (LDL) was 2.35 (2.14–2.99) mmol/l
246 and very-low-density lipoprotein was 0.64±0.4556 mmol/l.
247 Nine children had a serum cholesterol >5 mmol/l, eight
248 had a serum HDL of <1 mmol/l and four had a serum
249 LDL of >3.5 mmol/l.
250 For those children with a serum cholesterol of >5 mmol/l,
251 mean cIMT was 0.47±0.05 mm and mean PWV was 5.49±
252 0.7m/s;forthosewithaserumcholesterolof<5mmol/l,mean
253 cIMTwaslowerat0.45±0.04mmandPWVwasalsolowerat
254 5.24±0.8 m/s. Neither result reached statistical significance.
255 Abnormalitiesinserumlipidswerecorrelatedwithdurationof
256 disease, younger age of diagnosis, mean cIMT, PWV, eGFR,
257 increased systolic blood pressure (SBP) and increased BMI.
258 Those childrenwitha serumcholesterolof>5mmol/lwereon
259 a lower mean dose of prednisolone (0.26±0.27 mg/kg) than
260 thosewithaserumcholesterolof<5mmol/l(4.28±5.9mg/kg)
261 (p=0.054), possibly indicating that higher cholesterol was
262 associated with disease activity rather than secondary to
263 medications.
264 Mean BMI percentile was 65.63±28.8. The median phys-
265 ical activity score was 1773 (IQR 676–2854) METs, which
266 correlated with duration of disease (r
2=0.33, p=0.04). The
267 median physical activity score was 1,773 (IQR 676–2,854)
268 METs, which correlated with duration of disease (r
2=0.325,
269 p=0.038). These results correspond to a high level of activity,
270 but there was significant heterogeneity within the group.
271 Interestingly, children with a positive family history of CVD
272 had a higher median MET score than those with no family
273 history of CVD [1,738 (IQR 677–2,741) vs. 568 (IQR 0–1,
274 689) METs, respectively], but this difference did not reach
275 statistical significance. Not surprisingly, there was a strong
276 correlation between BMI percentile and physical activity.
277 The median BMI percentile for children with a low MET
278 score,i.e. <600MET, was 88.2(IQR49.9–97.5) and for those
279 with a high MET score, i.e. >1500 MET, it was 65.8 (32.5–
280 85.5); this difference did not reach statistical significance.
281 Vascular phenotype
282 Carotid intima media thickness
283 Forty-four children with JSLE had cIMT measurements; the
284 control group consisted of 40 patients. Mean cIMT for the
285 control group and JSLE group was 0.37±0.06 and 0.45±
286 0.04 mm, respectively (Fig. 1). Children with JSLE had a
287 significant increase in mean cIMT of 0.08 mm when com-
288 pared with the controls (p<0.0001.) There was no statistically
t2:1 Table 2 Q2 Comparison of patient demographic data for the UK Juvenile-
onset Systemic Lupus Erythematosus (JSLE) Cohort Study and the CV
JSLE study




t2:3 Total number of children 196 45
t2:4 Gender
t2:5 Female 168 (85) 39 (87)
t2:6 Female:male 5.1:1 6.5:1
t2:7 Age
t2:8 At diagnosis (years) 12.6 9.6
t2:9 At analysis (years) 17.4 13.5
t2:10 Ethnicity
t2:11 Caucasian 103 (52) 13 (29)
t2:12 Black Afro-Caribbean 29 (15) 19 (42)
t2:13 Other Asian 12 (6) 3 (7)
t2:14 Indian 18 (9) 5 (11)




48 (24) 12 (27)
t2:18 Angiotensin receptor blocker (ARB) 24 (12) 1 (2)
t2:19 Renal function
t2:20 pBILAG-2004 (A–D) 141/176 (80) 25/28 (89)
t2:21 Proteinuria 7(3.5) 12 (27)
t2:22 Estimated glomerular filtration rate
(eGFR) <50 %
1 (0.5) 0
Data are presented as the number with the percentage in parenthesis
pBILAG-2004, Paediatric British Isles Lupus Assessment Group disease
activity index
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289 significant association between cIMT and upper or lower
290 quartiles of age, METs, pBILAG–2004 score, pBILAG–
291 2004 renal score or disease duration. An increase in cIMT
292 was also not associated with male gender or a family history
293 of CVD. However, cIMT did correlate weakly with the num-
294 ber of sitting min/week (r
2=0.234, p=0.176) and BMI per-
295 centile (r
2=0.276, p=0.077).
296 Pulse wave velocity
297 Forty-three children with JSLE had PWV measurements; the
298 control group consisted of 40 children. Mean PWV for the
299 control and patient groups was 5.34±0.97 and 5.27±0.88 m/s,
300 respectively (Fig. 2). Children and young adults with JSLE had
301 a1 . 2%l o w e rP W Vt h a nt h ec o n t r o l s ,b u tt h i sd i f f e r e n c ew a s
302 not statistically significant (p=0.77).IncreasedPWVwasasso-
303 ciated with disease duration (r
2=0.37, p=0.02), age (r
2=0.35,
304 p=0.02), SBP (r
2=0.35, p=0.02), LDL (r
2=0.37, p=0.048)
305 and eGFR (r
2=0.331,p=0.06).
306 There was no statistically significant association between
307 PWVand the upper or lower quartiles of age, pBILAG–2004
308 score, pBILAG–2004 renal score, prednisolone dose, METs
309 or disease duration. An increase in PWV was also not associ-
310 ated with male gender or a family history of CVD (Table 3).
311 Renal function and hypertension
312 All 45 JSLE patients were normotensive at the time of the
313 study. Twenty-six were not taking any anti-hypertensive med-
314 ication, and 15 were on a single medication [enalapril (9 pa-
315 tients), amlodipine (4) furosemide (1) and irbesartan (1)], two
316 were on two medications, one was on three medications and
317 one patient required four medications to maintain normal
318 blood pressure.
319 There was a significant association between the use of an-
320 tihypertensives and an increase in cIMT. The cIMT in the
321 normotensive group not treated with antihypertensives and
322 in the normotensive group treated with antihypertensives
323 was 0.45±0.04 and 0.47±0.05 mm, respectively (p=0.04).
324 The relationship between antihypertensive use and cIMT
325 remained significant even after controlling for total
326 pBILAG–2004 score, prednisolone dose, age, family history
327 of CVD and gender (p=0.04). In the absence of antihyperten-
328 sive medication, the mean cIMT for patients with JSLE was
329 significantly higher than that of controls at 0.45±0.04 mm
330 (p<0.0001). (see Fig. 3).
331 There was a significant association between the use of an-
332 tihypertensives and an increase in PWV. The PWV in the
333 normotensive and anti-hypertensive groups was 5.13±0.6
334 and 5.69±1.13 m/s, respectively (p=0.043). Similar to the
335 cIMTfindings,the PWVwasincreasedinthesechildrencom-
336 pared to the controls, even in the absence of anti-hyperten-
337 sives, from 5.34±0.97 to 5.13±0.06 m/s; however this differ-
338 ence was not statistically significant (p=0.132).
339 Those children defined as hypertensive may only have had
340 a low level of hypertension (HTN) and proteinuria. The me-
341 dian urine albumin-to-creatinine ratio (UaUc) for the JSLE
342 cohortwas2.9(IQR1.2–55.3)mg/mmol.Inanefforttoassess
343 the effect of renal dysfunction on the vascular phenotype we
344 examined only those children with a grossly elevated UaUc
345 (>20 mg/mmol) and compared their vascular phenotype with
346 both the group asa wholeandwitha those with a UaUccloser
347 to the normal range (Table 3). The median UaUc of the two
348 subgroups were similar to that of the overall cohort with
349 regards to age, gender, disease duration and BMI. Not unsur-
350 prisingly, the children with elevated UaUc were significantly
351 more likely to be concurrently treated with antihypertensive
352 medication, most commonly an angiotensin-converting en-
353 zyme inhibitor (ACEi), which was used as much for the man-
354 agement of proteinuria as for the management of HTN.
355 With regards to their vascular phenotype, children with an
356 elevated UaUc had an elevated cIMT [0.455 (IQR 0.43–0.49)
357 vs. 0.435 (0.42–0.49) mm] and a prolonged PWV (5.564±
358 0.72 vs, 5.172±0.92 m/s). However, the numbers were too
359 small to reach statistical significance.
360 Median eGFR was 103.3 (IQR 95.65–113.3) ml/min/
361 1.73 m




Fig. 1 Comparison of carotid intima media thickness (cIMT) between
controls and patients with juvenile-onset systemic lupus erythematosus
(JSLE)
Fig. 2 Comparison of pulse wave velocity (PSV) between controls and
patients with JSLE
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363 Median cIMT for the children with an eGFR of <90 ml/min/
364 1.73 m
2 ml/min/1.73 m
2 and for those with an eGFR of
365 <70 ml/min/1.73 m
2 ml/min/1.73 m
2 was 0.45 (IQR 0.4–
366 0.5) and 0.45 (IQR 0.36–0.55) mm, respectively. There was
367 no difference when compared to children with JSLE and an
368 eGFR >90 ml/min/1.73 m
2. The difference between medians
369 was not significant (p=0.556). However, median PWV for
370 children with an eGFR of <90 ml/min/1.73 m
2 and those with
371 an eGFR of <70 ml/min/1.73 m
2 was 5.7 (IQR 5.5–6.6) and
372 6.8 (IQR 5.7–6.9) m/s, respectively. This is an increase of
373 1.1 m/s when compared to children with an eGFR of
374 >90 ml/min/1.73 m
2 and JSLE, and this difference did reach
375 statistical significance despite the small numbers (p=0.0277).
376 Renal involvement was also assessed using the pBILAG–
377 2004 score for those who had performed this test, and the data
378 are summarised in Table 4. One child was diagnosed with
379 severerenaldiseaseactivity(categoryA),fivewerediagnosed
380 with moderate renal disease activity (category B), five were
381 diagnosed with stable renal disease activity (category C), 16
382 were diagnosed with currently quiescent but previously active
383 renal disease (category D) and only three of the 30 children
384 testedweredefinedasnorenalinvolvementever(categoryE).
385 Those with current LN (categories A/BC) had slightly in-
386 creased cIMT (0.46±0.06 mm) compared with those with
387 quiescent LN (categories D/E; 0.45±0.04 mm) (p=0.73).
388 Similarly, there was little change in the PWV (5.46±0.95 vs.
389 5.43±0.74 m/s; p=0.78).
390 Prednisolone and the vascular phenotype
391 There was significant increase in cIMT between controls and
392 patients receiving no prednisolone, and those receiving the
393 lower and upper quartiles of prednisolone (0.087 and
394 0.315 mg/kg, respectively). The cIMT of those receiving no
395 prednisolone measured 0.43±0.04 mm, which increased to
396 0.5±0.04 mm for those on low doses and to 0.45±0.05 mm
397 forthoseonhigherdoses.Therewasasignificantdifferencein
398 cIMT between controls and those onall doses ofprednisolone
399 (p<0.05) andbetweenthoseonnoprednisoloneandthe lower
400 quartile (p=0.0018) (Fig. 4).
Fig. 3 Comparison of cIMT between controls and patients with JSLE
according to use of anti-hypertensive medication
t4:1 Table 4 Pulse wave velocity and carotid intima media thickness bythe
pBILAG–2004 score
t4:2 pBILAG renal score
a n Mean cIMT Mean PWV
t4:3 A/B 5 0.45±0.07 mm 5.7±1.09 m/s
t4:4 C 5 0.48±0.04 mm 5.18±0.88 m/s
t4:5 D 14 0.46±0.05 mm 5.24±0.79 m/s
t4:6 E 3 0.44±0.02 mm 5.43±0.95 m/s
All data are presented as the mean±SD
aPBILAG–2004 categories: A, very active disease; B, moderate disease;
C, mild stable disease; D, previous disease; E, no current or previous
disease
t3:1 Table 3 Demographic, clinical and anthropometric characteristics of children and young adults with JSLE and a normal or grossly elevated urine
albumin-to-creatinine ratio
t3:2 Demographic, clinical and anthropometric characteristics Children with JSLE (n=45) UaUc <20 mg/mmol (n=33) UaUc >20 mg/mmol (n=12)
t3:3 UaUc (mg/mmol) 2.9 (1.2–55.3) 1. (0.95–3.5) 164.6 (55.3–304.9)
t3:4 Age (months) 162±35 160±38 165±20
t3:5 Gender (♀:♂) 39:6 29:4 10:2
t3:6 BMI 21.6 (18.2–24.6) 21.3 (18.2–24.3) 22.29 (18.7–25.2)
t3:7 BMI centile 65.63±28.8 63.7±29 70.5±28.8
t3:8 Disease duration (months) 39 (20.5–64.5) 22 (21.8–71) 36.5 (7.5–49.5)
t3:9 Positive family history of CVD 11 (24.4 %) 9 (27.3 %) 2 (16.6 %)
t3:10 Treatment for hypertension 16 (35.5 %) 9 (27.3 %) 8 (66.7 %)
t3:11 METS/week 1,773 (676.5–2,854) 2,190 (1,127–3,306) 886 (615–1,648)
t3:12 Median cIMT (mm) 0.445 (0.42–0.49) 0.435 (0.42–0.495) 0.455 (0.43–0.49)
t3:13 Mean PWV (m/s) 5.272±0.88 5.172±0.92 5.564±0.72
Data are presented as the mean±SD or median with the IQR in parenthesis, unless indicated otherwise
UaUc, Urine albumin-to-creatinine ratio
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401 Ethnicity and the vascular phenotype
402 When analysed by ethnicity there was a significant difference
403 between the Asian population and both the Caucasian and
404 Afro-Caribbean population, despite the small overall num-
405 bers. One Caucasian child was unable to remain still for the
406 PWV reading and one Afro-Caribbean child declined to con-
407 sent to vascular scanning. Mean cIMT was highest in the
408 Afro-Caribbean cohort (0.47±0.04 mm) and lowest in the
409 Asian cohort (0.429±0.04 mm); the Caucasian cohort had a
410 median cIMT of 0.448±0.04 mm. This difference was statis-
411 tically significant for the Afro-Caribbean cohort compared to
412 the Asian cohort (p=0.017), but it did not meet statistical
413 significance when comparing the other cohorts (Fig. 5).
414 There was a similar difference noted among the PWV re-
415 sults. Mean PWV was highest for the Afro-Caribbean cohort
416 (5.339±0.74 m/s) but lowest for the Caucasian population
417 (5.225±1.148). The high standard deviation suggests greater
418 spread amongst this group. Mean PWVamong the Asian co-
419 hort was 5.31±0.69 m/s. None of these comparisons reached
420 statistical significance.
421 Discussion
422 There is strong epidemiological evidence to show that adult
423 onset SLE is associated with an increased risk of clinical and
424 preclinical CVD. However, the increased prevalence of tradi-
425 tional risk factors in this cohort, such as smoking and obesity,
426 makes it difficult to study the effect of SLE-specific factors
427 and interventions, since many SLE patients will already have
428 a significant lifetime CV risk due to non-modifiable risk fac-
429 tors, such as a lifetime of smoking. The aim of our study was
430 to establish the risk of CVD in a population free from these
431 traditional risk factors and, thereby, perform a closer analysis
432 of disease-specific risk factors.
433 Patients with JSLE generally have more severe disease,
434 with a greater prevalence of LN [21], and will have a longer
435 lifetime burden of disease. To date, the results of published
436 studies examining CVD in JSLE have been conflicting, and
437 many of the published studies have lacked control groups and
438 thus relied on the correlation of risk factors with changes in
439 vascular measures.
440 cIMT is a measurement of the intima and media layers
441 lining the carotid artery. It is a measure of very early structural
442 changes in the artery and an important surrogate marker for
443 atherosclerosis. Carotid–femoral PWV is a measurement of
444 the time delay between the foot of the pulse pressure arriving
445 at the carotid and femoral arteries, and it is a widely used
446 method to determine arterial stiffness [39, 40]. This cohort
447 of children and adolescents with SLE and normal renal func-
448 tion have an increased cIMT, i.e. a structural change in the
449 vessel wall, but without an increase in PWV, which is a func-
450 tionalmeasurementofvesselhealth.Indeed,the medianPWV
451 was lower in our JSLE cohort than in the controls, suggesting
452 alternate pathways for the development of CVD in JSLE or a
453 degreeofcompensationintheearlystagesofSLE,whichmay
454 be overwhelmed in time.
455 In a study designed to assess the effect of atorvastatin on
456 the progression of subclinical atherosclerosis, as measured by
457 cIMT, Schanberg et al. [22, 24]f o u n dam e a nc I M To f
458 0.468 mm, similar to our data. Increased cIMTwas associated
459 with both a high and low dose of prednisolone, BMI, in-
460 creasedageandcreatinineclearance.This studyincludedchil-
461 dren with mildly active disease (mean SLEDAI 4.6), with
462 36 % having LN and 34 % having HTN. In contrast, our
463 patients showed a greater prevalence of active LN.
464 Secondary analysis of the data reported by Schanberg et al.
465 [22, 24] showed that atorvastatin may slow the progression of
466 cIMT thickening only in a subgroup of pubertal patients with
467 higher high-sensitivity C-reactive protein [23]. In contrast to
468 our findings, Boros et al. [27] found an increase in PWV, but
469 no increase in cIMT or flow-mediated dilatation, among a
470 cohort of children with SLE. Although these authors showed
471 an increased burden of traditional and non-traditional CVrisk
472 factorsamongthecohort,suchasHTN,thesedidnotcorrelate
Fig. 4 Comparison of cIMT between controls and patients with JSLE
according to daily dose of prednisolone [quartiles: none lower, higher
(mg/kg/day)]
Fig. 5 Comparison of cIMT between patients with JSLE erythematosus
by ethnic background
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473 with changes in vascular measures. When subdivided by dis-
474 ease activity, El Gamal et al. [26] showed increased PWV in
475 hypertensive patientswith active SLE when compared tocon-
476 trols, but no difference between controls and patients with
477 inactive disease as defined by SLEDAI.
478 Interestingly, Sozeri et al. [25] showed significantly in-
479 creasedcIMTandPWVinpatientswithlupuswhencompared
480 with controls. In this study, cIMT correlated with disease ac-
481 tivity but not with HTN or LN. However, in the ten patients
482 (20 %) with HTN (8 of whom had left ventricular hypertro-
483 phy),theauthorsfoundanincreasedPWV;theyalsoshoweda
484 marginal increase in PWV in those with biopsy-proven LN
485 when compared to those with normal renal biopsies.
486 The increase incIMTinour cohortwas mostmarked inthe
487 patients treated with antihypertensives. Since the commonest
488 antihypertensive in use was an ACEi, which is also used to
489 control proteinuria, the difference between groups may be
490 explained by renal involvement or severity of disease.
491 However, there we found no correlation between cIMT or
492 PWVand either the overall or the renal pBILAG–2004 score,
493 or indeed the prednisolone dose, which could be presumed to
494 be a reasonable surrogate marker for disease severity.
495 In this study, we found no difference in BMI percentiles
496 between patients and controls, a low prevalence of sedentary
497 behavior and no effect of smoking. Indeed, in contrast to their
498 adult counterparts [37], this cohort of children with JSLE
499 showed high levels of activity, with a median of 1,773
500 METs per week, corresponding to a high level of physical
501 activity. Encouraging an active lifestyle during clinical en-
502 counters is one way in which paediatricians could potentially
503 reduce their patients’ future burden of CVD.
504 Disease duration has been shown to increase the risk of a
505 CV event in adults with SLE and has been associated with
506 subclinical CVD as measured by coronary calcium scores
507 [6, 7, 41–46]. Since the length of disease is correlated with
508 CV risk, there is justifiable concern that children, whose
509 disease has an earlier onset, will be at an increased risk as
510 they age.
511 The difference invascularphenotype between ethnicitiesis
512 similartothatfoundinpreviousstudieswhichshowedthatthe
513 presence of carotid plaque was higher in African American
514 women with SLE compared with Caucasian women in con-
515 trast to studies of non-SLE subjects [47]. Likewise, Ghosh
516 et al. observed increased fibromuscular dysplasia (FMD) and
517 cIMT in 60 Indian patients with SLE who showed impaired
518 FMD and abnormal IMT [48]. Our group has a greater pro-
519 portion of African American patients than other paediatric
520 studies [22–27], and this may have affected the results.
521 The authors acknowledge a number of limitations of this
522 study: the numbers are small, the patient cohort is heteroge-
523 neous and the controls were historical. Nonetheless, this is a
524 previously undescribed cohort taken from the largest referral
525 centre for JSLE in the UK and we used a rigorous study
526 protocol which will enable long-term follow up to determine
527 if the increase in surrogate markers for CVD will result in
528 clinical outcomes.
529 Insummary,thisstudydescribesearlystructuralchangesin
530 the blood vessels of children and adolescents with JSLE,
531 which may be related to ethnicity and renal involvement and
532 which are associated with CVD in adults. The patients in our
533 study cohort had minimal modifiable risk factors and were
534 physically active, limiting the potential for lifestyle advice.
535 Patients should be made aware of this potentially increased
536 risk as they grow up, and efforts should be made to encourage
537 healthy lifestyle choices in order to decrease their CV risk
538 from traditional, modifiable risk factors. Follow-up data from
539 this cohort are needed to determine if the early compensatory
540 changes resulting in normal PWV readings are overwhelmed
541 with time and if the increase in pre-clinical markers of CVD
542 are followed by hard CVendpoints.
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Data# was# collected# to# establish# disease# duraHon,# disease#
acHvity,# medicaHon# use# and# acHvity# levels# as# well# as#
demographic# data# including# family# history# of# CVD.# Vascular#






















involvement,# and# which# could# become# clinically# signiﬁcant# with#
Hme.# InteresHngly# this# occurred# without# an# increase# in# PWV,# a#
funcHonal#measurement#of#vessel#health.#Indeed,#the#median#PWV#
was#lower#in#the#JSLE#cohort#than#in#controls,#suggesHng#alternate#
pathways# for# the# development# of# CVD# in# JSLE# or# a# degree# of#






to# determine# if# the# early# compensatory# changes# resulHng# in#











considered# merely# a# passive# storage# place# for# energy# it# is# now#
recognised# as# an# acHve# endocrine# organ.# Obesity# is# a# chronic#
inﬂammatory#state#and#likely#has#many#similariHes#with#autoLimmune#
disease.##
White# adipose# Hssue# interacts# with# the# vasculature# through# the#




proliferaHon,# leading# to# plaque# destabilizaHon# and# increased#
thrombosis.# AdiponecHn# acts# to# protect# the# vasculature# from#
atherosclerosis#decreasing#endothelial#cell#apoptosis#and#reducing#the#
adhesion# of# surface# molecules# thus# reducing# the# endothelial# injury,#




Children# with# JSLE# were# recruited# from# the# nephrology# and#
rheumatology# departments# in# Great# Ormond# Street# Hospital# for#
Children#NHS#Trust,#the#largest#paediatric#centre#in#the#UK#caring#for#
children# with# JSLE.# Controls# for# the# adipokine# assays# were# recruited#
from#healthy#children#in#The#Children’s#University#Hospital,#Dublin.#






LepHn# levels# were# 16.52(8.27# –# 27.27)ng/ml# in# the# JSLE# group# and#
7.56(0.99L16.7)ng/ml#in#the#control#group,#the#diﬀerence#between#the#
medians#was#signiﬁcant#(p=0.0238).#Signiﬁcant#correlaHons#were#found#




acHve# renal# disease# (A/B/C)# but# this# did# not# reach# staHsHcal#
signiﬁcance,# see# ﬁgure# 34.# However,# those# with# an# elevated# UaUc#
(>20mg/mmol)#had#a#corresponding#rise#in#their#serum#lepHn#levels,#












































































































































































































































AdiponecHn#m a y #h a v e #b o t h #a n H L i n ﬂ a m m a t o r y #e ﬀ e c t s #a n d #p r o L
inﬂammatory# eﬀects.# In# contrast# to# published# data# we# found# an#
increase#in#both#lepHn#and#adiponecHn#between#controls#and#paHents.#
Given# the# role# played# by# adiponecHn# in# protecHng# endothelial# nitric#
oxide# mediated# vasodilaHon# we# speculate# that# higher# serum#







#Cardiovascular Morbidity in Juvenile-onset Systemic 
Lupus Erythematosus 
Quinlan C, Kari J, Marks S, Tullus K.  
The Royal Children’s Hospital, Melbourne, Australia 
Great Ormond Street Hospital for Children NHS Trust, United Kingdom 
Study Design 
1.Assessment of vascular phenotype 
2.Evaluation of clinical and laboratory 
characteristics/data from routine care 
3.Novel biomarkers to evaluate ongoing 
disease and inflammation 
Conclusion 
1. There is a low prevalence of traditional CV risk factors in patients with JSLE 
2. Patients had evidence of structural changes in blood vessels with possible functional adaptation 
3. There was an increase in serum leptin and adiponectin levels which was associated with increased cIMT 
4. There was no clear evidence of increased CV risk in patients with JSLE at this stage 
Results 
• Children with JSLE had a 23% higher mean cIMT (p <0.0001), 0.37 ± 0.06 V 0.45 ±0.0 mm  
• There was a significant association between the presence of HTN and an increase in IMT, whether it was treated or not. 
In the non-HTN group cIMT was 0.45±0.04mm and in the HTN group it was 0.47±0.05mm, p=0.0374 
• There was a significant difference in cIMT between patients divided into upper and lower quartiles of prednisolone dose  
• PWV did not differ between patients and controls 5.27 ±0.88 V 5.34 ±0.97 m/s, p=0.77 
• Leptin levels were 16.52(8.27 – 27.27)ng/ml in the JSLE group and 7.56(0.99-16.7)ng/ml in the control group, p=0.0238 
• cIMT increased with increasing leptin levels when analysed by quartiles. The lower leptin quartile group had a cIMT of 
0.44±0.03mm increasing to 0.47±0.06mm in the higher quartile group, p=0.0004 
• Adiponectin levels were 14.2±9.5ug/ml in the JSLE group and 12.4±4.4ug/ml in the control group. The difference 
between the means was not significant (p=0.49) and there was no increase with renal pBILAG score. 
Hypotheses 
 
1. JSLE is associated with an increased risk of CVD and that this is 
associated with an abnormal vascular phenotype.  
2. Children with JSLE have a low prevalence of the classical risk 
factors for CVD and thus represent a “clean” population in 
which to study the effect of SLE and the treatment of SLE on 
the vascular phenotype.  
3. The increased risk of CVD in JSLE is related to increased disease 
activity leading to abnormalities in serum lipids and adipokine 
activity followed by the development of an abnormal vascular 
phenotype. 
4. The increased risk of CVD in JSLE is further exacerbated by the 
presence of hypertension, renal impairment, the use of 
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Cardiovascular Morbidity in Children with SLE 
R+D number 10NU14  1 
 
 
Information for PARENTS / GUARDIANS of young people who are 
patients at Great Ormond Street Hospital & UCLH Adolescent Unit 
 
 
Cardio-Vascular risk in children and young people with  
Systemic Lupus Erythematosus (SLE)  
 
 
We would like to ask for you and your child to help us with this study on the optimal 
management of the heart and blood vessel changes in patients with SLE. 
 
 
Why is the study being done? 
We know that young adults with SLE have an increased risk of heart attack and 
stroke compared to their unaffected peers. We are trying to identify those most at risk 
earlier in life to help minimise the long term problems. 
 
The researchers believe this study will lead to the development of guidelines for the 
correct investigations and thus optimal management of the patient’s cardio-vascular 
health as they grow. We want to do that by gathering information about how blood 
vessels are affected by SLE and what causes those changes. 
 
 
How is the study to be done? 
Your child will be in the study for a minimum of two years and a maximum of five 
years  to  monitor  their  disease  progress.  We  want  to  monitor  the  effects  of  the 
disease and its treatment on their cardio-vascular health.  
 
The treatment of your child will not be influenced by the investigations in the study. 
This will, as always, be decided by how your child is doing in him or herself and the 
results of the routine blood tests.  
 
The  extra  blood  samples  will  be  taken  with  your  child’s  routine  blood  tests.  The 
physiological  investigations  may  possibly  need  to  be  done  at  an  alternative  time 
which we will ensure is convenient for you. You will be reimbursed for the travel costs 
on these occasions.  
 
The results from the lupus children will be compared to those of a control group 
made up of children with diseases that should not have any influence on the studied 
parameters; from other clinics at GOSH.   
Parent / Guardian Information Sheet: version 2 – June 2011 
Cardiovascular Morbidity in Children with SLE 
R+D number 10NU14  2 
This control group will be of children similar in age, sex and ethnicity to the study 
group and be approximately the same size to ensure accurate results  
 
We will collect a urine sample and an extra 10mls of blood with routine tests. The 
blood and the urine will be analysed for different blood substances and cells. We will 
also look for evidence of blood vessel damage.  
 
We will ask your permission to use some of the blood taken for ethically approved 
research such as, (but not exclusively) tests for analysing cardio-vascular health / 
medication effectiveness / genetic causes of SLE; which may be inherited by their 
children. 
 
We will study the blood vessels and blood flow in two ways using ultra-sound, when 
they enter the study and again if they have any relapses while on routine treatment.  
 
1) Measure thickness of the artery walls in the neck 
2) Measure how quickly blood travels down the arms and legs   
 
 
Are there risks and discomforts? 
There is of course a small risk that we will discover something abnormal during the 
research investigations that we did not previously know about your child; we will of 
course discuss these findings with you. 
 
Your child will not need any extra blood tests. The tests to examine the blood vessels 
with ultra-sound are painless.  
Parent / Guardian Information Sheet: version 2 – June 2011 
Cardiovascular Morbidity in Children with SLE 









Parent / Guardian Information Sheet: version 2 – June 2011 
Cardiovascular Morbidity in Children with SLE 
R+D number 10NU14  4 
What are the potential benefits? 
As  your  child  will  be  receiving  additional  investigations  looking  specifically  at  risk 
factors during the study we may be able to make changes to their treatment and thus 
minimise future problems. 
 
 
Who will have access to my child’s case notes and research records? 
The  information  gathered  will  be  stored  in  a  secure  data  base  using  their  JSLE 
registration number; accessible only to your usual doctors, nurses, members of the 
research team and representatives of the Research Ethics Committee.  
 
 
Do we have to take part in this study? 
If you decide that you do not wish your child to participate in this research project, 
which is entirely your right,  it  will  not  in  any  way  prejudice  any  present  or  future 
treatment. If they do enter the study and then wish to withdraw, at a later date, this 
still applies but we will keep all anonymised data collected until that time.   
 
 
Who can we ask about this study? 
You can ask your family, the doctors and nurses you usually see in clinic; you can 
also discuss anything you may need further information about with Catherine  the 
assistant researcher - 0207 905 2695 
 
 
What are the arrangements for compensation, should any harm come? 
An independent research ethics committee who believe that it is of minimal risk to 
your child has approved this project.  However, research can carry unforeseen risks 
and we want you to be informed of your rights in the unlikely event that any harm 
should  occur  as  a  result  of  taking  part  in  this  study.  No  special  compensation 
arrangements  have  been  made  for  this  project  but  you  have  the  right  to  claim 
damages in a court of law. This would require you to prove fault on the part of the 
hospital or any manufacturer involved. 
 
 
Who do we speak to if problems arise? 
If you have any complaints about the way in which this research project has been, or 
is being conducted, please discuss them with the researchers.  If the problems are 
not resolved, or you wish to comment in any other way, please contact – PALS via 
the hospital switchboard 0207 405 9200  
 
 
Information for your GP 
We will write to your GP to inform them of your child’s participation in this study and 
inform them of any relevant results via the GP clinic letter. 
 
 
Researchers who will have contact with the family 
 
Dr Kjell Tullus                                      Dr Clarissa Pilkington 
Consultant Paediatric Nephrologist     Consultant Paediatric Rheumatologist 
0207 405 9200 ext 0292                      0207 405 9200 ext 5334  
Patient info sheet version 2 – June 2011 
Cardiovascular Morbidity in Children with SLE 




Information for PATIENTS attending  
Great Ormond Street Hospital & UCLH Adolescent Unit 
 
Cardio-Vascular risk in children and young people with  
Systemic Lupus Erythematosus (SLE) 
 
 
We would like to ask for your help with this study on the optimal management of 
heart and blood vessel changes in patients with SLE. 
 
Why is the study being done? 
We know that young adults with SLE have an increased risk of heart attack and 
stroke compared to their unaffected peers. We are trying to identify those at most risk 
earlier in life to help minimise the long term problems. 
 
The researchers believe this study will lead to the development of guidelines for the 
correct investigations and thus optimal management of the patient’s cardio-vascular 
health as they grow. We want to do that by gathering information about how blood 
vessels are affected by SLE and what causes those changes. 
 
 
How is the study to be done? 
You will be in the study for a minimum of two years and a maximum of five years to 
monitor your disease progress. We want to monitor the effects of the disease and its 
treatment on your cardio-vascular health. 
 
Your treatment will not be influenced by the investigations in the study. This will, as 
always, be decided by how you are doing in yourself and the results of the routine 
blood tests.  
 
The  blood  samples  will  be  taken  with  your  regular  blood  tests.  The  physiological 
investigations  may  possibly  need  to  be  done  at  an  alternative  time  which  we  will 
ensure is convenient for you. You will be reimbursed for the travel costs on these 
occasions.  
 
The results from the lupus children will be compared to those of a control group 
made up of children with diseases that should not have any influence on the studied 
parameters; from other clinics at GOSH.   
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This control group will be of children similar in age, sex and ethnicity to the study 
group and be approximately the same size to ensure accurate results  
 
We will collect a urine sample and an extra 10mls of blood with routine tests. The 
blood and the urine will be analysed for different blood substances and cells. We will 
also look for evidence of blood vessel damage.  
 
We will ask your permission to use the blood taken for ethically approved research 
such as, (but not exclusively) tests for analysing cardio-vascular health / medication 
effectiveness / genetic causes of SLE; which may be inherited by your children. 
 
We will study the blood vessels and blood flow in two ways using ultra-sound, when 
you enter the study and again if you have any relapses while on routine treatment. 
 
1) Measure thickness of the artery walls in the neck. 
2) Measure how quickly blood travels down the arms and legs.   
 
 
Are there risks and discomforts? 
There is of course a small risk that we will discover something abnormal during the 
research investigations that we did not previously know about you; we will of course 
discuss these findings with you. 
 
You will not need any extra blood tests. The tests to examine the blood vessels with 
ultra-sound are painless and the test to see response of the vessels to occluding 
blood flow causes the same amount of discomfort as the electronic BP machine  
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What are the potential benefits? 
As you will be receiving additional investigations looking specifically at risk factors 
during  the  study  we  may  be  able  to  make  changes  to  your  treatment  and  thus 
minimise future problems. 
 
 
Who will have access to my case notes and research records? 
The  information  gathered  will  be  stored  in  a  secure  data  base  using  your  JSLE 
registration number; accessible only to your usual doctors, nurses, members of the 
research team and representatives of the Research Ethics Committee.  
 
 
Do I have to take part in this study? 
If you decide that you do not wish to participate in this research project, which is 
entirely your right, it will not in any way prejudice any present or future treatment. If 
you do enter the study and then wish to withdraw, at a later date, this still applies but 
we will keep all anonymised data collected until that time.   
 
 
Who can I ask about this study? 
You can ask your family, the doctors and nurses you usually see in clinic; you can 
also discuss anything you may need further information about with Catherine who is 
the assistant researcher - 0207 905 2695 
 
 
What are the arrangements for compensation, should any harm come? 
An independent research ethics committee who believe that it is of minimal risk to 
you has approved this project.  However, research can carry unforeseen risks and 
we want you to be informed of your rights in the unlikely event that any harm should 
occur as a result of taking part in this study. No special compensation arrangements 
have been made for this project but you have the right to claim damages in a court of 
law.  This  would  require  you  to  prove  fault  on  the  part  of  the  hospital  or  any 
manufacturer involved. 
 
Who do I speak to if problems arise? 
If you have any complaints about the way in which this research project has been, or 
is being conducted, please discuss them with the researchers.  If the problems are 
not resolved, or you wish to comment in any other way, please contact – PALS via 
the hospital switchboard 0207 405 9200.  
 
Information for your GP 
We will write to your GP to inform them of your participation in this study and inform 
them of any relevant results via the GP clinic letter. 
 
Researchers who will have contact with the family 
 
Dr Kjell Tullus                                         Dr Clarissa Pilkington 
Consultant Paediatric Nephrologist        Consultant Paediatric Rheumatologist 
0207 405 9200 ext 0292                        0207 405 9200 ext 5334 
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Information for parents and guardians of young people who are being 
investigated as CONTROL SUBJECTS in a cardio-vascular study. 
 
Cardio-Vascular risk in children and young people with  
Systemic Lupus Erythematosus (SLE)  
 
 
We would like to ask for you and your child to help us with this study on the optimal 
management of the heart and blood vessel changes in patients with SLE; by your 
child  being  investigated  as  a  control  subject  so  we  can  look  at  the  differences 
between young people with SLE and young people without SLE. 
 
Why is the study being done? 
 
We  know that young adults with SLE have an increased risk  of heart attack and 
stroke compared to their unaffected peers. We are trying to identify those at most risk 
earlier in life to help minimise the long term problems. 
 
We want to do that by gathering information about how blood vessels are affected by 
SLE  and  what  causes  those  changes.  To  ensure  accurate  results  we  need  to 
investigate a control group of young people without SLE. 
 
How is the study to be done? 
 
We will collect a urine sample and 10mls (two teaspoons) of blood, which will be 
analysed for known indicators of blood vessel damage.  
 
We will ask your permission to use some of the blood taken for ethically approved 
research such as tests for analysing cardio-vascular health in children without SLE. 
 
The extra blood samples will be taken with your child’s routine blood tests, if your 
child does not have routine blood tests they will have to agree with having these 
done to take part in the study; neither you nor the researchers can force your child to 
have a blood test against their will. 
 
The physiological investigations may possibly need to be done at an alternative time 
which we will ensure is convenient for you. You will be reimbursed for the travel costs 
on these occasions.  
 
We will study the blood vessels and blood flow in three ways using ultra-sound – 
 R&D - 
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1) Measure thickness of the artery walls in the neck 
2) Measure how quickly blood travels down the arms and legs   
3) Measure the effect of occluding the blood flow down the arms using a BP cuff and  




Are there risks and discomforts? 
 
There is of course a small risk that we will discover something abnormal during the 
research  investigation  that  was  previously  unknown  about  your  child;  we  will  of 
course discuss these findings with you and your child’s consultant. 
 
There is a risk of pain and bruising at the blood test site, but this will be minimised by 
local anaesthetic agents and the sample will be taken by an expert practitioner. 
 
The tests to examine the blood vessels with ultra-sound are painless and the test to 
see response of the vessels to occluding blood flow causes the same discomfort as 
the  electronic  Blood  Pressure  machine,  if  your  child  has  no  experience  of  the 
electronic BP machine we will offer them a chance to experience what it feels like 
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What are the potential benefits? 
 
There are no expected benefits for your child but obviously there is a chance we may 
discover something that needs further investigation and we will refer your child to the 
appropriate medical team if this occurs. 
 
 
Do we have to take part in this study? 
 
If you decide that you do not wish your child to participate in this research project, 
which is entirely your right, it will not in any way prejudice any present or  future 
treatment. If they do enter the study and then wish to withdraw, at a later date, this 
still applies but we will keep all anonymised data collected until that time.   
 
 
Who can we ask about this study? 
 
You can ask your family, the doctors and nurses you usually see in clinic; you can 
also  discuss  anything  you  may  need  further  information  about  with  Ambrose  and 
Cathy who are the assistant researchers - 0207 905 2695 
 
 
Who will have access to my child’s case notes and research records? 
 
The information gathered will be stored in a secure data base using their hospital 
registration number; accessible only to your usual doctors, nurses, members of the 
research team and representatives of the Research Ethics Committee.  
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What are the arrangements for compensation, should any harm come? 
 
An independent research ethics committee who believe that it is of minimal risk to 
your child has approved this project.  However, research can carry unforeseen risks 
and we want you to be informed of your rights in the unlikely event that any harm 
should  occur  as  a  result  of  taking  part  in  this  study.  No  special  compensation 
arrangements  have  been  made  for  this  project  but  you  have  the  right  to  claim 
damages in a court of law. This would require you to prove fault on the part of the 
hospital or any manufacturer involved. 
 
 
Who do we speak to if problems arise? 
 
If you have any complaints about the way in which this research project has been, or 
is being conducted, please discuss them with the researchers.  If the problems are 
not resolved, or you wish to comment in any other way, please contact – PALS via 
the hospital switchboard 0207 405 9200  
 
 
Information for your GP 
 
We will write to your GP to inform them of your child’s participation in this study and 




Researchers who will have contact with the family 
 
Dr Kjell Tullus                                      Dr Clarissa Pilkington 
Consultant Paediatric Nephrologist     Consultant Paediatric Rheumatologist 
0207 405 9200 ext 0292                      0207 405 9200 ext 5334 
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Information for young people who are being investigated as  
CONTROL SUBJECTS in a cardio-vascular study. 
 
Cardio-Vascular risk in children and young people with  
Systemic Lupus Erythematosus (SLE)  
 
 
We would like to ask for your help with this study on the optimal management of the 
heart and blood vessel changes in patients with SLE; by being investigated as a 
control subject, so we can look at the differences between young people with SLE 
and young people without SLE. 
 
Why is the study being done? 
 
We  know that young adults with SLE have an increased risk  of heart attack and 
stroke compared to their unaffected peers. We are trying to identify those at most risk 
earlier in life to help minimise the long term problems. 
 
We want to do that by gathering information about how blood vessels are affected by 
SLE  and  what  causes  those  changes.  To  ensure  accurate  results  we  need  to 
investigate a control group of young people without SLE. 
 
How is the study to be done? 
 
We will collect a urine sample and 10mls (two teaspoons) of blood, which will be 
analysed for known indicators of blood vessel damage.  
 
We will ask your permission to use some of the blood taken for ethically approved 
research such as tests for analysing cardio-vascular health in children without SLE. 
 
The extra blood samples will be taken with your routine blood tests, if you do not 
normally have blood tests, you will have to agree with having these to take part in the 
study; your parents or the researchers cannot force you to have a blood test against 
your will. 
 
The physiological investigations may possibly need to be done at an alternative time 
which we will ensure is convenient for you. You will be reimbursed for the travel costs 
on these occasions.  
 
We will study the blood vessels and blood flow in three ways using ultra-sound – 
1) Measure thickness of the artery walls in the neck R&D - 
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2) Measure how quickly blood travels down the arms and legs   
3) Measure the effect of occluding the blood flow down the arms using a BP cuff and  




Are there risks and discomforts? 
 
There is of course a small risk that we will discover something abnormal during the 
research  investigation  that  was  previously  unknown  about  you;  we  will  of  course 
discuss these findings with you and your consultant. 
 
There is a risk of pain and bruising at the blood test site, but this will be minimised by 
local anaesthetic agents and the sample will be taken by an expert practitioner. 
 
The tests to examine the blood vessels with ultra-sound are painless and the test to 
see response of the vessels to occluding blood flow causes the same discomfort as 
the electronic Blood Pressure machine, if you have no experience of the electronic 
BP machine we will offer you a chance to experience what it feels like prior to dong 
that part of the investigations. 
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What are the potential benefits? 
 
There are no expected benefits, but obviously there is a chance we may discover 
something that needs further investigation and we will refer you to the appropriate 
medical team if this occurs. 
 
 
Do I have to take part in this study? 
 
If you decide that you do not wish to participate in this research project, which is 
entirely your right, it will not in any way prejudice any present or future treatment. If 
you do enter the study and then wish to withdraw, at a later date, this still applies but 
we will keep all anonymised data collected until that time.   
 
 
Who can I ask about this study? 
 
You can ask your family, the doctors and nurses you usually see in clinic; you can 
also  discuss  anything  you  may  need  further  information  about  with  Ambrose  and 
Cathy who are the assistant researchers - 0207 905 2695 
 
 
Who will have access to my case notes and research records? 
 
The information gathered will be stored in a secure data base using your hospital 
registration number; accessible only to your usual doctors, nurses, members of the 
research team and representatives of the Research Ethics Committee.  
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What are the arrangements for compensation, should any harm come? 
 
An independent research ethics committee who believe that it is of minimal risk to 
your child has approved this project.  However, research can carry unforeseen risks 
and we want you to be informed of your rights in the unlikely event that any harm 
should  occur  as  a  result  of  taking  part  in  this  study.  No  special  compensation 
arrangements  have  been  made  for  this  project  but  you  have  the  right  to  claim 
damages in a court of law. This would require you to prove fault on the part of the 
hospital or any manufacturer involved. 
 
 
Who do I speak to if problems arise? 
 
If you have any complaints about the way in which this research project has been, or 
is being conducted, please discuss them with the researchers.  If the problems are 
not resolved, or you wish to comment in any other way, please contact – PALS via 
the hospital switchboard 0207 405 9200  
 
 
Information for your GP 
 
We will write to your GP to inform them of your participation in this study and any 
relevant results that need further investigation. 
 
 
Researchers who will have contact with the family 
 
Dr Kjell Tullus                                      Dr Clarissa Pilkington 
Consultant Paediatric Nephrologist     Consultant Paediatric Rheumatologist 
0207 405 9200 ext 0292                      0207 405 9200 ext 5334 
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Information for young people age 12 – 15 yrs. who are being 
investigated as CONTROL SUBJECTS in a cardio-vascular study. 
 
Cardio-Vascular risk in children and young people with  
Systemic Lupus Erythematosus (SLE)  
 
 
We would like to ask for your help with this study by being investigated as a control 
subject,  so  we  can  look  at  the  differences  between  young  people  with  SLE  and 
young people without SLE. 
 
 
Why is the study being done? 
 
We are trying to identify those at most risk of heart problems earlier in life to help 
minimise the long term problems. 
 
We want to do that by gathering information about how blood vessels are affected 
and what causes those changes. 
 




How is the study to be done? 
 
We will collect a urine sample and 10mls (two teaspoons) of blood, which we will look 
at for signs of blood vessel damage.  
 
The extra blood samples will be taken with your routine blood tests, if you do not 
normally have blood tests, you will have to agree with having them to take part in the 
study; your parents or the researchers cannot force you to have a blood test against 
your will. 
 
We will study the blood vessels and blood flow in three ways using ultra-sound – 
 
1) Measure thickness of the artery walls in the neck 
2) Measure how quickly blood travels down the arms and legs   
3) Measure the effect of occluding the blood flow down the arms using a BP cuff and  
    how the blood vessels respond to this R&D - 
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Are there risks and discomforts? 
 
There is a risk of pain and bruising at the blood test site, but this will be minimised by 
local anaesthetic agents and the sample will be taken by an expert practitioner. 
 
The tests to examine the blood vessels with ultra-sound are painless and the test to 
see response of the vessels to occluding blood flow causes the same discomfort as 
the electronic Blood Pressure machine, if you have no experience of the electronic 
BP machine we will offer you a chance to experience what it feels like prior to dong 
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What are the potential benefits? 
 
There are no expected benefits, but obviously there is a chance we may discover 
something that needs further investigation and we will refer you to the appropriate 
medical team if this occurs. 
 
 
Do I have to take part in this study? 
 
If you decide that you do not wish to participate in this research project, which is 
entirely your right, it will not change anything and if you do enter the study and then 
want to stop again, that is ok too.  
 
Who can I ask about this study? 
 
You can ask your family, the doctors and nurses you usually see in clinic; you can 
also  discuss  anything  you  may  need  further  information  about  with  Ambrose  and 
Cathy who are the assistant researchers - 0207 905 2695 
 
Who will have access to my case notes and research records? 
 
The information gathered will be stored in a secure data base using your hospital 
registration number; accessible only to your usual doctors, nurses, members of the 
research team and representatives of the Research Ethics Committee.  
 
Information for your GP 
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We will write to your GP to inform them of your participation in this study and any 




Researchers who will have contact with the family 
 
Dr Kjell Tullus                                      Dr Clarissa Pilkington 
Consultant Paediatric Nephrologist     Consultant Paediatric Rheumatologist 
0207 405 9200 ext 0292                      0207 405 9200 ext 5334 
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Great Ormond Street Hospital for Children NHS Trust and Institute of Child Health 
Research Ethics Committee 
 
  Consent Form for PARENTS / GUARDIANS 
  of Children Participating in Research Studies 
 
Cardio-Vascular risk in children and young people with  
Systemic Lupus Erythematosus (SLE / Lupus)  
 
 
NOTES FOR PARENTS OR GUARDIANS 
 
1.  Your child has been asked to take part in a research study.  The person organising that 
study is responsible for explaining the project to you before you give consent. 
 
2.  Please ask the researcher any questions you may have about this project, before you 
decide whether you wish to participate. 
 
3.  If you decide, now or at any other stage, that you do not wish your child to participate in 
the research project, that is entirely your right, and if your child is a patient it will not in any 
way prejudice any present or future treatment. 
 
4.  You will be given an information sheet which describes the research (version 2 dated 
June 2011). This information sheet is for you to keep and refer to, please read it carefully. 
 
5.  If you have any complaints about the way in which this research project has been or is 
being conducted, please, in the first instance, discuss them with the researcher.  If the 
problems are not resolved, or you wish to comment in any other way, please contact 
PALS via the hospital switchboard. 
 
6.     I / We give permission for my child’s GP to be informed of their participation.    
 
7.     I / We give permission for my child’s blood samples to be used in ethically approved  





being the parent(s)/guardian(s) of ________________________________________ agree that 
the research project has been explained to my/our satisfaction and I/We give permission for our 
child to take part in this study.  I/We have read the notes and the information sheets and 
understand what the research study involves. 
 








Copies: Researcher / Notes / family  
Cardiovascular Morbidity in Children with SLE 
R+D number 10NU14 
   
Great Ormond Street Hospital for Children NHS Trust and Institute of Child Health 
Research Ethics Committee 
 
Consent Form for PARTICIPANTS in Research Studies 
 
Cardio-Vascular risk in children and young people with  
Systemic Lupus Erythematosus (SLE / Lupus)  
 
NOTES FOR PARTICIPANTS 
 
1.  You have been asked to take part in some research.  The person organising that study must 
explain the project to you before you agree to take part. 
 
2.   Please ask the researcher any questions you like about this project, before you decide  
      whether to join the study. 
 
3.   If you decide, now or at any other time, that you do not wish to be involved in the research   
      project, just tell us and we will stop the research.  If you are a patient your treatment will  
      carry on as normal. 
 
4.   You will be given an information sheet which describes the research (version 2 dated June 
2011).  This  information  is  for  you  to  keep  and  refer  to  at  any  time,  please  read  it 
carefully. 
 
5.   If you have any complaints about the research project, discuss them with the researcher. If  
     the problems are not resolved, or you wish to comment in any other way, please contact  
     PALS via the hospital switchboard. 
 
6.   I give permission for my GP to be informed of my participation in this project.          
 
7.   I give permission for my blood samples to be used in ethically approved research  





I ________________________________________ agree that the research project has been 
explained to my satisfaction and I agree to take part in this study. I have read the notes and the 
information sheets about the project, and understand what the research study involves. 
 










Copies: Researcher / Notes / family 
  
Consent.  version 2 – June 2011 
Cardiovascular Morbidity in Children with SLE 
R+D number 10NU14 
   
Great Ormond Street Hospital for Children NHS Trust and Institute of Child Health 
Research Ethics Committee 
 
Consent Form for PARTICIPANTS in Research Studies 
 
Cardio-Vascular risk in children and young people with  
Systemic Lupus Erythematosus (SLE / Lupus)  
 
NOTES FOR PARTICIPANTS 
 
1.  You have been asked to take part in some research.  The person organising that study must 
explain the project to you before you agree to take part. 
 
2.   Please ask the researcher any questions you like about this project, before you decide  
      whether to join the study. 
 
3.   If you decide, now or at any other time, that you do not wish to be involved in the research   
      project, just tell us and we will stop the research.  If you are a patient your treatment will  
      carry on as normal. 
 
4.   You will be given an information sheet which describes the research (version 2 dated June 
2011).  This  information  is  for  you  to  keep  and  refer  to  at  any  time,  please  read  it 
carefully. 
 
5.   If you have any complaints about the research project, discuss them with the researcher. If  
     the problems are not resolved, or you wish to comment in any other way, please contact  
     PALS via the hospital switchboard. 
 
6.   I give permission for my GP to be informed of my participation in this project.          
 
7.   I give permission for my blood samples to be used in ethically approved research  





I ________________________________________ agree that the research project has been 
explained to my satisfaction and I agree to take part in this study. I have read the notes and the 
information sheets about the project, and understand what the research study involves. 
 

























Dear Doctor  
 
I am writing to inform you that xxxx has been enrolled into the Cardio-Vascular risk in 
children and young people with Systemic Lupus Erythematosus (SLE), please find 
enclosed the information sheet 
 





Dr Kjell Tullus PhD FRPCH 
Consultant Paediatric Nephrologist 
 
c.c. family 















Dear Doctor  
 
I am writing to inform you that xxxx has been enrolled into the Cardio-Vascular risk in 
children and young people with Systemic Lupus Erythematosus (SLE) study please 
find enclosed the information sheet 
 





Dr Clarissa Pilkington MBBS MRCP (paeds) 
Consultant Paediatric Rheumatologist 
 
c.c. family 
 R&D 10NU14 :  
Parent / Guardian consent 
Version 1 March 2012 
The Children’s University Hospital, Temple Street, Dublin 1 
And 
Great Ormond Street Hospital for Children NHS Foundation Trust 
Consent Form for PARENTS / GUARDIANS of Children Participating 
in Research Studies 
 
Cardio-Vascular risk in Children and Young People  
NOTES FOR PARENTS OR GUARDIANS 
1.  Your child has been asked to take part in a research study.  The person organising that 
study is responsible for explaining the project to you before you give consent. 
2.  Please ask the researcher any questions you may have about this project, before you 
decide whether you wish to participate. 
3.  If you decide, now or at any other stage, that you do not wish your child to participate in 
the research project, that is entirely your right, and if your child is a patient it will not in 
any way prejudice any present or future treatment. 
4.  You will be given an information sheet which describes the research (version 1 dated 
March 2012).  This  information  sheet  is  for  you  to  keep  and  refer  to,  please  read  it 
carefully. 
5.  If you have any complaints about the way in which this research project has been or is 
being conducted, please, in the first instance, discuss them with the researcher. 
6.  I give permission for my child’s GP to be informed of their participation.    
7.  I give permission for my child’s blood samples to be used in ethically approved research 




being the parent(s)/guardian(s) of ________________________________________ agree that 
the research project has been explained to my/our satisfaction and I/We give permission for our 
child to take part in this study.  I/We have read the notes and the information sheets and 
understand what the research study involves. 
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Information for parents and guardians of young people who are being 
investigated as CONTROL SUBJECTS in a study investigating 
cardiovascular risk in children and young people  
We would like to ask for you and your child to help us with this study on the optimal 
management of the heart and blood vessel changes in patients with SLE. Your child 
could be investigated as a control subject so we can look at the differences between 
young people with SLE and young people without SLE. 
Why is the study being done? 
We  know that young adults with SLE have an increased risk  of heart attack and 
stroke compared to their unaffected peers. We are trying to identify those at most risk 
earlier in life to help minimise the long term problems. 
We want to do that by gathering information about how blood vessels are affected by 
SLE  and  what  causes  those  changes.  To  ensure  accurate  results  we  need  to 
investigate a control group of young people without SLE. 
How is the study to be done? 
We will collect a urine sample and 7.5mls (1½  teaspoons) of blood, which will be 
analysed for known indicators of blood vessel damage.  
We will ask your permission to use some of the blood taken for ethically approved 
research such as tests for analysing cardio-vascular health in children without SLE. 
These tests will be analysed in: 
•  The Children’s University Hospital, Temple Street, Dublin 1 
•  Our Lady’s Children’s Hospital, Crumlin, Dublin 12 
•  Great Ormond Street Hospital for Children NHS Foundation Trust, London 
The extra blood samples will be taken with your child’s routine blood tests and will 
involve no extra needles. 
If possible, we would like to measure your child’s height, weight and blood pressure. 
Are there risks and discomforts? 
There is of course a small risk that we will discover something abnormal during the 
research  investigation  that  was  previously  unknown  about  your  child;  we  will  of 
course discuss these findings with you, your GP and your child’s consultant. 
We will use an electronic blood pressure machine, this can be uncomfortable for the 
duration of the test (approx 30-60 seconds).  
What are the potential benefits? R&D 10NU14 
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There are no expected benefits for your child but obviously there is a chance we may 
discover something that needs further investigation and we will refer your child to the 
appropriate medical team if this occurs. 
Do we have to take part in this study? 
If you decide that you do not wish your child to participate in this research project, 
which is entirely your right, it will not in any way prejudice any present or  future 
treatment. If they do enter the study and then wish to withdraw, at a later date, this 
still applies but we will keep all anonymised data collected until that time.   
Who can we ask about this study? 
You can ask your family, the doctors you usually see in clinic; you can also discuss 
anything you may need further information about with Dr Catherine Quinlan who is 
the main researcher for the Irish site. She can be contacted via the switchboard in 
Temple Street on 01 878 4200. 
Who will have access to my child’s case notes and research records? 
The information gathered will be stored in a secure data base using their hospital 
registration number; accessible only to your usual doctors, nurses, members of the 
research team and representatives of the Research Ethics Committee.  
What are the arrangements for compensation, should any harm come? 
An independent research ethics committee who believe that it is of minimal risk to 
your child has approved this project.  However, research can carry unforeseen risks 
and we want you to be informed of your rights in the unlikely event that any harm 
should  occur  as  a  result  of  taking  part  in  this  study.  No  special  compensation 
arrangements  have  been  made  for  this  project  but  you  have  the  right  to  claim 
damages in a court of law. This would require you to prove fault on the part of the 
hospital or any manufacturer involved. 
Who do we speak to if problems arise? 
If you have any complaints about the way in which this research project has been, or 
is being conducted, please discuss them with the researchers.  If the problems are 
not resolved, or you wish to comment in any other way, please contact – PALS via 
the hospital switchboard 0207 405 9200  
Information for your GP 
We will write to your GP if we discover something abnormal during the course of the 
study,  to  inform  them  of  your  child’s  participation  in  this  study  and  any  relevant 
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Study Code 
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Weight  Kg 
Height  Cm 
Blood Pressure  Manual   !  Automated   ! 
Systolic  mmHg 
Diastolic  mmHg 
Birthweight  Kg 
Gestation  /40 
     
Last Menstrual Period  Day / Month   




If yes, when started?  Month / Year 
Brand name   






If yes, how many  Cigarettes/day 
If yes, when started  Month / Year 
Is there a family Hx of cardiovascular disease?  No !  Yes ! 
If yes, please give details   
What relative(s)?   
At what age?   
CVA/TIA/MI/Angina/other   
Current Medications     
Name  Dose  Frequency    Name  Dose  Frequency 
Prednisolone        Cyclophosphamide     
MMF        Hydroxycholorquin     
Rituximab        Cyclosporin     
Azathioprine        NSAIDs     
Cumulative Prednisolone dose over last 6 months  g 
Previous Medications   
Cyclophosphamide   
Rituximab   
MMF   
Azathioprine    
Cardiovascular Morbidity in Children with SLE 
R+D number 10NU14 
Study Code 
4 






If yes, how many  Cigarettes/day 
If yes, when started  Month / Year 
 
Physical Activity   
Vigorous Activity  Days per week 
Time on one day  Hours / Minutes 
Moderate Activity  Days per week 
Time on one day  Hours / Minutes 
Walking >10 minutes  Days per week 
Time on one day  Hours / Minutes / Unsure 
Sitting time per day  Hours / Minutes / Unsure 
 
Sun Exposure   
Time outside in Summer on 
weekdays – 1000 – 1600  
Hours/Day 
Time outside in Summer on 
weekend days – 1000 – 1600 
Hours/Day 
Number of red/painful sunburns in 
last 12 months 
1  2  3  4  5 
Outside on a warm sunny day  Never  Rarely  Sometimes  Often  Always 
How often do you wear 
sunscreen? 
         
How often do you were a shirt 
with sleeves that covers 
shoulders? 
         
How often do you wear a hat?           
How often do you stay in the 
shade/use umbrella? 
         
How often do you wear 
sunglasses? 
         
How often do you spend time in 
the sun to get a tan? 
         
Colour of untanned skin 
Very 
Fair 
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Waist  cm 
Hip  cm 
WHR   
   
Age  Months 
Ethnicity   
Gender  Male  Female 
   
BILAG at presentation   
BILAG today   
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Carotid to SS notch:      cm 
 
SS notch to Femoral: 
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! !2 to 20 years: Girls
Body mass index-for-age percentiles
NAME
RECORD #




























































y the National Center for Health Statistics in collaboration with
the National Center for Chronic Disease Prevention and Health Promotion
http://www.cdc.gov/growthcharts
Published May 30, 2000 (modified 10/16/00).2 to 20 years: Boys
Body mass index-for-age percentiles
NAME
RECORD #
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Guidelines for Data Processing and 
Analysis of the International Physical 
Activity Questionnaire (IPAQ) 
 










1.  Introduction 
2.   Uses of IPAQ Instruments 
3.  Summary Characteristics of Short and Long Forms 
4.  Overview of Continuous and Categorical Analyses of IPAQ 
5.  Protocol for Short Form 
6.  Protocol for Long Form 
7.  Data Processing Rules 
8.  Summary Algorithms 
 
Appendix 1.     At A Glance IPAQ Scoring Protocol – Short Forms 
Appendix 2.     At A Glance IPAQ Scoring Protocol – Long Forms 
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1.  Introduction 
 
This document describes recommended methods of scoring the data derived from 
the telephone / interview administered and self-administered IPAQ short and long 
form instruments. The methods outlined provide a revision to earlier scoring protocols 
for the IPAQ short form and provide for the first time a comparable scoring method 
for IPAQ long form. Latest versions of IPAQ instruments are available from 
www.ipaq.ki.se.  
 
Although there are many different ways to analyse physical activity data, to date 
there is no formal consensus on a ‘correct’ method for defining or describing levels of 
physical activity based on self–report population surveys. The use of different scoring 
protocols makes it very difficult to compare within and between countries, even when 
the same instrument has been used. Use of these scoring methods will enhance the 
comparability between surveys, provided identical sampling and survey methods 
have been used.  
 
2.  Uses of IPAQ Instruments 
 
IPAQ short form is an instrument designed primarily for population surveillance of 
physical activity among adults. It has been developed and tested for use in adults 
(age range of 15-69 years) and until further development and testing is undertaken 
the use of IPAQ with older and younger age groups is not recommended.  
  
IPAQ short and long forms are sometimes being used as an evaluation tool in 
intervention studies, but this was not the intended purpose of IPAQ. Users should 
carefully note the range of domains and types of activities included in IPAQ  before 
using it in this context. Use as an outcome measure in small scale intervention 
studies is not recommended.  
 
 
3.  Summary Characteristics of IPAQ Short and Long Forms 
 
1.  IPAQ assesses physical activity undertaken across a comprehensive set of 
domains including: 
a.   leisure time physical activity 
b.   domestic and gardening (yard) activities 
c.  work-related physical activity  
d.  transport-related physical activity; 
 
2.  The IPAQ short form asks about three specific types of activity undertaken in 
the four domains introduced above. The specific types of activity that are 
assessed are walking, moderate-intensity activities and vigorous-intensity 
activities.  
 
3.  The items in the short IPAQ form were structured to provide separate scores on 
walking, moderate-intensity and vigorous-intensity activity. Computation of the 
total score for the short form requires summation of the duration (in minutes) 
and frequency (days) of walking, moderate-intensity and vigorous-intensity 
activities. Domain specific estimates cannot be estimated.   Revised November2005  3
4.  The IPAQ long form asks details about the specific types of activities 
undertaken within each of the four domains. Examples include walking for 
transportation and moderate-intensity leisure-time activity. 
 
5.  The items in the long IPAQ form were structured to provide separate domain 
specific scores for walking, moderate-intensity and vigorous-intensity activity 
within each of the work, transportation, domestic chores and gardening (yard) 
and leisure-time domains. Computation of the total scores for the long form 
requires summation of the duration (in minutes) and frequency (days) for all the 
types of activities in all domains. Domain specific scores or activity specific sub-
scores may be calculated. Domain specific scores require summation of the 
scores for walking, moderate-intensity and vigorous-intensity activities within the 
specific domain, whereas activity-specific scores require summation of the 
scores for the specific type of activity across domains. 
 
 
4.  Overview of Continuous and Categorical Analyses of IPAQ 
 
Both categorical and continuous indicators of physical activity are possible from both 
IPAQ forms. However, given the non-normal distribution of energy expenditure in 
many populations, it is suggested that the continuous indicator be presented as 
median minutes/week or median MET–minutes/week rather than means (such as 
mean minutes/week or mean MET-minutes/week).  
 
 
4.1  Continuous Variables 
 
Data collected with IPAQ can be reported as a continuous measure. One measure of 
the volume of activity can be computed by weighting each type of activity by its 
energy requirements defined in METs to yield a score in MET–minutes. METs are 
multiples of the resting metabolic rate and a MET-minute is computed by multiplying 
the MET score of an activity by the minutes performed.  MET-minute scores are 
equivalent to kilocalories for a 60 kilogram person. Kilocalories may be computed 
from MET-minutes using the following equation:  MET-min x (weight in kilograms/60 
kilograms).  MET-minutes/day or MET-minutes/week can be presented although the 
latter is more frequently used and is thus suggested.  
 
Details for the computation for summary variables from IPAQ short and long forms 
are detailed below. As there are no established thresholds for presenting MET-
minutes, the IPAQ Research Committee propose that these data are reported as 
comparisons of median values and interquartile ranges for different populations. 
 
4.2  Categorical Variable: Rationale for Cut Point Values 
 
There are three levels of physical activity proposed to classify populations: 
1.  Low 
2.  Moderate 
3.  High 
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The algorithms for the short and long forms are defined in more detail in Sections 5.3 
and 6.3, respectively. Rules for data cleaning and processing prior to computing the 
algorithms appear in Section 7. 
 
Regular participation is a key concept included in current public health guidelines for 
physical activity.
1 Therefore, both the total volume and the number of days/sessions 
are included in the IPAQ analysis algorithms.  
 
The criteria for these levels have been set taking into account that IPAQ asks 
questions in all domains of daily life, resulting in higher median MET-minutes 
estimates than would have been estimated from leisure-time participation alone. The 
criteria for these three levels are shown below.  
 
Given that measures such as IPAQ assess total physical activity in all domains, the 
“leisure time physical activity” based public health recommendation of 30 minutes on 
most days will be achieved by most adults in a population. Although widely accepted 
as a goal, in absolute terms 30 minutes of moderate-intensity activity is low and 
broadly equivalent to the background or basal levels of activity adult individuals 
would accumulate in a day. Therefore a new, higher cutpoint is needed to describe 
the levels of physical activity associated with health benefits for measures such as 
IPAQ, which  report on a broad range of domains of physical activity. 
 
 ‘High’  
 
This category was developed to describe higher levels of participation. Although it is 
known that greater health benefits are associated with increased levels of activity 
there is no consensus on the exact amount of activity for maximal benefit. In the 
absence of any established criteria, the IPAQ Research Committee proposes a 
measure which equates to approximately at least one hour per day or more, of at 
least moderate-intensity activity above the basal level of physical activity  Considering 
that basal activity may be considered to be equivalent to approximately 5000 steps 
per day, it is  proposed that “high active” category be considered as those who move 
at least 12,500 steps per day, or the equivalent in moderate and vigorous activities. 
This represents at least an hour more moderate-intensity activity over and above the 
basal level of activity, or half an hour of vigorous-intensity activity over and above 




This category provides a higher threshold of measures of total physical activity and is 
a useful mechanism to distinguish variation in population groups. Also it could be 
used to set population targets  for health-enhancing physical activity when multi-
domain instruments, such as IPAQ are used.  
                                                 
1 Pate RR, Pratt M, Blair SN, Haskell WL , Macera CA, Bouchard C et al. Physical activity and public health. A recommendation 
from the Centers for Disease Control and Prevention and the American College of Sports Medicine. Journal of American 
Medical Association 1995; 273(5):402-7. and U.S. Department of Health and Human Services.  Physical Activity and Health: A 
Report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, 
National Center for Chronic Disease Prevention and Health Promotion, The Presidents' Council on Physical Fitness and Sports: 
Atlanta, GA:USA.  1996.  
2 Tudor-Locke C, Bassett DR Jr.  How many steps/day are enough? Preliminary pedometer indices for public health. Sports 




This category is defined as doing some activity, more than the low active category. It 
is proposed that it is a level of activity equivalent to “half an hour of at least 
moderate-intensity PA on most days”, the former leisure time-based physical activity 








5.  Protocol for IPAQ Short Form 
 
5.1  Continuous Scores 
 
Median values and interquartile ranges can be computed for walking (W), moderate-
intensity activities (M), vigorous-intensity activities (V) and a combined total physical 
activity score. All continuous scores are expressed in MET-minutes/week as defined 
below. 
 
5.2  MET Values and Formula for Computation of MET-minutes/week  
 
The selected MET values were derived from work undertaken during the IPAQ 
Reliability Study undertaken in 2000-2001
3. Using the Ainsworth et al. Compendium 
(Med Sci Sports Med 2000) an average MET score was derived for each type of 
activity. For example; all types of walking were included and an average MET value 
for walking was created. The same procedure was undertaken for moderate-intensity 
activities and vigorous-intensity activities. The following values continue to be used 
for the analysis of IPAQ data: Walking = 3.3 METs, Moderate PA = 4.0 METs and 
Vigorous PA = 8.0 METs. Using these values, four continuous scores are defined: 
 
Walking MET-minutes/week = 3.3 * walking minutes * walking days 
Moderate MET-minutes/week = 4.0 * moderate-intensity activity minutes * moderate days 
Vigorous MET-minutes/week = 8.0 * vigorous-intensity activity minutes * vigorous-intensity days 
Total physical activity MET-minutes/week = sum of Walking + Moderate + Vigorous MET-
minutes/week scores.   
 
 
5.3  Categorical Score    
 
Category 1   Low 
 
This is the lowest level of physical activity.  Those individuals who not meet criteria 
for Categories 2 or 3 are considered to have a ‘low’ physical activity level. 
 
                                                 
3 Craig CL,Marshall A , Sjostrom M et al.  International Physical Activity Questionnaire: 12 country reliability and 
validity Med Sci Sports Exerc 2003;August Revised November2005  6
Category 2   Moderate 
 
The pattern of activity to be classified as ‘moderate’ is either of the following criteria: 
a)  3 or more days of vigorous-intensity activity of at least 20 minutes per day 
OR 
b)  5 or more days of moderate-intensity activity and/or walking of at least 30 
minutes per day  
OR 
c)  5 or more days of any combination of walking, moderate-intensity or vigorous 
intensity activities achieving a minimum Total physical activity of at least 600 
MET-minutes/week.   
 
  
Individuals meeting at least one of the above criteria would be defined as 
accumulating a minimum level of activity and therefore be classified as ‘moderate’. 
See Section 7.5 for information about combining days across categories. 
 
Category 3  High 
 
A separate category labelled ‘high’ can be computed to describe higher levels of 
participation.  
The two criteria for classification as ‘high’ are:  
a)  vigorous-intensity activity on at least 3 days achieving a minimum Total 
physical activity of at least 1500 MET-minutes/week  
OR 
b)  7 or more days of any combination of walking, moderate-intensity or 
vigorous-intensity activities achieving a minimum Total physical activity 
of at least 3000 MET-minutes/week.   
 
See Section 7.5 for information about combining days across categories. 
 
 
5.4  Sitting Question in IPAQ Short Form 
 
The IPAQ sitting question is an additional indicator variable of time spent in 
sedentary activity and is not included as part of any summary score of physical 
activity. Data on sitting should be reported as median values and interquartile ranges.  
To-date there are few data on sedentary (sitting) behaviours and no well-accepted 
thresholds for data presented as categorical levels. 
 
 
6.  Protocol for IPAQ Long Form 
 
The long form of IPAQ asks in detail about walking, moderate-intensity and vigorous-
intensity physical activity in each of the four domains. Note: asking more detailed 
questions regarding physical activity within domains is likely to produce higher 
prevalence estimates than the more generic IPAQ short form.   Revised November2005  7
6.1  Continuous Score 
 
Data collected with the IPAQ long form can be reported as a continuous measure 
and reported as median MET-minutes. Median values and interquartile ranges can 
be computed for walking (W), moderate-intensity activities (M), and vigorous-intensity 
activities (V) within each domain using the formulas below. Total scores may also be 
calculated for walking (W), moderate-intensity activities (M), and vigorous-intensity 
activities (V); for each domain (work, transport, domestic and garden, and leisure) 
and for an overall grand total. 
 
 
6.2  MET Values and Formula for Computation of MET-minutes  
 
Work Domain 
Walking MET-minutes/week at work = 3.3 * walking minutes * walking days at work 
Moderate MET-minutes/week at work=  4.0 * moderate-intensity activity minutes * moderate-intensity 
days at work  
Vigorous MET-minutes/week at work= 8.0 * vigorous-intensity activity minutes * vigorous-intensity 
days at work 
Total Work MET-minutes/week =sum of Walking + Moderate + Vigorous MET-minutes/week scores at 
work.   
 
Active Transportation Domain 
Walking MET-minutes/week for transport = 3.3 * walking minutes * walking days for transportation 
Cycle MET-minutes/week for transport= 6.0 * cycling minutes * cycle days for transportation  
Total Transport MET-minutes/week = sum of Walking + Cycling MET-minutes/week scores for 
transportation.   
 
Domestic and Garden [Yard Work] Domain 
Vigorous MET-minutes/week yard chores= 5.5 * vigorous-intensity activity minutes * vigorous-intensity 
days doing yard work (Note: the MET value of 5.5 indicates that vigorous garden/yard work should 
be considered a moderate-intensity activity for scoring and computing total moderate intensity 
activities.) 
Moderate MET-minutes/week yard chores= 4.0 * moderate-intensity activity minutes * moderate-
intensity days doing yard work  
Moderate  MET-minutes/week inside chores= 3.0* moderate-intensity activity minutes * moderate-
intensity days doing inside chores. 
Total Domestic and Garden MET-minutes/week =sum of Vigorous yard + Moderate yard + Moderate 
inside chores MET-minutes/week scores.   
 
Leisure-Time Domain 
Walking MET-minutes/week leisure = 3.3 * walking minutes * walking days in leisure 
Moderate MET-minutes/week leisure = 4.0 * moderate-intensity activity minutes * moderate-intensity 
days in leisure 
Vigorous  MET-minutes/week leisure = 8.0 * vigorous-intensity activity minutes * vigorous-intensity 
days in leisure 
Total Leisure-Time MET-minutes/week = sum of Walking + Moderate + Vigorous MET-minutes/week 
scores in leisure.   
 Revised November2005  8
Total Scores for all Walking, Moderate and Vigorous Physical Activities  
Total Walking MET-minutes/week = Walking MET-minutes/week (at Work + for Transport + in Leisure) 
Total Moderate MET-minutes/week total = Moderate MET-minutes/week (at Work + Yard chores + 
inside chores + in Leisure time) + Cycling Met-minutes/week for Transport + Vigorous Yard chores 
MET-minutes/week  
Total Vigorous MET-minutes/week = Vigorous MET-minutes/week (at Work + in Leisure) 
 
Note: Cycling MET value and Vigorous garden/yard work MET value fall within the coding range of 
moderate-intensity activities. 
 
Total Physical Activity Scores 
 
An overall total physical activity MET-minutes/week score can be computed as: 
Total physical activity MET-minutes/week = sum of Total (Walking + Moderate + Vigorous) MET-
minutes/week scores. 
This is equivalent to computing: 
Total physical activity MET-minutes/week = sum of Total Work + Total Transport + Total Domestic and 
Garden + Total Leisure-Time MET-minutes/week scores.  
 
As there are no established thresholds for presenting MET-minutes, the IPAQ 
Research Committee proposes that these data are reported as comparisons of 
median values and interquartile ranges for different populations. 
 
 
6.3  Categorical Score 
 
As noted earlier, regular participation is a key concept included in current public 
health guidelines for physical activity.
4 Therefore, both the total volume and the 
number of day/sessions are included in the IPAQ analysis algorithms. There are 
three levels of physical activity proposed to classify populations – ‘low’,  ’moderate’, 
and ‘high’. The criteria for these levels are the same as for the IPAQ short [described 
earlier in Section 4.2]  
 
Category 1   Low 
 
This is the lowest level of physical activity.  Those individuals who not meet criteria 
for Categories 2 or 3 are considered ‘low’. 
 
Category 2   Moderate 
 
The pattern of activity to be classified as ‘moderate’ is either of the following criteria: 
d)  3 or more days of vigorous-intensity activity of at least 20 minutes per day 
OR 
e)  5 or more days of moderate-intensity activity and/or walking of at least 30 
minutes per day  
OR 
                                                 
4 Pate RR, Pratt M, Blair SN, Haskell WL , Macera CA, Bouchard C et al. Physical activity and public health. A recommendation 
from the Centers for Disease Control and Prevention and the American College of Sports Medicine. Journal of American 
Medical Association 1995; 273(5):402-7. and U.S. Department of Health and Human Services. Physical Activity and Health: A 
Report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, 
National Center for Chronic Disease Prevention and Health Promotion, The Presidents' Council on Physical Fitness and Sports: 
Atlanta, GA:USA.  1996.  Revised November2005  9
f)  5 or more days of any combination of walking, moderate-intensity or vigorous-
intensity activities achieving a minimum Total physical activity of at least 600 
MET-minutes/week.   
 
Individuals meeting at least one of the above criteria would be defined as 
accumulating a moderate level of activity. See Section 7.5 for information about 
combining days across categories. 
 
Category 3  High 
 
A separate category labelled ‘high’ can be computed to describe higher levels of 
participation.  
The two criteria for classification as ‘high’ are:  
a)  vigorous-intensity activity on at least 3 days achieving a minimum Total 
physical activity of at least 1500 MET-minutes/week  
OR 
b)  7 or more days of any combination of walking, moderate-intensity or 
vigorous-intensity activities achieving a minimum Total physical activity 
of at least 3000 MET-minutes/week. 
 
See Section 7.5 for information about combining days across categories. 
 
 
6.4  IPAQ Sitting Question IPAQ Long Form 
 
The IPAQ sitting question is an additional indicator variable and is not included as 
part of any summary score of physical activity. To-date there are few data on 
sedentary (sitting) behaviours and no well-accepted thresholds for data presented as 
categorical levels. For the sitting question ‘Minutes’ is used as the indicator to reflect 
time spent in sitting rather than MET-minutes which would suggest an estimate of 
energy expenditure. 
 
IPAQ long assesses an estimate of sitting on a typical weekday, weekend day and 
time spent sitting during travel (see transport domain questions).  
 
Summary sitting variables include 
Sitting Total Minutes/week =  weekday sitting minutes* 5 weekdays +  weekend day sitting minutes* 2 
weekend days 
Average Sitting Total Minutes/day = (weekday sitting minutes* 5 weekdays + weekend day sitting 
minutes* 2 weekend days) / 7 
 
Note: The above calculation of ‘Sitting Total’ excludes time spent sitting during travel because the 
introduction in IPAQ long directs the responder to NOT include this component as it would have 
already been captured under the Transport section. If a summary sitting variable including time spent 
sitting for transport is required, it should be calculated by adding the time reported (travelling in a 
motor vehicle) under transport to the above formula. Care should be taken in reporting these alternate 
data to clearly distinguish the ‘total sitting’ variable from a ‘total sitting – including transport’ variable. 
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7.  Data Processing Rules 
 
In addition to a standardized approach to computing categorical and continuous 
measures of physical activity, it is necessary to undertake standard methods for the 
cleaning and treatment of IPAQ datasets. The use of different approaches and rules 
would introduce variability and reduce the comparability of data.  
 
There are no established rules for data cleaning and processing on physical activity. 
Thus, to allow more accurate comparisons across studies IPAQ Research Committee 
has established and recommends the following guidelines: 
 
7.1  Data Cleaning   
 
I.  Any responses to duration (time) provided in the hours and minutes response 
option should be converted from hours and minutes into minutes.   
II.  To ensure that responses in ‘minutes’ were not entered in the ‘hours’ column by 
mistake during self-completion or during data entry process, values of ‘15’, ‘30’, 
‘45’, ‘60’ and ‘90’ in the ‘hours’ column should be converted to ‘15’, ‘30’, ‘45’, ‘60’ 
and ‘90’ minutes, respectively, in the minutes column. 
III.  In some cases duration (time) will be reported as weekly (not daily) e.g., 
VWHRS, VWMINS. These data should be converted into an average daily time 
by dividing by 7. 
IV.  If ‘don’t know’ or ‘refused ‘  or data are missing for time or days then that case is 
removed from analysis.  
 
Note: Both the number of days and daily time are required for the creation of categorical and 
continuous summary variables 
 
  
7.2  Maximum Values for Excluding Outliers  
 
This rule is to exclude data which are unreasonably high; these data are to be 
considered outliers and thus are excluded from analysis. All cases in which the sum 
total of all Walking, Moderate and Vigorous time variables is greater than 960 
minutes (16 hours) should be excluded from the analysis. This assumes that on 
average an individual of 8 hours per day is spent sleeping.  
 
The ‘days’ variables can take the range 0-7 days, or 8, 9 (don’t know or refused); 
values greater than 9 should not be allowed and those cases excluded from analysis.   
 
 
7.3  Minimum Values for Duration of Activity 
 
Only values of 10 or more minutes of activity should be included in the calculation of 
summary scores. The rationale being that the scientific evidence indicates that 
episodes or bouts of at least 10 minutes are required to achieve health benefits. 
Responses of less than 10 minutes [and their associated days] should be re-coded to 
‘zero’.   
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7.4  Truncation of Data Rules 
 
This rule attempts to normalize the distribution of levels of activity which are usually 
skewed in national or large population data sets.  
 
In IPAQ short - it is recommended that all Walking, Moderate and Vigorous time 
variables exceeding ‘ 3 hours’ or ‘180 minutes’ are truncated (that is re-coded) to be 
equal to ‘180 minutes’ in a new variable.  This rule permits a maximum of 21 hours of 
activity in a week to be reported for each category (3 hours * 7 days). 
 
In IPAQ long – the truncation process is more complicated, but to be consistent with 
the approach for IPAQ short requires that the variables total Walking, total Moderate-
intensity and total Vigorous-intensity activity are calculated and then, for each of 
these summed behaviours, the total value should be truncated to 3 hours (180 
minutes).   
 
When analysing the data as categorical variable or presenting median and 
interquartile ranges of the MET-minute scores, the application of the truncation rule 
will not affect the results. This rule does have the important effect of preventing 
misclassification in the ‘high’ category. For example, an individual who reports 
walking for 10 minutes on 6 days and 12 hours of moderate activity on one day could 
be coded as ‘high’ because this pattern meets the ‘7 day” and “3000 MET-min” 
criteria for ‘high’.  However, this uncommon pattern of activity is unlikely to yield the 
health benefits that the ‘high’ category is intended to represent.  
 
Although using median is recommended due to the skewed distribution of scores, if 
IPAQ data are analysed and presented  as a continuous variable using mean values, 
the application of the truncation rule will produce slightly lower mean values than 
would otherwise be obtained.  
 
 
7.5  Calculating MET-minute/week Scores  
 
Data processing rules 7.2, 7.3, and 7.4 deals first with excluding outlier data, then 
secondly, with recoding minimum values and then finally dealing with high values. 
These rules will ensure that highly active people remain classified as ‘high’, while 
decreasing the chances that less active individuals are misclassified and coded as 
‘high’. 
 
Using the resulting variables, convert time and days to MET-minute/week scores  
[see above Sections 5.2 and 6.2; METS x days x daily time].   
 
 
7.6  Calculating Total Days for Presenting Categorical Data on Moderate and 
High Levels 
 
Presenting IPAQ data using categorical variables requires the total number of ‘days’ 
on which all physical activity was undertaken to be assessed. This is difficult because 
frequency in ‘days’ is asked separately for walking, moderate-intensity and vigorous-
intensity activities, thus allowing the total number of ‘days’ to range from a minimum Revised November2005  12
of 0 to a maximum of 21’days’ per week in IPAQ short and higher in IPAQ long. The 
IPAQ instrument does not record if different types of activity are undertaken on the 
same day.  
 
In calculating ‘moderately active’, the primary requirement is to identify those 
individuals who undertake activity on at least ‘5 days’/week [see Sections 4.2 and 
5.3]. Individuals who meet this criterion should be coded in a new variable called “at 
least five days” and this variable should be used to identify those meeting criterion b) 
at least 30 minutes of moderate-intensity activity and/or walking; and those meeting 
criterion c) any combination of walking, moderate-intensity or vigorous-intensity 
activities achieving a minimum of 600 MET-minutes/week. 
 
Below are two examples showing this coding in practice: 
i)  an individual who reports ‘2 days of moderate-intensity’ and ‘3 days of walking’ 
should be coded as a value indicating  “at least five days”;  
ii)  an individual reporting ‘2 days of vigorous-intensity’, ‘2 days of moderate-
intensity’ and ‘2 days of walking should be coded as a value to indicate  “at 
least five days”  [even though the actual total is 6].  
 
The original frequency of ‘days’ for each type of activity should remain in the data file 
for use in the other calculations. 
 
The same approach as described above is used to calculate total days for computing 
the ‘high’ category. The primary requirement according to the stated criteria is to 
identify those individuals who undertake a combination of walking, moderate-intensity 
and or vigorous-intensity activity on at least 7 days/week [See section 4.2]. 
Individuals who meet this criterion should be coded as a value in a new variable to 
reflect “at least 7 days”. 
 
Below are two examples showing this coding in practice: 
i)  an individual who reports ‘4 days of moderate-intensity’ and ‘3 days of walking’ 
should be coded as the new variable “at least 7 days”. 
ii)  an individual reporting ‘3 days of vigorous-intensity’, ‘3 days moderate-
intensity’ and ‘3 days walking’  should be coded as “at least 7 days”  [even 
though the total adds to 9] .  
    
 
8.  Summary algorithms 
 
The algorithms in Appendix 1 and Appendix 2 to this document show how these rules 
work in an analysis plan, to develop the categories 1 [Low], 2 [Moderate], and 3 
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APPENDIX 1   
 
 At A Glance  




Expressed as MET-min per week:  MET level x minutes of activity/day x days per week 
 
           Sample Calculation 
 
MET levels          MET-minutes/week for 30 min/day, 5 days 
Walking = 3.3 METs        3.3*30*5 =     495 MET-minutes/week 
Moderate Intensity = 4.0 METs    4.0*30*5 =     600 MET-minutes/week 
Vigorous Intensity = 8.0 METs     8.0*30*5 =  1,200 MET-minutes/week 
      _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
      T O T A L       =       2 , 2 9 5   M E T - m i n u t e s / w e e k  
 




Categorical Score- three levels of physical activity are proposed  
 
1.  Low 
 
• N o   a c t i v i t y   i s   r e p o r t e d   OR 
• S o m e   a c t i v i t y   i s   r e p o r t e d   b u t   n o t   e n o u g h   t o   m e e t   C a t e g o r i e s   2   o r   3 .  
 
2.  Moderate 
 
Either of the following 3 criteria 
• 3   o r   m o r e   d a y s   o f   v i g o r o u s   a c t i v i t y   o f   a t   l e a s t   2 0   m i n u t e s   p e r   d a y   OR 
• 5   o r   m o r e   d a y s   o f   m o d e r a t e - i n t e n s i t y   a c t i v i t y   a n d / o r   w a l k i n g   o f   a t   l e a s t   3 0   m i n u t e s  
per day OR 
• 5   o r   m o r e   d a y s   o f   a n y   c o m b i n a t i o n   o f   w a l k i n g ,   m o d e r a t e - i n t e n s i t y   o r   v i g o r o u s -
intensity activities achieving a minimum of at least 600 MET-minutes/week.   
 
3.  High 
 
Any one of the following 2 criteria  
• V i g o r o u s - i n t e n s i t y   a c t i v i t y   o n   a t   l e a s t   3   d a y s   a n d   a c c u m u l a t i n g   a t   l e a s t   1 5 0 0  
MET-minutes/week OR 
• 7   o r   m o r e   d a y s   o f   a n y   c o m b i n a t i o n   o f   w a l k i n g ,   m o d e r a t e -   o r   v i g o r o u s - i n t e n s i t y  





Please review the full document “Guidelines for the data processing and analysis of the International 
Physical Activity Questionnaire” for more detailed description of IPAQ analysis and recommendations for 
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APPENDIX 2   
 
At A Glance 








MET levels          MET-minutes/week for 30 min/day, 5 days 
Walking at work= 3.3 METs        3.3*30*5 =     495 MET-minutes/week 
Cycling for transportation= 6.0 METs   6.0*30*5 =     900 MET-minutes/week 
Moderate yard work= 4.0 METs    4.0*30*5 =     600 MET-minutes/week 
Vigorous intensity in leisure= 8.0 METs   8.0*30*5 = 1,200 MET-minutes/week 
      _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
      T O T A L       =       3 , 1 9 5   M E T - m i n u t e s / w e e k  
 
Domain Sub Scores 
Total MET-minutes/week at work = Walk (METs*min*days) + Mod (METs*min*days) + Vig 
(METs*min*days) at work 
 
Total MET-minutes/week for transportation = Walk (METs*min*days) + Cycle 
(METs*min*days) for transportation 
 
Total MET-minutes/week from domestic and garden = Vig (METs*min*days) yard work + 
Mod (METs*min*days) yard work + Mod (METs*min*days) inside chores   
 
Total MET-minutes/week in leisure-time = Walk (METs*min*days) + Mod (METs*min*days) 
+ Vig (METs*min*days) in leisure-time 
 
 
Walking, Moderate-Intensity and Vigorous-Intensity Sub Scores 
 
Total Walking MET-minutes/week = Walk MET-minutes/week (at Work + for Transport + in 
Leisure) 
 
Total Moderate MET-minutes/week = Cycle MET-minutes/week for Transport + Mod MET-
minutes/week (Work + Yard chores + Inside chores + Leisure) + Vigorous Yard chores MET-
minutes 
 
Note: The above is a total moderate activities only score. If you require a total of all moderate-intensity 
physical activities you would sum Total Walking and Total Moderate  
 
Total Vigorous MET-minutes/week = Vig MET-minutes/week (at Work + in Leisure) 
 
Total Physical Activity Score 
Total Physical Activity MET-minutes/week = Walking MET-minutes/week + Moderate MET-
minutes/week + Total Vigorous MET-minutes/week 
 
Continued      ..Revised November2005  15
Also 
 
Total Physical Activity MET-minutes/week = Total MET-minutes/week (at Work + for 
Transport + in Chores + in Leisure) 
 
 
Categorical Score- three levels of physical activity are proposed  
 
1.  Low   
 
No activity is reported OR 
a.  Some activity is reported but not enough to meet Categories 2 or 3. 
 
2.  Moderate 
 
Either of the following 3 criteria 
a.  3 or more days of vigorous-intensity activity of at least 20 minutes per day OR 
b.  5 or more days of moderate-intensity activity and/or walking of at least 30 
minutes per day OR 
c.  5 or more days of any combination of walking, moderate-intensity or vigorous-
intensity activities achieving a minimum of at least 600 MET-min/week.   
 
3.  High 
 
Any one of the following 2 criteria  
• V i g o r o u s - i n t e n s i t y   a c t i v i t y   o n   a t   l e a s t   3   d a y s   a n d   a c c u m u l a t i n g   a t   l e a s t   1 5 0 0  
MET-minutes/week OR 
• 7   o r   m o r e   d a y s   o f   a n y   c o m b i n a t i o n   o f   w a l k i n g ,   m o d e r a t e -   o r   v i g o r o u s -   i n t e n s i t y  





Please review the full document “Guidelines for the data processing and analysis of the International 
Physical Activity Questionnaire” for more detailed description of IPAQ analysis and recommendations for 
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INTRODUCTION
Human Leptin (gene name OB) is a 16 kDa, 146 amino acid (aa) residue, non-glycosylated 
polypeptide that regulates adipose tissue mass and energy balance (1-6). The name Leptin is 
derived from the Greek (leptos, or "thin") because of its ability to reduce fat stores (7). In mice 
(ob/ob) and humans, inactivating mutations of the OB gene can cause obesity (1-6). Mature 
human Leptin shares 87% and 84% aa identity with mouse and rat Leptin, respectively (1, 8). 
Human Leptin is active in both the mouse and rat systems (9, 10). Leptin is expressed almost 
exclusively by adipocytes and its production is influenced by hormones, cytokines and 
nutrients (5, 8, 11). For example, Leptin expression is enhanced by insulin and glucocorticoids, 
which are associated with positive energy balance, while catecholamines decrease Leptin 
production during negative energy balance (5). It circulates in the plasma, crosses the blood-
brain barrier, and is present in human breast milk (3-6, 12).
The human Leptin receptor (designated ObR or LEPR) is a 150 kDa, 1144 aa residue, type I 
transmembrane glycoprotein of the IL-6 receptor family of Class I cytokine receptors (13, 14). 
The gene for ObR undergoes considerable splicing, forming variants a-d with cytoplasmic 
domains of variable length, plus the potentially soluble form ObRe (14, 15). The long form, 
ObRb (formerly OB RL), is expressed mainly in the hypothalamic arcuate nucleus and is 
essential for signal transduction (6, 16, 17). Of the short forms, ObRa is ubiquitous, and ObRa, 
ObRc, and ObRd are all thought to mediate Leptin binding and endocytosis, but not signal 
transduction (16). Upon binding of Leptin dimers, ObRb dimers may form signaling tetramers 
with shorter forms (16). Mutations of ObRb can cause obese phenotypes in both the mouse 
and rat. The mouse mutation (db/db for diabetes) occurs in the cytoplasmic domain, while the 
rat mutation (fa/fa for fatty) occurs in the extracellular domain of the receptor (18, 19). In a 
concentration-dependent manner, Leptin signaling can have diverse effects, causing neurons 
that express pro-opiomelanocortin (POMC) peptides to reduce food intake, and neurons that 
express neuropeptide Y and agouti-related protein (NpY and AgRP) to increase food intake  
(4, 6).
Leptin is fundamentally a "starvation signal" that, when low, prompts increased appetite and 
decreased energy expenditure (4, 6, 10). Adipocytes increase Leptin expression as cell size 
increases, which should result in depressed appetite and increased energy expenditure (5). 
However, obese humans are often resistant to these effects of Leptin (3). Leptin resistance is in 
part due to saturation of the blood-brain transporter, which is influenced by high circulating 
triglycerides, and in part due to decreased cellular response to Leptin (6). Rarely, obese humans 
are genetically Leptin-deficient (3-6). Leptin deficiency also influences the immune system, 
depressing Th1 responses and causing increased frequency of infections (4). Leptin also 
regulates puberty, blocking the onset of puberty, or of menses if Leptin deficiency exists due to 
excessive thinness, such as results from starvation, extreme exercise-induced weight loss, 
anorexia or cancer-induced cachexia (3, 4).
The Quantikine Human Leptin Immunoassay is a 3.5 hour solid phase ELISA designed to 
measure soluble human Leptin in cell culture supernates, serum, and plasma. It contains  
E. coli-expressed recombinant human Leptin and antibodies raised against the recombinant 
factor. This immunoassay has been shown to quantitate recombinant Leptin accurately. Results 
obtained measuring natural human Leptin showed dose-response curves that were parallel to 
the standard curves obtained using the recombinant Quantikine kit standards. These results 
indicate that this kit can be used to determine relative mass values for natural human Leptin.For research use only. Not for use in diagnostic procedures. 2
PRINCIPLE OF THE ASSAY
This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal 
antibody specific for Leptin has been pre-coated onto a microplate. Standards and samples are 
pipetted into the wells and any Leptin present is bound by the immobilized antibody. After 
washing away any unbound substances, an enzyme-linked monoclonal antibody specific for 
Leptin is added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution is added to the wells and color develops in proportion to the 
amount of Leptin bound in the initial step. The color development is stopped and the intensity 
of the color is measured.
LIMITATIONS OF THE PROCEDURE
• FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
• The kit should not be used beyond the expiration date on the kit label.
• Do not mix or substitute reagents with those from other lots or sources.
• If samples fall outside the dynamic range of the assay, dilute samples appropriately with 
Calibrator Diluent and repeat the assay. If cell culture supernate samples require large 
dilutions, perform an intermediate dilution with culture media and the final dilution with the 
appropriate Calibrator Diluent.
• Any variation in standard diluent, operator, pipetting technique, washing technique, 
incubation time or temperature, and kit age can cause variation in binding.
• Variations in sample collection, processing, and storage may cause sample value differences.
• This assay is designed to eliminate interference by other factors present in biological samples. 
Until all factors have been tested in the Quantikine Immunoassay, however, the possibility of 
interference cannot be excluded.
TECHNICAL HINTS
• When mixing or reconstituting protein solutions, always avoid foaming.
• To avoid cross-contamination, change pipette tips between additions of each standard level, 
between sample additions, and between reagent additions. Also, use separate reservoirs for 
each reagent.
• To ensure accurate results, proper adhesion of plate sealers during incubation steps is 
necessary.
• When using an automated plate washer, adding a 30 second soak period following the 
addition of Wash Buffer, and/or rotating the plate 180 degrees between wash steps may 
improve assay precision.
• Substrate Solution should remain colorless until added to the plate. Keep Substrate Solution 
protected from light. Substrate Solution should change from colorless to gradations of blue.
• Stop Solution should be added to the plate in the same order as the Substrate Solution. The 
color developed in the wells will turn from blue to yellow upon addition of the Stop Solution. 
Wells that are green in color indicate that the Stop Solution has not mixed thoroughly with 
the Substrate Solution.www.RnDSystems.com 3
MATERIALS PROVIDED & STORAGE CONDITIONS










890573 1 plate 6 plates 96 well polystyrene microplate 
(12 strips of 8 wells) coated with 
a mouse monoclonal antibody 
against Leptin.
Return unused wells to the foil 
pouch containing the desiccant 
pack. Reseal along entire edge 
of the zip-seal. May be stored for 
up to 1 month at 2-8 °C.*
Leptin 
Conjugate
890574 1 vial 6 vials 21 mL/vial of mouse monoclonal 
antibody against Leptin conjugated 
to horseradish peroxidase with 
preservatives.
May be stored for up to  
1 month at 2-8 °C.*
Leptin 
Standard
890575 1 vial 6 vials 10 ng/vial of recombinant human 








895151 1 vial 6 vials 21 mL/vial of a concentrated 




895003 1 vial 6 vials 21 mL/vial of a 25-fold 
concentrated solution of buffered 
surfactant with preservative.  
May turn yellow over time.
Color Reagent A 895000 1 vial 6 vials 12 mL/vial of stabilized hydrogen 
peroxide.
Color Reagent B 895001 1 vial 6 vials 12 mL/vial of stabilized chromogen 
(tetramethylbenzidine).
Stop Solution 895032 1 vial 6 vials 6 mL/vial of 2 N sulfuric acid.
Plate Sealers N/A 4 strips 24 strips Adhesive strips.
* Provided this is within the expiration date of the kit.
DLP00 contains sufficient materials to run an ELISA on one 96 well plate. 
SLP00 (SixPak) contains sufficient materials to run ELISAs on six 96 well plates.
This kit is also available in a PharmPak (R&D Systems, Catalog # PDLP00). PharmPaks contain 
sufficient materials to run ELISAs on 50 microplates. Specific vial counts of each component 
may vary. Please refer to the literature accompanying your order for specific vial counts.For research use only. Not for use in diagnostic procedures. 4
OTHER SUPPLIES REQUIRED
• Microplate reader capable of measuring absorbance at 450 nm, with the correction 
wavelength set at 540 nm or 570 nm.
• Pipettes and pipette tips.
• Deionized or distilled water.
• Squirt bottle, manifold dispenser, or automated microplate washer.
• 100 mL and 500 mL graduated cylinders.
• Polypropylene test tubes for dilution of standards and samples.
• Human Leptin Controls (optional; available from R&D Systems).
PRECAUTIONS
The Stop Solution provided with this kit is an acid solution.
Some components in this kit contain ProClin® which may cause an allergic skin reaction. Avoid 
breathing mist.
Color Reagent B may cause skin, eye, and respiratory irritation. Avoid breathing fumes.
Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after 
handling. Please refer to the MSDS on our website prior to use.
SAMPLE COLLECTION & STORAGE
The sample collection and storage conditions listed below are intended as general 
guidelines. Sample stability has not been evaluated.
Cell Culture Supernates - Remove particulates by centrifugation and assay immediately or 
aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.
Serum - Use a serum separator tube (SST) and allow samples to clot for 30 minutes at room 
temperature before centrifugation for 15 minutes at 1000 x g. Remove serum and assay 
immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.
Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. Centrifuge for  
15 minutes at 1000 x g within 30 minutes of collection. Assay immediately or aliquot and store 
samples at ≤ - 20 °C. Avoid repeated freeze-thaw cycles.
SAMPLE PREPARATION
Most serum and plasma samples require a 100-fold dilution. A 100-fold dilution may be 
achieved by adding 10 μL of sample to 990 μL of Calibrator Diluent RD5P (1X).
If samples fall outside the dynamic range of the assay, a lower or higher dilution may be 
required.www.RnDSystems.com 5
REAGENT PREPARATION
Bring all reagents to room temperature before use.
Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix 
gently until the crystals have completely dissolved. Add 20 mL of Wash Buffer Concentrate to 
deionized or distilled water to prepare 500 mL of Wash Buffer.
Substrate Solution - Color Reagents A and B should be mixed together in equal volumes 
within 15 minutes of use. Protect from light. 200 μL of the resultant mixture is required per well.
Calibrator Diluent RD5P (1X) - Add 20 mL of Calibrator Diluent RD5P Concentrate to 80 mL of 
deionized or distilled water to prepare 100 mL of Calibrator Diluent RD5P (1X).
Leptin Standard - Reconstitute the Leptin Standard with 1.0 mL of deionized or distilled water. 
This reconstitution produces a stock solution of 10,000 pg/mL. Allow the standard to sit for a 
minimum of 15 minutes with gentle agitation prior to making dilutions.
Use polypropylene tubes. Pipette 900 μL of Calibrator Diluent RD5P (1X) into the 1000 pg/mL 
tube. Pipette 500 μL of Calibrator Diluent RD5P (1X) into each of the remaining tubes. Use the 
stock solution to produce a dilution series (below). Mix each tube thoroughly before the next 
transfer. The 1000 pg/mL standard serves as the high standard. Calibrator Diluent RD5P (1X) 
serves as the zero standard (0 pg/mL).
100 µL Std.
10,000 pg/mL 1000 pg/mL 500 pg/mL 250 pg/mL 125 pg/mL 62.5 pg/mL 31.3 pg/mL 15.6 pg/mL
500 µL 500 µL 500 µL 500 µL 500 µL 500 µLFor research use only. Not for use in diagnostic procedures. 6
ASSAY PROCEDURE 
Bring all reagents and samples to room temperature before use. It is recommended that 
all standards, samples, and controls be assayed in duplicate.
1. Prepare all reagents, working standards, and samples as directed in the previous sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, and reseal.
3. Add 100 μL of Assay Diluent RD1-19 to each well.
4. Add 100 μL of Standard, Control, or sample* per well. Cover with the adhesive strip 
provided. Incubate for 2 hours at room temperature. A plate layout is provided to record 
standards and samples assayed.
5. Aspirate each well and wash, repeating the process three times for a total of four washes. 
Wash by filling each well with Wash Buffer (400 μL) using a squirt bottle, manifold 
dispenser, or autowasher. Complete removal of liquid at each step is essential to good 
performance. After the last wash, remove any remaining Wash Buffer by aspirating or 
decanting. Invert the plate and blot it against clean paper towels.
6. Add 200 μL of Leptin Conjugate to each well. Cover with a new adhesive strip. Incubate for 
1 hour at room temperature.
7. Repeat the aspiration/wash as in step 5.
8. Add 200 μL of Substrate Solution to each well. Incubate for 30 minutes at room 
temperature. Protect from light.
9. Add 50 μL of Stop Solution to each well. The color in the wells should change from blue 
to yellow. If the color in the wells is green or the color change does not appear uniform, 
gently tap the plate to ensure thorough mixing.
10. Determine the optical density of each well within 30 minutes, using a microplate reader 
set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength 
correction is not available, subtract readings at 540 nm or 570 nm from the readings at 
450 nm. This subtraction will correct for optical imperfections in the plate. Readings made 
directly at 450 nm without correction may be higher and less accurate.
*Serum and plasma samples require dilution. See Sample Preparation section.www.RnDSystems.com 7
CALCULATION OF RESULTS
Average the duplicate readings for each standard, control, and sample and subtract the 
average zero standard optical density (O.D.).
Create a standard curve by reducing the data using computer software capable of generating a 
log/log curve-fit. As an alternative, construct a standard curve by plotting the mean 
absorbance for each standard on the y-axis against the concentration on the x-axis and draw a 
best fit curve through the points on a log/log graph. The data may be linearized by plotting the 
log of the Leptin concentrations versus the log of the O.D. on a linear scale, and the best fit line 
can be determined by regression analysis.
If the samples have been diluted, the concentration read from the standard curve must be 
multiplied by the dilution factor.
TYPICAL DATA
This standard curve is provided for demonstration only. A standard curve should be generated 
for each set of samples assayed.
(pg/mL) O.D. Average Corrected
0 0.015 0.015 —
0.015
15.6 0.044 0.044 0.029
0.044
31.3 0.073 0.074 0.059
0.075
62.5 0.136 0.140 0.125
0.144
125 0.282 0.284 0.269
0.285
250 0.581 0.584 0.569
0.588
500 1.195 1.203 1.188
1.211
1000 2.339 2.377 2.362
2.415For research use only. Not for use in diagnostic procedures. 8
PRECISION
Intra-assay Precision (Precision within an assay) 
Three samples of known concentration were tested twenty times on one plate to assess intra-
assay precision.
Inter-assay Precision (Precision between assays) 
Three samples of known concentration were tested in forty separate assays to assess inter-
assay precision.
Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean (pg/mL) 64.5 146 621 65.7 146 581
Standard deviation 2.14 4.32 20.0 3.56 6.17 20.6
CV (%) 3.3 3.0 3.2 5.4 4.2 3.5
RECOVERY
The recovery of Leptin spiked to three different levels in samples throughout the range of the 
assay in various matrices was evaluated.
Sample Type   Average % Recovery Range
Cell culture media (n=5) 98 94-102%
Serum* (n=5) 95 89-109%
EDTA plasma* (n=5) 99 85-112%
Heparin plasma* (n=5) 90 81-100%
Citrate plasma* (n=5) 95 87-105%
*Samples were diluted prior to assay as directed in the Sample Preparation section.
SENSITIVITY
The minimum detectable dose (MDD) of Leptin is typically less than 7.8 pg/mL.
The MDD was determined by adding two standard deviations to the mean optical density 
value of twenty zero standard replicates and calculating the corresponding concentration.www.RnDSystems.com 9
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations 
of Leptin were diluted with Calibrator Diluent RD5P (1X) to produce samples with values within 

















Average % of Expected 105 99 99 99 98
Range (%) 103-107 99-101 97-102 96-104 96-99
1:4
Average % of Expected 109 97 95 97 96
Range (%) 106-114 94-102 94-99 93-100 93-99
1:8
Average % of Expected 109 92 92 94 93
Range (%) 107-115 89-95 90-94 90-97 89-97
1:16
Average % of Expected 109 92 91 96 93
Range (%) 106-113 87-97 86-94 90-100 89-96
*Samples were diluted prior to assay.
CALIBRATION
This immunoassay is calibrated against a highly purified E. coli-expressed recombinant human 
Leptin produced at R&D Systems.For research use only. Not for use in diagnostic procedures. 10
SAMPLE VALUES
Serum - Samples from apparently healthy volunteers were evaluated for the presence of Leptin 
in this assay. No medical histories were available for the donors used in this study.
Sample Type Range (pg/mL) Mean (pg/mL)
Male Serum (n = 16) 2205-11,149 4760
Female Serum (n = 36) 3877-77,273 20,676
Five additional male serum samples fell below the lowest standard, 15.6 pg/mL, when diluted 
100-fold.
Note: Values in EDTA and heparin plasma have been found to be comparable to paired serum 
samples. Values in citrate plasma have been found to be slightly decreased compared to paired 
serum, EDTA or heparin plasma samples.
Cell Culture Supernates: 
Human peripheral blood mononuclear cells (5 x 106 cells/mL) were cultured in RPMI 
supplemented with 5% fetal calf serum, 50 μM β-mercaptoethanol, 2 mM L-glutamine,  
100 U/mL penicillin, and 100 μg/mL streptomycin sulfate. The cells were cultured unstimulated 
or stimulated with 10 μg/mL PHA. Aliquots of the cell culture supernates were removed on 
days 1 and 5 and assayed for levels of natural Leptin.




BeWo human choriocarcinoma cells (1 x 106 cells/mL) were cultured in F-12 media 
supplemented with 15% fetal bovine serum. The cells were cultured unstimulated or 
stimulated with 2 μM forskolin and 20 μM forskolin. Aliquots of the cell culture supernates  
were removed on days 1, 2, and 3 and assayed for levels of natural Leptin.
Condition Day 1 (pg/mL) Day 2 (pg/mL) Day 3 (pg/mL)
Unstimulated* 849 1549 1667
2 μM forskolin* 1231 1699 2054
20 μM forskolin* 1137 1725 2747
*Samples were diluted 20-fold prior to assay.www.RnDSystems.com 11
SPECIFICITY
This assay recognizes natural and recombinant human Leptin.
The factors listed below were prepared at 50 ng/mL in Calibrator Diluent RD5P (1X) and 
assayed for cross-reactivity. Preparations of the following factors prepared at 50 ng/mL in a 






































































































Recombinant human Leptin R/Fc chimera and recombinant mouse Leptin R/Fc chimera do not 
cross-react in this assay; however, interference was observed at concentrations ≥ 0.78 ng/mL.For research use only. Not for use in diagnostic procedures. 12
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PLATE LAYOUT
Use this plate layout to record standards and samples assayed.For research use only. Not for use in diagnostic procedures. 14
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